[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 1271
1. Blix HS, Røed J, Sti MO: Large variation in antibacterial use among Norwegian nursing homes. Scand J Infect Dis; 2007;39(6-7):536-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Antibacterial data were collected for ATC group J01 antibacterials for systemic use, A07AA09 vancomycin and P01AB01 metronidazole in DDDs/y.
  • On average, 49% of the therapeutic antibacterials were drugs used for UTI, range 12%-88%.
  • [MeSH-major] Anti-Bacterial Agents / therapeutic use. Bacterial Infections / drug therapy
  • [MeSH-minor] Cross Infection / drug therapy. Cross Infection / epidemiology. Cross-Sectional Studies. Drug Resistance, Multiple, Bacterial. Drug Therapy / statistics & numerical data. Humans. Methenamine / therapeutic use. Metronidazole / therapeutic use. Norway / epidemiology. Nursing Homes / statistics & numerical data. Pharmacoepidemiology. Retrospective Studies. Vancomycin / therapeutic use

  • MedlinePlus Health Information. consumer health - Antibiotics.
  • MedlinePlus Health Information. consumer health - Bacterial Infections.
  • Hazardous Substances Data Bank. METHENAMINE .
  • Hazardous Substances Data Bank. Vancomycin .
  • Hazardous Substances Data Bank. METRONIDAZOLE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17577815.001).
  • [ISSN] 0036-5548
  • [Journal-full-title] Scandinavian journal of infectious diseases
  • [ISO-abbreviation] Scand. J. Infect. Dis.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Sweden
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 140QMO216E / Metronidazole; 6Q205EH1VU / Vancomycin; J50OIX95QV / Methenamine
  •  go-up   go-down


2. van Schie HT, de Vos RJ, de Jonge S, Bakker EM, Heijboer MP, Verhaar JA, Tol JL, Weinans H: Ultrasonographic tissue characterisation of human Achilles tendons: quantification of tendon structure through a novel non-invasive approach. Br J Sports Med; 2010 Dec;44(16):1153-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To assess whether three-dimensional imaging of the Achilles tendon by ultrasonographic tissue characterisation (UTC) can differentiate between symptomatic and asymptomatic tendons.
  • INTERVENTIONS: Symptomatic and asymptomatic tendons were scanned using the UTC procedure.
  • UTC categorises four different echotypes that represent (I) highly stable;.
  • Finally, the inter-observer reliability of UTC was determined.
  • CONCLUSION: UTC can quantitatively evaluate tendon structure and thereby discriminate symptomatic and asymptomatic tendons.
  • As such, UTC might be useful to monitor treatment protocols.

  • MedlinePlus Health Information. consumer health - Tendinitis.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19666626.001).
  • [ISSN] 1473-0480
  • [Journal-full-title] British journal of sports medicine
  • [ISO-abbreviation] Br J Sports Med
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] England
  •  go-up   go-down


3. Wawruch M, Bozekova L, Tisonova J, Raganova A, Lassanova M, Hudec R, Vojtko R, Gazova A, Kriska M: The Slovak Drug Information (Druginfo) Centre during the period 1997-2004. Bratisl Lek Listy; 2005;106(3):133-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • According to the ATC classification the questions were most often related to antiinfective drugs, cardiovascular drugs and psychiatric drugs.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16026149.001).
  • [ISSN] 0006-9248
  • [Journal-full-title] Bratislavské lekárske listy
  • [ISO-abbreviation] Bratisl Lek Listy
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Slovakia
  •  go-up   go-down


Advertisement
4. Ito Y, Takano T, Miyauchi A: Apolipoprotein e expression in anaplastic thyroid carcinoma. Oncology; 2006;71(5-6):388-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Apolipoprotein e expression in anaplastic thyroid carcinoma.
  • However, recently the relationship between Apo E and carcinoma progression has been investigated.
  • In this study, we investigated Apo E expression in thyroid carcinoma at both the protein and molecular levels.
  • METHODS: We investigated Apo E expression at the protein and molecular level in 124 thyroid neoplasms.
  • RESULTS: In RT-PCR and in situ hybridization, the Apo E mRNA expression level was very low in papillary and follicular carcinomas as well as normal thyroid, but was dramatically elevated in anaplastic carcinoma.
  • In an immunohistochemical study, 32 of 33 anaplastic carcinomas (97.0%) showed high levels of Apo E expression, but this phenomenon was seen only in 1 of 51 papillary carcinomas (2.0%).
  • None of the follicular carcinomas or adenomas showed high levels of Apo E expression.
  • CONCLUSIONS: These findings suggest that Apo E is one of the typical biological characteristics of anaplastic thyroid carcinoma.
  • [MeSH-major] Adenoma / metabolism. Apolipoproteins E / biosynthesis. Biomarkers, Tumor / biosynthesis. Carcinoma / metabolism. Carcinoma, Papillary / metabolism. Thyroid Neoplasms / metabolism
  • [MeSH-minor] Humans. Immunohistochemistry. In Situ Hybridization. RNA, Messenger / biosynthesis. Reverse Transcriptase Polymerase Chain Reaction. Thyroid Gland / metabolism. Thyroid Gland / pathology

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 S. Karger AG, Basel.
  • (PMID = 17690558.001).
  • [ISSN] 1423-0232
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Apolipoproteins E; 0 / Biomarkers, Tumor; 0 / RNA, Messenger
  •  go-up   go-down


5. Knobel M, Medeiros-Neto G: Relevance of iodine intake as a reputed predisposing factor for thyroid cancer. Arq Bras Endocrinol Metabol; 2007 Jul;51(5):701-12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relevance of iodine intake as a reputed predisposing factor for thyroid cancer.
  • Iodine is a trace element that is essential for the synthesis of thyroid hormone.
  • This may be associated to thyroid cancer risk, particularly in women.
  • Experimental studies have documented thyroid cancer induction by elevation of endogenous TSH, although in a small number of animals.
  • Iodine deficiency associated with carcinogenic agents and chemical mutagens will result in a higher incidence of thyroid malignancy.
  • Inadequate low iodine intake will result in increased TSH stimulation, increased thyroid cell responsiveness to TSH, increased thyroid cell EGF-induced proliferation, decreased TGFbeta 1 production and increased angiogenesis, all phenomena related to promotion of tumor growth.
  • Epidemiological studies associating iodine intake and thyroid cancer led to controversial and conflicting results.
  • There is no doubt that introduction of universal iodine prophylaxis in population previously in chronic iodine-deficiency leads to a changing pattern of more prevalent papillary thyroid cancer and declining of follicular thyroid cancer.
  • Also anaplastic thyroid cancer is practically not seen after years of iodine supplementation.
  • Iodine excess has also been indicated as a possible nutritional factor in the prevalence of differentiated thyroid cancer in Iceland, Hawaii and, more recently, in China.
  • IN CONCLUSION: available evidence from animal experiments, epidemiological studies and iodine prophylaxis has demonstrated a shift towards a rise in papillary carcinoma, but no clear relationship between overall thyroid cancer incidence and iodine intake.
  • [MeSH-major] Adenocarcinoma, Follicular / etiology. Adenocarcinoma, Papillary / etiology. Iodine. Thyroid Neoplasms / etiology
  • [MeSH-minor] Animals. Argentina / epidemiology. Diet. Disease Models, Animal. Epidemiologic Studies. Epidermal Growth Factor / metabolism. Female. Hawaii / epidemiology. Humans. Iceland / epidemiology. Italy / epidemiology. Male. Thyroid Gland / drug effects. Thyroid Gland / metabolism. Thyrotropin / drug effects. Thyrotropin / metabolism

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • Hazardous Substances Data Bank. IODINE, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17891233.001).
  • [ISSN] 0004-2730
  • [Journal-full-title] Arquivos brasileiros de endocrinologia e metabologia
  • [ISO-abbreviation] Arq Bras Endocrinol Metabol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Brazil
  • [Chemical-registry-number] 62229-50-9 / Epidermal Growth Factor; 9002-71-5 / Thyrotropin; 9679TC07X4 / Iodine
  • [Number-of-references] 89
  •  go-up   go-down


6. Ion-Nedelcu N, Radu L, Firulescu S, Truţă E, Sîrbu M, Barbu G, Calistru P: [Use of systemic antibacterial agents at a university emergency clinic in Bucharest, in the year 2008]. Bacteriol Virusol Parazitol Epidemiol; 2009 Jan-Mar;54(1):53-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Observaţii privind utilizarea agenţilor antibacterieni sistemici într-o clinică universitară de urgenţă din municipiul Bucureşti în anul 2008.
  • OBJECTIVE: use of ATC/DDD (Anatomic Therapeutic Classification/Daily Defined Dose) methodology promoted by World Health Organization for calculating and analysis of systemic antimicrobial agents' annual rates of usage among the adult patients hospitalized in Bucharest municipality.
  • Consumption of systemic antimicrobial agents, taken from the clinic pharmacy's records, regarding the 2008 year, has been transformed in defined daily doses and aggregated by ATC subgroups.
  • At the level of entire clinic the consumption rate of all systemic antimicrobial agents was 72.6 defined daily doses per 100 de patient days (DDD/PD); by medical specialties the indicator's values were 61.2 DDD/100 PD in the department of internal medicine specialties, 62.8 DDD/100 PD in the departament of surgical specialties and 126 DDD/100 PD in the medical/surgical intensive care unit, respectively.
  • By ATC subgroups, the top three consumption rates included penicillin plus beta-lactamase inhibitors, 2nd generation cefalosporines and fluorochinolons, respectively.
  • Comparing the own rate with the distributions of NNIS (National Nosocomial Infection Surveillance) system form USA, demonstrated that the usage was into the expected limits for the majority of antimicrobial agents groups considered, excess usage being detected only in the case of 2nd generation cefalosporins (in non-intensive care sector) and in the case of carbapenems in the intensive care units, respectively.
  • [MeSH-major] Anti-Infective Agents / therapeutic use. Emergency Service, Hospital / statistics & numerical data. Hospitals, University / statistics & numerical data

  • Hazardous Substances Data Bank. METRONIDAZOLE .
  • Hazardous Substances Data Bank. CIPROFLOXACIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20524396.001).
  • [ISSN] 1220-3696
  • [Journal-full-title] Bacteriologia, virusologia, parazitologia, epidemiologia (Bucharest, Romania : 1990)
  • [ISO-abbreviation] Bacteriol Virusol Parazitol Epidemiol
  • [Language] rum
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Multicenter Study
  • [Publication-country] Romania
  • [Chemical-registry-number] 0 / Anti-Infective Agents; 0 / Carbapenems; 140QMO216E / Metronidazole; 5E8K9I0O4U / Ciprofloxacin; 74469-00-4 / Amoxicillin-Potassium Clavulanate Combination; 7U75I1278D / Cefoperazone; O1R9FJ93ED / Cefuroxime; S4TF6I2330 / Sulbactam
  •  go-up   go-down


7. Zito G, Richiusa P, Bommarito A, Carissimi E, Russo L, Coppola A, Zerilli M, Rodolico V, Criscimanna A, Amato M, Pizzolanti G, Galluzzo A, Giordano C: In vitro identification and characterization of CD133(pos) cancer stem-like cells in anaplastic thyroid carcinoma cell lines. PLoS One; 2008;3(10):e3544
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In vitro identification and characterization of CD133(pos) cancer stem-like cells in anaplastic thyroid carcinoma cell lines.
  • BACKGROUND: Recent publications suggest that neoplastic initiation and growth are dependent on a small subset of cells, termed cancer stem cells (CSCs).
  • Anaplastic Thyroid Carcinoma (ATC) is a very aggressive solid tumor with poor prognosis, characterized by high dedifferentiation.
  • The existence of CSCs might account for the heterogeneity of ATC lesions.
  • METHODOLOGY/PRINCIPAL FINDINGS: ATC cell lines ARO, KAT-4, KAT-18 and FRO were analyzed for CD133 expression.
  • Furthermore, ARO/CD133(pos) showed levels of thyroid transcription factor TTF-1 similar to the fetal thyroid cell line TAD-2, while the expression in ARO/CD133(neg) was negligible.
  • CONCLUSIONS/SIGNIFICANCE: We describe CD133(pos) cells in ATC cell lines.
  • The simultaneous positivity for thyroid specific factor TTF-1 and onfFN suggest they might represent putative thyroid cancer stem-like cells.
  • Our in vitro findings might provide new insights for novel therapeutic approaches.
  • [MeSH-major] Antigens, CD / metabolism. Carcinoma / pathology. Glycoproteins / metabolism. Neoplastic Stem Cells / pathology. Peptides / metabolism. Thyroid Neoplasms / pathology


8. Romanchishen AF, Kolosiuk VA, Bagaturiia GO: [Surgical treatment of local-expanded forms of thyroid carcinoma]. Vestn Khir Im I I Grek; 2005;164(2):17-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Surgical treatment of local-expanded forms of thyroid carcinoma].
  • An analysis of surgical treatment of 377 patients with advanced thyroid carcinoma is presented.
  • It was shown that surgical treatment in advanced thyroid carcinoma gave good results in the majority of cases (recovery or long-term palliation).
  • Combined and expanded operations were non effective in anaplastic thyroid carcinoma.
  • In well-differentiated thyroid carcinoma the 10-year survival was noted in 70.2% of patients.
  • [MeSH-major] Thyroid Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Palliative Care

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16082829.001).
  • [ISSN] 0042-4625
  • [Journal-full-title] Vestnik khirurgii imeni I. I. Grekova
  • [ISO-abbreviation] Vestn. Khir. Im. I. I. Grek.
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


9. Leitzmann MF, Brenner A, Moore SC, Koebnick C, Park Y, Hollenbeck A, Schatzkin A, Ron E: Prospective study of body mass index, physical activity and thyroid cancer. Int J Cancer; 2010 Jun 15;126(12):2947-56
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prospective study of body mass index, physical activity and thyroid cancer.
  • Increased body size and physical inactivity are positively related to risk of several cancers, but only few epidemiologic studies have investigated body-mass index (BMI) and physical activity in relation to thyroid cancer.
  • We examined the relations of BMI and physical activity to thyroid cancer in a prospective cohort of 484,326 United States men and women, followed from 1995/1996 to 2003.
  • During 3,490,300 person-years of follow-up, we documented 352 newly incident cases of thyroid cancer.
  • The multivariate relative risks (RR) of thyroid cancer for BMI values of 18.5-24.9 (reference), 25.0-29.9 and >/=30 kg m(-2) were 1.0, 1.27 and 1.39 [95% confidence interval (CI) = 1.05-1.85].
  • Adiposity predicted papillary thyroid cancers (RR comparing extreme BMI categories = 1.47; 95% CI = 1.03-2.10) and, based on small numbers, suggestively predicted follicular thyroid cancers (RR = 1.49; 95% CI = 0.79-2.82) and anaplastic thyroid cancers (RR = 5.80; 95% CI = 0.99-34.19).
  • No relation with BMI was noted for medullary thyroid cancers (RR = 0.97; 95% CI = 0.27-3.43).
  • The positive relation of BMI to total thyroid cancer was evident for men but not for women.
  • Physical activity was unassociated with thyroid cancer.
  • The RRs of total thyroid cancer for low (reference), intermediate, and high level of physical activity were 1.0, 1.01 and 1.01 (95% CI = 0.76-1.34, p for trend = 0.931), respectively.
  • Our results support an adverse effect of adiposity on risk for developing total and papillary, and possibly follicular thyroid cancers.
  • Based on only 15 cases, adiposity was unrelated to medullary thyroid cancers.
  • Physical activity was unrelated to total thyroid cancer.
  • [MeSH-major] Adenocarcinoma, Follicular / epidemiology. Body Mass Index. Carcinoma, Papillary / epidemiology. Exercise. Thyroid Neoplasms / epidemiology

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Exercise and Physical Fitness.
  • MedlinePlus Health Information. consumer health - Exercise for Seniors.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Causes Control. 2000 Feb;11(2):137-44 [10710197.001]
  • [Cites] Res Q Exerc Sport. 2000 Jun;71(2 Suppl):S1-14 [10925819.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Mar;86(3):1072-7 [11238488.001]
  • [Cites] Int J Cancer. 2001 Sep 1;93(5):745-50 [11477590.001]
  • [Cites] Am J Epidemiol. 2001 Dec 15;154(12):1119-25 [11744517.001]
  • [Cites] Cancer Causes Control. 2003 Oct;14(8):787-9 [14674743.001]
  • [Cites] Cancer Causes Control. 2004 Feb;15(1):35-43 [14970733.001]
  • [Cites] Med Sci Sports Exerc. 1990 Apr;22(2):265-74 [2355825.001]
  • [Cites] Cancer Causes Control. 1990 Nov;1(3):223-34 [2102295.001]
  • [Cites] World Health Organ Tech Rep Ser. 1995;854:1-452 [8594834.001]
  • [Cites] Med Sci Sports Exerc. 1997 Jun;29(6 Suppl):S1-205 [9243481.001]
  • [Cites] Cancer Causes Control. 1999 Apr;10(2):157-66 [10231164.001]
  • [Cites] Scand J Surg. 2004;93(4):249-60 [15658665.001]
  • [Cites] JAMA. 2005 Apr 20;293(15):1861-7 [15840860.001]
  • [Cites] Br J Sports Med. 2005 May;39(5):294-7; discussion 294-7 [15849294.001]
  • [Cites] J Clin Oncol. 2005 Jul 20;23(21):4742-54 [16034050.001]
  • [Cites] Obes Surg. 2005 Sep;15(8):1171-6 [16197792.001]
  • [Cites] MMWR Morb Mortal Wkly Rep. 2005 Dec 2;54(47):1208-12 [16319815.001]
  • [Cites] Diabetologia. 2006 May;49(5):945-52 [16557372.001]
  • [Cites] Cancer Causes Control. 2006 Sep;17(7):901-9 [16841257.001]
  • [Cites] Br J Cancer. 2006 Aug 7;95(3):366-70 [16832414.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Nov;91(11):4295-301 [16868053.001]
  • [Cites] Curr Pharm Des. 2007;13(7):729-35 [17346187.001]
  • [Cites] Eur J Cancer. 2007 Mar;43(5):891-900 [17289376.001]
  • [Cites] Clin Endocrinol (Oxf). 2007 Aug;67(2):265-9 [17547687.001]
  • [Cites] Am J Epidemiol. 2007 Nov 15;166(10):1140-9 [17855390.001]
  • [Cites] CMAJ. 2007 Nov 20;177(11):1357-61 [18025426.001]
  • [Cites] Arch Intern Med. 2007 Dec 10;167(22):2453-60 [18071167.001]
  • [Cites] Lancet. 2008 Feb 16;371(9612):569-78 [18280327.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2009 Mar;18(3):784-91 [19240234.001]
  • [Cites] Cancer Causes Control. 2001 Dec;12(10):881-5 [11808706.001]
  • [Cites] Ann Epidemiol. 2002 Aug;12(6):395-401 [12160598.001]
  • [Cites] Eur J Cancer. 2003 Sep;39(13):1912-9 [12932671.001]
  • [Cites] J Steroid Biochem Mol Biol. 2003 Sep;86(3-5):225-30 [14623515.001]
  • (PMID = 19795465.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z01 CP010131-13; United States / Intramural NIH HHS / / Z01 CP010197-01
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS216879; NLM/ PMC2919690
  •  go-up   go-down


10. Goutsouliak V, Hay JH: Anaplastic thyroid cancer in British Columbia 1985-1999: a population-based study. Clin Oncol (R Coll Radiol); 2005 Apr;17(2):75-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic thyroid cancer in British Columbia 1985-1999: a population-based study.
  • AIMS: To review the outcome of patients diagnosed with anaplastic thyroid carcinoma in British Columbia between January 1985 and December 1999.
  • Survival curves were calculated using Kaplan-Meier estimates, and the charts of the 62 patients referred to a British Columbia Cancer Agency (BCCA) facility were reviewed.
  • The overall- and cancer-specific 5-year survival rates for the whole group were 5%.
  • non-referred cases: nine out of 13 patients were women; median age at diagnosis 84 years.
  • Eleven of the 13 patients died within 1 month of diagnosis.
  • Forty-eight patients presented with tumours that extended through the thyroid capsule, 10 presented with distant metastases.
  • CONCLUSION: Long-term, disease-free survival was achieved in a few patients who were able to receive high-dose radiotherapy, preferably after adequate surgery.
  • [MeSH-major] Thyroid Neoplasms / epidemiology. Thyroid Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. British Columbia / epidemiology. Carcinoma / epidemiology. Carcinoma / therapy. Female. Humans. Male. Middle Aged. Registries. Retrospective Studies. Survival Analysis


11. Russo A, Autelitano M, Bisanti L: Metabolic syndrome and cancer risk. Eur J Cancer; 2008 Jan;44(2):293-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metabolic syndrome and cancer risk.
  • OBJECTIVE: The purpose of this population-based study is to explore for the first time the link between metabolic syndrome and cancer risk using information from the health information system of the Cancer Registry.
  • METHODS: Referring to all pharmaceutical prescriptions between 1 January 1999 and 31 December 2005, coded with the Anatomical Therapeutic Chemical classification, all subjects aged 40 and over resident in Milan, which were simultaneously prescribed with antihypertensive, hypolypemic and hypoglycaemic drugs, were considered affected by metabolic syndrome.
  • New cancer cases among cohort subjects were identified trough the local Cancer Registry and standardised incidence ratios (and corresponding 95% exact confidence intervals) were computed.
  • RESULTS: Overall 16,677 subjects were identified corresponding to 45,828 person-years; among them 823 incidents cancers occurred.
  • Significantly increased risks for pancreatic cancer in males--SIR 178 (114-266)--and colorectal cancer in females--SIR 133 (101-170)--were observed.
  • Non-significantly increased risks were also observed in women for liver, gallbladder and biliary tract, breast and endometrial cancers.
  • CONCLUSIONS: Our study suggests that the risk for several cancers increases in subjects affected by metabolic syndrome.
  • The pharmacological control of the syndrome seems to be inadequate for reducing cancer risk, even though both a high competitive mortality effect and short duration of follow up have to be considered.

  • MedlinePlus Health Information. consumer health - Metabolic Syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18055193.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


12. Harmer PA: Incidence and characteristics of time-loss injuries in competitive fencing: a prospective, 5-year study of national competitions. Clin J Sport Med; 2008 Mar;18(2):137-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Experienced certified athletic trainers (ATC) evaluated and documented all incidents that resulted in withdrawal from competition.
  • [MeSH-major] Athletic Injuries / classification. Athletic Injuries / epidemiology. Injury Severity Score

  • MedlinePlus Health Information. consumer health - Sports Injuries.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18332688.001).
  • [ISSN] 1050-642X
  • [Journal-full-title] Clinical journal of sport medicine : official journal of the Canadian Academy of Sport Medicine
  • [ISO-abbreviation] Clin J Sport Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Swartz EE, Nowak J, Shirley C, Decoster LC: A comparison of head movement during back boarding by motorized spine-board and log-roll techniques. J Athl Train; 2005 Jul-Sep;40(3):162-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PATIENTS OR OTHER PARTICIPANTS: Thirteen certified athletic trainers, emergency first responders, and emergency medical technicians (6 men, 7 women).

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Emerg Med. 1992 Oct;21(10):1185-8 [1416294.001]
  • [Cites] J Trauma. 1987 May;27(5):525-31 [3573109.001]
  • [Cites] Ann Emerg Med. 1986 Jan;15(1):50-3 [3942357.001]
  • [Cites] J Trauma. 1983 Jun;23(6):461-5 [6864837.001]
  • [Cites] Anesthesiology. 1993 Mar;78(3):580-3 [8457057.001]
  • [Cites] Am J Emerg Med. 1996 Jul;14(4):369-72 [8768157.001]
  • [Cites] Anesth Analg. 2000 Nov;91(5):1274-8 [11049921.001]
  • [Cites] J Emerg Med. 1996 Sep-Oct;14(5):603-13 [8933323.001]
  • [Cites] BMJ. 1999 Jul 17;319(7203):171-2 [10406758.001]
  • [Cites] J Clin Anesth. 1999 Jun;11(4):349-52 [10470642.001]
  • [Cites] Clin J Sport Med. 2000 Jan;10(1):82-3 [10695856.001]
  • [Cites] Emerg Med J. 2003 Sep;20(5):476-8 [12954698.001]
  • [Cites] J Emerg Med. 1996 Sep-Oct;14(5):553-9 [8933314.001]
  • (PMID = 16284635.001).
  • [ISSN] 1938-162X
  • [Journal-full-title] Journal of athletic training
  • [ISO-abbreviation] J Athl Train
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC1250254
  •  go-up   go-down


14. Zhao L, Zheng ZM, Huang Y, Sun HM: A comparative analysis of mitochondrial genomes in Orthoptera (Arthropoda: Insecta) and genome descriptions of three grasshopper species. Zoolog Sci; 2010 Aug;27(8):662-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The putative initiation codon for the cox1 gene is ATC in E. fusigeniculatus, CTG in M. xiangchengensis and CCG in M. xizangensis.
  • [MeSH-major] DNA, Mitochondrial / genetics. Grasshoppers / classification. Grasshoppers / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20695782.001).
  • [ISSN] 0289-0003
  • [Journal-full-title] Zoological science
  • [ISO-abbreviation] Zool. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / DNA, Mitochondrial; 0 / RNA, Ribosomal; 9014-25-9 / RNA, Transfer
  •  go-up   go-down


15. Sorrentino R, Libertini S, Pallante PL, Troncone G, Palombini L, Bavetsias V, Spalletti-Cernia D, Laccetti P, Linardopoulos S, Chieffi P, Fusco A, Portella G: Aurora B overexpression associates with the thyroid carcinoma undifferentiated phenotype and is required for thyroid carcinoma cell proliferation. J Clin Endocrinol Metab; 2005 Feb;90(2):928-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aurora B overexpression associates with the thyroid carcinoma undifferentiated phenotype and is required for thyroid carcinoma cell proliferation.
  • Loss of mitotic regulation is believed to induce aneuploidy in cancer cells and act as a driving force during the malignant progression.
  • We analyzed Aurora B expression in human thyroid carcinomas.
  • Immunohistochemical analysis of archive samples showed a high expression of Aurora B in anaplastic thyroid carcinomas; conversely, Aurora B expression was not detectable in normal thyroid tissue.
  • Real-time PCR analysis confirmed a strong expression of Aurora B in anaplastic thyroid carcinomas.
  • The block of Aurora B expression induced by RNA interference or by using an inhibitor of Aurora kinase activity significantly reduced the growth of thyroid anaplastic carcinoma cells.
  • [MeSH-major] Protein-Serine-Threonine Kinases / genetics. Thyroid Neoplasms / genetics
  • [MeSH-minor] Animals. Aurora Kinase B. Aurora Kinases. Base Sequence. Carcinoma / enzymology. Carcinoma / genetics. Carcinoma / pathology. Cell Division. Cell Line, Tumor. DNA Primers. Gene Expression Regulation, Enzymologic. Gene Expression Regulation, Neoplastic. Humans. Mice. Mice, Nude. Phenotype. Reverse Transcriptase Polymerase Chain Reaction. Transplantation, Heterologous

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15562011.001).
  • [ISSN] 0021-972X
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Primers; EC 2.7.11.1 / AURKB protein, human; EC 2.7.11.1 / Aurkb protein, mouse; EC 2.7.11.1 / Aurora Kinase B; EC 2.7.11.1 / Aurora Kinases; EC 2.7.11.1 / Protein-Serine-Threonine Kinases
  •  go-up   go-down


16. Higashiyama T, Ito Y, Hirokawa M, Fukushima M, Uruno T, Miya A, Matsuzuka F, Miyauchi A: Induction chemotherapy with weekly paclitaxel administration for anaplastic thyroid carcinoma. Thyroid; 2010 Jan;20(1):7-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Induction chemotherapy with weekly paclitaxel administration for anaplastic thyroid carcinoma.
  • BACKGROUND: Anaplastic thyroid carcinoma (ATC) has a very dire prognosis and no effective therapeutic strategies have been established for ATC patients, especially those with stage IVB or IVC.
  • Our objective was to investigate the effectiveness of weekly paclitaxel administered as induction chemotherapy and to establish novel therapeutic strategies for ATC.
  • METHODS: We performed induction chemotherapy by weekly paclitaxel administration for patients with stage IVB (nine patients) and IVC (four patients) disease.
  • Overall survival was compared with that of ATC patients with stage IVB (n = 50) and IVC (n = 13) treated without paclitaxel.
  • Curative surgery and adjuvant therapy were performed for four patients with stage IVB, and 32 months after treatment, all the four are alive and free of disease.
  • One CR patient and one stable disease patient were assessed as grade IV (complete remission) and grade III (nearly CR) on histological response, respectively.
  • All four patients with stage IVC died of carcinoma within 8 months.
  • CONCLUSIONS: Induction chemotherapy by weekly paclitaxel is a promising therapeutic strategy for stage IVB ATC patients.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / therapeutic use. Carcinoma / drug therapy. Paclitaxel / therapeutic use. Thyroid Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant / adverse effects. Chemotherapy, Adjuvant / methods. Drug Administration Schedule. Female. Follow-Up Studies. Humans. Infusions, Intravenous. Male. Middle Aged. Neoplasm Staging. Peripheral Nervous System Diseases / chemically induced. Survival Analysis. Time Factors. Tumor Burden / drug effects

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20025538.001).
  • [ISSN] 1557-9077
  • [Journal-full-title] Thyroid : official journal of the American Thyroid Association
  • [ISO-abbreviation] Thyroid
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


17. Heymann RS, Brent GA, Hershman JM: Anaplastic thyroid carcinoma with thyrotoxicosis and hypoparathyroidism. Endocr Pract; 2005 Jul-Aug;11(4):281-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic thyroid carcinoma with thyrotoxicosis and hypoparathyroidism.
  • OBJECTIVE: To describe a patient who presented with anaplastic thyroid carcinoma and thyrotoxicosis in whom hypoparathyroidism developed.
  • METHODS: We present the clinical and laboratory findings in a patient with anaplastic thyroid carcinoma and thyrotoxicosis.
  • We also review the literature for previous cases of anaplastic thyroid carcinoma with thyrotoxicosis.
  • Initial thyroid function tests revealed the following: thyrotropin (thyroid-stimulating hormone or TSH) 0.03 microIU/mL, free thyroxine 1.28 ng/dL, and total triiodothyronine 119 ng/dL.
  • A thyroid radioiodine uptake scan was 2.2% at 25 hours.
  • Pathology examination of the neck mass disclosed anaplastic thyroid carcinoma.
  • The thyroid carcinoma was treated palliatively with external beam irradiation.
  • At week 15, he died of complications attributable to anaplastic thyroid carcinoma.
  • CONCLUSION: Thyrotoxicosis due to thyroiditis is a rare initial manifestation of anaplastic thyroid carcinoma.
  • Hypoparathyroidism due to anaplastic thyroid carcinoma has not been reported previously.
  • [MeSH-major] Carcinoma / complications. Hypoparathyroidism / complications. Thyroid Neoplasms / complications. Thyrotoxicosis / complications
  • [MeSH-minor] Adrenergic beta-Antagonists / therapeutic use. Aged. Calcium Gluconate / therapeutic use. Fatal Outcome. Humans. Male

  • Genetic Alliance. consumer health - Hypoparathyroidism.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CALCIUM GLUCONATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16006301.001).
  • [ISSN] 1530-891X
  • [Journal-full-title] Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
  • [ISO-abbreviation] Endocr Pract
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adrenergic beta-Antagonists; SQE6VB453K / Calcium Gluconate
  •  go-up   go-down


18. Toler JD, Petschauer MA, Mihalik JP, Oyama S, Halverson SD, Guskiewicz KM: Comparison of 3 airway access techniques during suspected spine injury management in American football. Clin J Sport Med; 2010 Mar;20(2):92-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PARTICIPANTS: Eighteen certified athletic trainers (ATCs) and 18 noncertified students (NCSs).

  • MedlinePlus Health Information. consumer health - Respiratory Failure.
  • MedlinePlus Health Information. consumer health - Spine Injuries and Disorders.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. OXYGEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20215890.001).
  • [ISSN] 1536-3724
  • [Journal-full-title] Clinical journal of sport medicine : official journal of the Canadian Academy of Sport Medicine
  • [ISO-abbreviation] Clin J Sport Med
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] S88TT14065 / Oxygen
  •  go-up   go-down


19. Marlow LA, D'Innocenzi J, Zhang Y, Rohl SD, Cooper SJ, Sebo T, Grant C, McIver B, Kasperbauer JL, Wadsworth JT, Casler JD, Kennedy PW, Highsmith WE, Clark O, Milosevic D, Netzel B, Cradic K, Arora S, Beaudry C, Grebe SK, Silverberg ML, Azorsa DO, Smallridge RC, Copland JA: Detailed molecular fingerprinting of four new anaplastic thyroid carcinoma cell lines and their use for verification of RhoB as a molecular therapeutic target. J Clin Endocrinol Metab; 2010 Dec;95(12):5338-47
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detailed molecular fingerprinting of four new anaplastic thyroid carcinoma cell lines and their use for verification of RhoB as a molecular therapeutic target.
  • CONTEXT: Anaplastic thyroid carcinoma (ATC) is a highly aggressive carcinoma in need of therapeutic options.
  • Up to 42% of human thyroid cancer cell lines are redundant or not of correct tissue origin, and a comprehensive analysis is currently nonexistent.
  • Mechanistically, RhoB has been identified as a novel molecular target for ATC therapy.
  • OBJECTIVE: The aim was to develop four ATC cell lines detailing genetic, molecular, and phenotypic characteristics and to test five classes of drugs on the cell lines to determine whether they inhibited cell proliferation in a RhoB-dependent fashion.
  • DESIGN: Four cell lines were derived from ATC tumors.
  • Each proved unique regarding expression of thyroid markers, oncogene status, amplified and deleted genes, and proliferative growth rates.
  • CONCLUSIONS: Molecular descriptions of thyroid lines were matched to the originating tumors, setting a new standard for cell line characterization.
  • Furthermore, suppressed RhoB is implicated as a molecular target for therapy against ATC because five classes of drugs up-regulate RhoB and inhibit growth dose-responsively.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Cellosaurus - a cell line knowledge resource. culture/stock collections - Cell lines described in this publication .
  • Hazardous Substances Data Bank. DIMETHYL SULFOXIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Endocr Relat Cancer. 2005 Sep;12(3):615-29 [16172195.001]
  • [Cites] J Clin Endocrinol Metab. 2009 Dec;94(12):5001-9 [19850689.001]
  • [Cites] Thyroid. 2001 Aug;11(8):725-31 [11525264.001]
  • [Cites] Methods. 2001 Dec;25(4):402-8 [11846609.001]
  • [Cites] Nat Rev Cancer. 2001 Nov;1(2):162-8 [11905808.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Jul;88(7):3021-6 [12843138.001]
  • [Cites] Endocrinology. 2003 Sep;144(9):3852-9 [12933658.001]
  • [Cites] Cancer Res. 2004 May 15;64(10):3629-37 [15150122.001]
  • [Cites] Nat Rev Cancer. 2010 Jun;10(6):441-8 [20448633.001]
  • [Cites] Cancer Res. 2005 Nov 15;65(22):10199-207 [16288007.001]
  • [Cites] Cancer Chemother Pharmacol. 2006 Oct;58(4):460-70 [16435154.001]
  • [Cites] Cancer Cell. 2007 Feb;11(2):175-89 [17292828.001]
  • [Cites] J Clin Endocrinol Metab. 2008 Nov;93(11):4331-41 [18713817.001]
  • [Cites] Cancer Res. 2009 Feb 15;69(4):1536-44 [19208833.001]
  • [Cites] Endocr Relat Cancer. 2009 Mar;16(1):17-44 [18987168.001]
  • [Cites] Nat Rev Drug Discov. 2009 Jul;8(7):547-66 [19568282.001]
  • [ErratumIn] J Clin Endocrinol Metab. 2013 Oct;98(10):4213
  • [ErratumIn] J Clin Endocrinol Metab. 2013 Nov;98(11):4546
  • (PMID = 20810568.001).
  • [ISSN] 1945-7197
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA015083; United States / NCI NIH HHS / CA / R01 CA136665; United States / NCI NIH HHS / CA / P30CA15083; United States / NCI NIH HHS / CA / R01CA136665
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / DNA, Neoplasm; 0 / Genetic Markers; EC 3.6.5.2 / rhoB GTP-Binding Protein; YOW8V9698H / Dimethyl Sulfoxide
  • [Other-IDs] NLM/ PMC2999968
  •  go-up   go-down


20. Hendrickson CD, Hill K, Carpenter JE: Injuries to the head and face in women's collegiate field hockey. Clin J Sport Med; 2008 Sep;18(5):399-402
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • SETTING AND PARTICIPANTS: Certified athletic trainers and athletes at 6 Division I institutions.

  • MedlinePlus Health Information. consumer health - Facial Injuries and Disorders.
  • MedlinePlus Health Information. consumer health - Head Injuries.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18806546.001).
  • [ISSN] 1536-3724
  • [Journal-full-title] Clinical journal of sport medicine : official journal of the Canadian Academy of Sport Medicine
  • [ISO-abbreviation] Clin J Sport Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Bhatia A, Rao A, Ang KK, Garden AS, Morrison WH, Rosenthal DI, Evans DB, Clayman G, Sherman SI, Schwartz DL: Anaplastic thyroid cancer: Clinical outcomes with conformal radiotherapy. Head Neck; 2010 Jul;32(7):829-36
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic thyroid cancer: Clinical outcomes with conformal radiotherapy.
  • BACKGROUND: The aim of this study was to review institutional outcomes for anaplastic thyroid cancer treated with conformal 3-dimensional radiotherapy (3DRT) or intensity-modulated radiotherapy (IMRT).
  • Patients without distant metastases receiving >or=50 Gy had superior survival outcomes; 5 such patients had no evidence of disease at last follow-up.
  • CONCLUSIONS: Outcomes for anaplastic thyroid cancer treated with 3DRT or IMRT remain equivalent to historical results.
  • Healthy patients with localized disease who tolerate full dose irradiation can potentially enjoy prolonged survival.
  • [MeSH-major] Radiotherapy, Intensity-Modulated. Thyroid Neoplasms / mortality. Thyroid Neoplasms / radiotherapy


22. Kritsotakis EI, Assithianakis P, Kanellos P, Tzagarakis N, Ioannides MC, Gikas A: Surveillance of monthly antimicrobial consumption rates stratified by patient-care area: a tool for triggering and targeting antibiotic policy changes in the hospital. J Chemother; 2006 Aug;18(4):394-401
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Aggregate data were analyzed according to the ATC/DDD methodology.
  • Surveillance of antimicrobial consumption using the ATC/DDD system provided a clear picture of its profile.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17024795.001).
  • [ISSN] 1120-009X
  • [Journal-full-title] Journal of chemotherapy (Florence, Italy)
  • [ISO-abbreviation] J Chemother
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Anti-Infective Agents
  •  go-up   go-down


23. Pao-Chun L, Chan PM, Chan W, Manser E: Cytoplasmic ACK1 interaction with multiple receptor tyrosine kinases is mediated by Grb2: an analysis of ACK1 effects on Axl signaling. J Biol Chem; 2009 Dec 11;284(50):34954-63
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this study, we have identified additional receptor tyrosine kinases, including Axl, leukocyte tyrosine kinase, and anaplastic lymphoma kinase, that can bind to the ACK1/MIG6 homology region.
  • The ability of ACK1 to modulate Axl and perhaps anaplastic lymphoma kinase (altered in anaplastic large cell lymphomas) might explain why ACK1 can promote metastatic and transformed behavior in a number of cancers.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] FEBS Lett. 2005 Sep 12;579(22):5040-8 [16137687.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Nov 1;102(44):15901-6 [16247015.001]
  • [Cites] Cancer Res. 2005 Nov 15;65(22):10514-23 [16288044.001]
  • [Cites] Neoplasia. 2005 Dec;7(12):1058-64 [16354588.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jun 27;103(26):9796-801 [16777958.001]
  • [Cites] Cytokine Growth Factor Rev. 2006 Aug;17(4):295-304 [16737840.001]
  • [Cites] J Biol Chem. 2006 Dec 8;281(49):37527-35 [17038317.001]
  • [Cites] Mol Biol Cell. 2007 Mar;18(3):732-42 [17182860.001]
  • [Cites] J Biol Chem. 1999 Dec 10;274(50):35301-4 [10585393.001]
  • [Cites] Nat Cell Biol. 1999 Dec;1(8):507-13 [10587647.001]
  • [Cites] Mol Cell. 2000 Jul;6(1):65-75 [10949028.001]
  • [Cites] Mol Cell Biol. 2000 Oct;20(20):7735-50 [11003669.001]
  • [Cites] Exp Cell Res. 2000 Nov 25;261(1):1-12 [11082269.001]
  • [Cites] Mol Cell Biol. 2001 Feb;21(3):902-15 [11154277.001]
  • [Cites] J Biol Chem. 2001 May 25;276(21):18392-8 [11278436.001]
  • [Cites] Ann Oncol. 2001 Jun;12(6):819-24 [11484958.001]
  • [Cites] J Biol Chem. 2001 Aug 24;276(34):31738-44 [11425860.001]
  • [Cites] Mol Cell Biol. 2002 Jan;22(2):599-613 [11756555.001]
  • [Cites] Oncogene. 2002 Jan 17;21(3):329-36 [11821945.001]
  • [Cites] Clin Cancer Res. 2002 Feb;8(2):361-7 [11839650.001]
  • [Cites] Biol Chem. 2001 Dec;382(12):1649-62 [11843178.001]
  • [Cites] Nat Cell Biol. 2002 May;4(5):343-50 [11988737.001]
  • [Cites] Mol Biol Cell. 2003 Mar;14(3):858-70 [12631709.001]
  • [Cites] Oncogene. 2003 Jul 3;22(27):4221-34 [12833145.001]
  • [Cites] Nat Cell Biol. 2004 Feb;6(2):154-61 [14743221.001]
  • [Cites] Breast Cancer Res Treat. 2004 Mar;84(1):49-60 [14999154.001]
  • [Cites] J Biol Chem. 2004 May 28;279(22):22893-901 [15044442.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Jul 2;319(3):871-8 [15184064.001]
  • [Cites] Am J Physiol Heart Circ Physiol. 2004 Sep;287(3):H1207-13 [15130893.001]
  • [Cites] Nat Biotechnol. 2004 Sep;22(9):1139-45 [15314609.001]
  • [Cites] J Biol Chem. 2004 Oct 15;279(42):44039-45 [15308621.001]
  • [Cites] Proc Natl Acad Sci U S A. 1988 Mar;85(6):1952-6 [3279421.001]
  • [Cites] Nature. 1988 Jun 16;333(6174):672-6 [2836739.001]
  • [Cites] Cell. 1988 Sep 9;54(6):787-93 [3409319.001]
  • [Cites] Oncogene Res. 1990;5(3):199-204 [2320375.001]
  • [Cites] Nature. 1993 May 6;363(6424):88-92 [8386805.001]
  • [Cites] Cell. 1993 May 7;73(3):611-20 [8490966.001]
  • [Cites] Science. 1993 May 28;260(5112):1338-43 [8493579.001]
  • [Cites] Nature. 1993 May 27;363(6427):364-7 [8497321.001]
  • [Cites] Mol Cell Biol. 1993 Aug;13(8):4976-85 [8336730.001]
  • [Cites] Mol Cell Biol. 1994 Jan;14(1):509-17 [8264620.001]
  • [Cites] Science. 1994 Mar 4;263(5151):1281-4 [8122112.001]
  • [Cites] Melanoma Res. 1994 Oct;4(5):313-9 [7858416.001]
  • [Cites] Int J Cancer. 1995 Mar 16;60(6):791-7 [7896447.001]
  • [Cites] Nature. 1995 Aug 31;376(6543):737-45 [7544443.001]
  • [Cites] Blood. 1995 Sep 1;86(5):1954-60 [7655022.001]
  • [Cites] Mol Cell Biol. 1996 Jan;16(1):135-45 [8524290.001]
  • [Cites] Oncogene. 1996 Feb 15;12(4):903-13 [8632913.001]
  • [Cites] Leukemia. 1996 May;10(5):781-7 [8656672.001]
  • [Cites] FEBS Lett. 1996 May 20;386(2-3):230-4 [8647288.001]
  • [Cites] Nature. 2007 Nov 29;450(7170):741-4 [18046415.001]
  • [Cites] Exp Cell Res. 2008 Apr 1;314(6):1292-300 [18262180.001]
  • [Cites] Breast Cancer Res. 2008;10(2):R36 [18435854.001]
  • [Cites] Exp Cell Res. 2008 Oct 15;314(17):3093-106 [18793634.001]
  • [Cites] J Biol Chem. 2009 Mar 20;284(12):8185-94 [19144635.001]
  • [Cites] Mol Oncol. 2009 Aug;3(4):297-307 [19615955.001]
  • [Cites] J Biol Chem. 1996 Aug 2;271(31):18355-62 [8702477.001]
  • [Cites] Science. 1996 Dec 20;274(5295):2086-9 [8953040.001]
  • [Cites] Oncogene. 1997 Jan 30;14(4):439-49 [9053841.001]
  • [Cites] Mol Cell Biol. 1997 Aug;17(8):4442-53 [9234702.001]
  • [Cites] J Biol Chem. 1999 Mar 26;274(13):8524-30 [10085085.001]
  • [Cites] Cancer Detect Prev. 1999;23(4):325-32 [10403904.001]
  • [Cites] Thyroid. 1999 Jun;9(6):563-7 [10411118.001]
  • [Cites] Clin Cancer Res. 1999 Jul;5(7):1745-51 [10430078.001]
  • [Cites] Oncogene. 1999 Jul 22;18(29):4224-36 [10435635.001]
  • [Cites] Int J Cancer. 1999 Nov 26;83(5):579-84 [10521789.001]
  • [Cites] J Cell Physiol. 2005 Jul;204(1):36-44 [15605394.001]
  • (PMID = 19815557.001).
  • [ISSN] 1083-351X
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / GRB2 Adaptor Protein; 0 / Intercellular Signaling Peptides and Proteins; 0 / Oncogene Proteins; 0 / Proto-Oncogene Proteins; 0 / Recombinant Fusion Proteins; 0 / growth arrest-specific protein 6; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.1 / axl receptor tyrosine kinase; EC 2.7.10.2 / TNK2 protein, human
  • [Other-IDs] NLM/ PMC2787358
  •  go-up   go-down


24. Lombardi MA, Hanson DW: The GOES Time Code Service, 1974-2004: A Retrospective. J Res Natl Inst Stand Technol; 2005;110(2):79-96
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • NIST ended its Geostationary Operational Environmental Satellites (GOES) time code service at 0 hours, 0 minutes Coordinated Universal Time (UTC) on January 1, 2005.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27308105.001).
  • [ISSN] 1044-677X
  • [Journal-full-title] Journal of research of the National Institute of Standards and Technology
  • [ISO-abbreviation] J Res Natl Inst Stand Technol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC4847573
  • [Keywords] NOTNLM ; Coordinated Universal Time (UTC) / broadcasting / orbit prediction / satellites / timekeeping
  •  go-up   go-down


25. Di Nocera F, Fabrizi R, Terenzi M, Ferlazzo F: Procedural errors in air traffic control: effects of traffic density, expertise, and automation. Aviat Space Environ Med; 2006 Jun;77(6):639-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The present study had two goals: first, to verify the occurrence of post-completion errors in air traffic control (ATC) tasks; and second, to assess effects on performance of medium term conflict detection (MTCD) tools.
  • METHODS: There were 18 military controllers who performed a simulated ATC task with and without automation support (MTCD vs. manual) in high and low air traffic density conditions.
  • During the task, which consisted of managing several simulated flights in an enroute ATC scenario, a trace suddenly disappeared "after" the operator took the aircraft in charge, "during" the management of the trace, or "before" the pilot's first contact.
  • DISCUSSION: Procedural errors can happen in ATC, but automation can mitigate this effect.
  • Lack of benefits for the "before" fault type may be due to the fact that operators extend their reliance to a part of the task that is unsupported by the automated system.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16780243.001).
  • [ISSN] 0095-6562
  • [Journal-full-title] Aviation, space, and environmental medicine
  • [ISO-abbreviation] Aviat Space Environ Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Hamada J, Tamai K, Ono W, Saotome K: Uremic tumoral calcinosis in hemodialysis patients: clinicopathological findings and identification of calcific deposits. J Rheumatol; 2006 Jan;33(1):119-26
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Periarticular massive calcifications, referred to as uremic tumoral calcinosis (UTC), represent solitary or multifocal calcium phosphate deposits.
  • Our objectives were to clinically analyze a series of 8 patients with UTC undergoing hemodialysis, and to characterize calcium deposits in UTC.
  • METHODS: The clinical, radiological, and pathological features of 8 consecutive patients (4 men and 4 women, mean age 49 yrs) with UTC were analyzed, and treatment and outcome were evaluated.
  • RESULTS: Unifocal UTC was observed in 5 patients, whereas multifocal lesions occurred in 3 patients.
  • The most common sites of UTC were the shoulders, elbows, and hands.
  • Medical intervention to decrease the Ca P product achieved complete remission in 3 of 5 patients with solitary UTC, whereas this treatment was ineffective for multiple UTC.
  • CONCLUSION: The most important pathogenic factors in UTC are an increased Ca P product and hyperphosphoremia, which is not necessarily related to hyperparathyroidism.
  • Medical intervention is effective for solitary UTC, but combined treatment (surgery and medical therapy) is required for multiple UTC.
  • Calcium deposits in UTC are composed of carbonate apatite.

  • MedlinePlus Health Information. consumer health - Dialysis.
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • Hazardous Substances Data Bank. PHOSPHORUS, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16395759.001).
  • [ISSN] 0315-162X
  • [Journal-full-title] The Journal of rheumatology
  • [ISO-abbreviation] J. Rheumatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Apatites; 0 / Calcium Phosphates; 0 / Parathyroid Hormone; 27YLU75U4W / Phosphorus; 55326-60-8 / carboapatite; 97Z1WI3NDX / calcium phosphate; SY7Q814VUP / Calcium
  •  go-up   go-down


27. Waryasz GR, McDermott AY: Patellofemoral pain syndrome (PFPS): a systematic review of anatomy and potential risk factors. Dyn Med; 2008;7:9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Applying preventive medicine strategies, the majority of cases of PFPS may be avoided if a pre-diagnosis can be made by clinician or certified athletic trainer testing the current researched potential risk factors during a Preparticipation Screening Evaluation (PPSE).
  • We provide a detailed and comprehensive review of the soft tissue, arterial system, and innervation to the patellofemoral joint in order to supply the clinician with the knowledge required to assess the anatomy and make recommendations to patients identified as potentially at risk.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Phys Med Rehabil. 2006 Nov;87(11):1428-35 [17084115.001]
  • [Cites] Clin Orthop Relat Res. 2006 Oct;451:223-8 [16788411.001]
  • [Cites] J Orthop Sports Phys Ther. 2005 Dec;35(12):793-801 [16848100.001]
  • [Cites] Am J Sports Med. 2006 Apr;34(4):630-6 [16365375.001]
  • [Cites] Am J Phys Med Rehabil. 2006 Mar;85(3):234-43 [16505640.001]
  • [Cites] J Electromyogr Kinesiol. 2006 Apr;16(2):167-74 [16102978.001]
  • [Cites] Clin J Pain. 2006 Feb;22(2):154-9 [16428949.001]
  • [Cites] J Bone Joint Surg Br. 2005 Nov;87(11):1498-501 [16260666.001]
  • [Cites] Med Sci Sports Exerc. 2005 Nov;37(11):1924-30 [16286863.001]
  • [Cites] Surg Radiol Anat. 2005 Nov;27(4):331-5 [16172870.001]
  • [Cites] Phys Ther. 2005 Nov;85(11):1201-7 [16253048.001]
  • [Cites] J Electromyogr Kinesiol. 2005 Dec;15(6):596-603 [15878289.001]
  • [Cites] Knee. 2005 Oct;12(5):362-5 [16146626.001]
  • [Cites] Clin Orthop Relat Res. 2005 Jul;(436):55-9 [15995420.001]
  • [Cites] Knee Surg Sports Traumatol Arthrosc. 2005 Mar;13(2):131-4 [15756617.001]
  • [Cites] Knee Surg Sports Traumatol Arthrosc. 2005 Mar;13(2):122-30 [15703965.001]
  • [Cites] Am J Sports Med. 2000 Sep-Oct;28(5):659-62 [11032220.001]
  • [Cites] Am J Sports Med. 2007 Oct;35(10):1668-73 [17567822.001]
  • [Cites] Med Sci Sports Exerc. 2007 Aug;39(8):1227-32 [17762354.001]
  • [Cites] Med Sci Sports Exerc. 2007 Jul;39(7):1153-9 [17596784.001]
  • [Cites] J Strength Cond Res. 2007 May;21(2):632-4 [17530958.001]
  • [Cites] Sports Med Arthrosc. 2007 Jun;15(2):95-104 [17505325.001]
  • [Cites] Br J Sports Med. 1998 Mar;32(1):68-70 [9562169.001]
  • [Cites] J Orthop Sports Phys Ther. 1993 Jan;17(1):11-6 [8467330.001]
  • [Cites] Arthroscopy. 1990;6(4):254-63 [1702291.001]
  • [Cites] Med Sci Sports Exerc. 1991 Sep;23(9):1008-15 [1943620.001]
  • [Cites] J Pediatr Orthop. 1991 Jan-Feb;11(1):77-82 [1988483.001]
  • [Cites] Clin Orthop Relat Res. 1989 Sep;(246):234-7 [2766612.001]
  • [Cites] Clin Orthop Relat Res. 1986 Jul;(208):119-25 [3522019.001]
  • [Cites] J Bone Joint Surg Br. 1984 Nov;66(5):685-93 [6501361.001]
  • [Cites] Am J Sports Med. 1987 Sep-Oct;15(5):490-3 [3674273.001]
  • [Cites] Am J Sports Med. 1987 Jan-Feb;15(1):79-85 [3812865.001]
  • [Cites] Med Sci Sports Exerc. 1986 Oct;18(5):526-30 [3773669.001]
  • [Cites] Clin Orthop Relat Res. 1986 Mar;(204):286-93 [3956015.001]
  • [Cites] Arch Phys Med Rehabil. 1985 Sep;66(9):620-5 [4038029.001]
  • [Cites] Phys Ther. 1990 Sep;70(9):561-5 [2392485.001]
  • [Cites] Clin Orthop Relat Res. 1983 Jun;(176):217-24 [6851329.001]
  • [Cites] Am J Sports Med. 1982 May-Jun;10(3):147-9 [7114350.001]
  • [Cites] Clin Orthop Relat Res. 1982 Sep;(169):186-9 [7105577.001]
  • [Cites] Am J Sports Med. 1982 Jan-Feb;10(1):12-5 [7053631.001]
  • [Cites] Clin Orthop Relat Res. 1980 Nov-Dec;(153):183-8 [7449213.001]
  • [Cites] Am J Sports Med. 1976 Nov-Dec;4(6):241-8 [12667.001]
  • [Cites] Am J Sports Med. 1979 Jan-Feb;7(1):5-11 [420389.001]
  • [Cites] Ann Rheum Dis. 1973 Sep;32(5):413-8 [4751776.001]
  • [Cites] Br J Sports Med. 2004 Oct;38(5):576-80 [15388542.001]
  • [Cites] Am J Sports Med. 2004 Jul-Aug;32(5):1122-30 [15262632.001]
  • [Cites] J Electromyogr Kinesiol. 2004 Aug;14(4):495-504 [15165599.001]
  • [Cites] J Orthop Res. 2004 Mar;22(2):267-74 [15013084.001]
  • [Cites] Dev Med Child Neurol. 2003 Nov;45(11):763-8 [14580132.001]
  • [Cites] J Orthop Sports Phys Ther. 2003 Nov;33(11):671-6 [14669962.001]
  • [Cites] Am J Sports Med. 2000 Jul-Aug;28(4):480-9 [10921638.001]
  • [Cites] Clin J Sport Med. 2000 Jan;10(1):22-8 [10695846.001]
  • [Cites] Br J Rheumatol. 1997 Dec;36(12):1324-7 [9448595.001]
  • [Cites] J Biomech. 1997 Jul;30(7):723-8 [9239552.001]
  • [Cites] Scand J Med Sci Sports. 1996 Aug;6(4):233-41 [8896097.001]
  • [Cites] Scand J Med Sci Sports. 1995 Aug;5(4):237-44 [7552769.001]
  • [Cites] Scand J Med Sci Sports. 1995 Aug;5(4):245-51 [7552770.001]
  • [Cites] J Orthop Sports Phys Ther. 1995 Jul;22(1):18-21 [7550298.001]
  • [Cites] Mil Med. 1994 Jun;159(6):421-6 [7984296.001]
  • [Cites] J Orthop Sports Phys Ther. 1993 Mar;17(3):144-8 [8472078.001]
  • [Cites] J Orthop Res. 2005 Mar;23(2):351-8 [15734248.001]
  • [Cites] Med Sci Sports Exerc. 2005 Feb;37(2):176-83 [15692311.001]
  • [Cites] Am J Sports Med. 1999 Jan-Feb;27(1):50-3 [9934418.001]
  • [Cites] J Bone Joint Surg Am. 1999 Mar;81(3):355-63 [10199273.001]
  • [Cites] Arthroscopy. 1998 May-Jun;14(4):347-59 [9620645.001]
  • [Cites] Med Sci Sports Exerc. 1998 Apr;30(4):556-69 [9565938.001]
  • [Cites] Med Sci Sports Exerc. 2000 Nov;32(11):1825-32 [11079510.001]
  • [Cites] Am J Sports Med. 2000;28(5 Suppl):S69-74 [11032110.001]
  • [Cites] J Orthop Sports Phys Ther. 2003 Nov;33(11):677-85 [14669963.001]
  • [Cites] Am J Sports Med. 2002 Nov-Dec;30(6):857-65 [12435653.001]
  • [Cites] Arch Phys Med Rehabil. 2002 Jul;83(7):989-95 [12098160.001]
  • [Cites] Am J Sports Med. 2002 May-Jun;30(3):447-56 [12016090.001]
  • [Cites] Arthritis Rheum. 2001 Sep;44(9):2138-45 [11592379.001]
  • [Cites] J Orthop Res. 2001 Sep;19(5):834-40 [11562129.001]
  • [Cites] Am J Sports Med. 2001 Jul-Aug;29(4):480-7 [11476390.001]
  • [Cites] Scand J Med Sci Sports. 2001 Apr;11(2):64-80 [11252464.001]
  • [Cites] Arch Phys Med Rehabil. 2001 Feb;82(2):183-9 [11239308.001]
  • [Cites] Sports Med Arthrosc. 2007 Jun;15(2):48-56 [17505317.001]
  • [Cites] Am J Sports Med. 2007 Mar;35(3):484-92 [17303819.001]
  • [Cites] Am Fam Physician. 2007 Jan 15;75(2):194-202 [17263214.001]
  • [Cites] Am J Sports Med. 2007 Feb;35(2):307-11 [17204587.001]
  • (PMID = 18582383.001).
  • [ISSN] 1476-5918
  • [Journal-full-title] Dynamic medicine : DM
  • [ISO-abbreviation] Dyn Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2443365
  •  go-up   go-down


28. Shahi N, Abdelhamid MF, Jindall M, Awad RW: Riedel's thyroiditis masquerading as anaplastic thyroid carcinoma: a case report. J Med Case Rep; 2010;4:15
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Riedel's thyroiditis masquerading as anaplastic thyroid carcinoma: a case report.
  • INTRODUCTION: Riedel's thyroiditis is a rare thyroid disease characterized by dense fibrous tissues that replace the thyroid gland and invade the adjacent structures that can mimic thyroid malignancy.
  • CASE PRESENTATION: We present a case of a 59-year-old African-Caribbean man who presented with a rapidly growing hard neck mass, a hoarse voice, dysphagia and breathing difficulty that clinically suggested thyroid malignancy.
  • CONCLUSION: It is important for clinicians to be aware of this diagnosis when managing patients with thyroid disease, because Riedel's thyroiditis can mimic malignancy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Otolaryngol Head Neck Surg. 1991 Feb;117(2):214-7 [1991068.001]
  • [Cites] Am J Clin Pathol. 1988 Dec;90(6):715-22 [3057862.001]
  • [Cites] Mayo Clin Proc. 1985 Dec;60(12):836-43 [3906289.001]
  • [Cites] Croat Med J. 2003 Apr;44(2):239-41 [12698518.001]
  • [Cites] Ann Intern Med. 1967 May;66(5):884-92 [6025229.001]
  • [Cites] Int J Clin Pract. 2004 Mar;58(3):312-5 [15117103.001]
  • [Cites] Br J Surg. 1976 Dec;63(12):929-31 [1009341.001]
  • (PMID = 20157436.001).
  • [ISSN] 1752-1947
  • [Journal-full-title] Journal of medical case reports
  • [ISO-abbreviation] J Med Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2821392
  •  go-up   go-down


29. Guilmette TJ, Malia LA, McQuiggan MD: Concussion understanding and management among New England high school football coaches. Brain Inj; 2007 Sep;21(10):1039-47
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PRIMARY OBJECTIVE: To determine high school football coaches' understanding, management and sources of information of concussion at schools without a certified athletic trainer (ATC) or without one at practice.
  • One hundred and nine (43%) surveys were returned, of which 62 respondents indicated there was no ATC either at the school or at practice.
  • [MeSH-minor] Athletic Injuries / diagnosis. Athletic Injuries / psychology. Humans. New England. Schools

  • MedlinePlus Health Information. consumer health - Concussion.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17891566.001).
  • [ISSN] 0269-9052
  • [Journal-full-title] Brain injury
  • [ISO-abbreviation] Brain Inj
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


30. Nielsen MW, Gundgaard J, Hansen EH, Rasmussen NK: Use of six main drug therapeutic groups across educational groups: self-reported survey and prescription records. J Clin Pharm Ther; 2005 Jun;30(3):259-69
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of six main drug therapeutic groups across educational groups: self-reported survey and prescription records.
  • OBJECTIVES: To assess whether the use of six main therapeutic groups was congruent with the occurrence of related diseases across educational groups.
  • The use of six therapeutic main groups (ATC groups A, B, C, M, N and R) and related diseases in educational groups was analysed by indirect standardization.
  • RESULTS: In general, respondents in the two least educated groups used medicines more frequently and a higher proportion of them reported the related disease than could be expected from indirect standardization.
  • CONCLUSION: The results show the uneven distribution of disease in the general population.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15896244.001).
  • [ISSN] 0269-4727
  • [Journal-full-title] Journal of clinical pharmacy and therapeutics
  • [ISO-abbreviation] J Clin Pharm Ther
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


31. Ulisse S, Delcros JG, Baldini E, Toller M, Curcio F, Giacomelli L, Prigent C, Ambesi-Impiombato FS, D'Armiento M, Arlot-Bonnemains Y: Expression of Aurora kinases in human thyroid carcinoma cell lines and tissues. Int J Cancer; 2006 Jul 15;119(2):275-82
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of Aurora kinases in human thyroid carcinoma cell lines and tissues.
  • An increase in the protein level of the 3 kinases was found, with respect to normal human thyrocytes (HTU5), in the human cell lines derived from follicular (FTC-133), papillary (B-CPAP) and anaplastic (8305C) thyroid carcinomas, but not in cells derived from a follicular adenoma (HTU42).
  • The expression at the protein level of all 3 Aurora kinases was significantly higher in 3 thyroid papillary carcinomas with respect to normal matched tissues obtained from the same patients.
  • Similar modifications, at the mRNA level, could be observed in 7 papillary carcinoma tissues for Aurora-A and B, but not for Aurora-C.
  • In conclusion, we demonstrated that normal human thyrocytes express all 3 members of the Aurora kinase family, and their expression is amplified in malignant thyroid cell lines and tissues.
  • These results suggest that the Aurora kinases may play a relevant role in malignant thyroid cancers, and may represent a putative therapeutic target for thyroid neoplasms.
  • [MeSH-major] Carcinoma / enzymology. Protein-Serine-Threonine Kinases / analysis. Thyroid Gland / enzymology. Thyroid Neoplasms / enzymology
  • [MeSH-minor] Adenocarcinoma, Follicular / enzymology. Aurora Kinase C. Aurora Kinases. Carcinoma, Papillary / enzymology. Cell Cycle. Cell Line, Tumor / enzymology. Cell Transformation, Neoplastic. Gene Expression Regulation, Enzymologic. Gene Expression Regulation, Neoplastic. Humans. RNA, Messenger / analysis. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2006 Wiley-Liss, Inc.
  • (PMID = 16477625.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger; EC 2.7.11.1 / AURKC protein, human; EC 2.7.11.1 / Aurora Kinase C; EC 2.7.11.1 / Aurora Kinases; EC 2.7.11.1 / Protein-Serine-Threonine Kinases
  •  go-up   go-down


32. Lu CL, Wang YC, Chen JY, Lai IC, Liou YJ: Support for the involvement of the ERBB4 gene in schizophrenia: a genetic association analysis. Neurosci Lett; 2010 Sep 6;481(2):120-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Furthermore, the frequency of haplotype ATC of rs3791709-rs2289086-rs3748962 was found to be significantly higher in the patients with schizophrenia than in the controls (case vs. control=36.0% vs. 24.4%, permutation p-value=0.0002).
  • [MeSH-major] Genetic Predisposition to Disease. Polymorphism, Single Nucleotide / genetics. Receptor, Epidermal Growth Factor / genetics. Schizophrenia / genetics

  • Genetic Alliance. consumer health - Schizophrenia.
  • MedlinePlus Health Information. consumer health - Schizophrenia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 20600594.001).
  • [ISSN] 1872-7972
  • [Journal-full-title] Neuroscience letters
  • [ISO-abbreviation] Neurosci. Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] EC 2.7.10.1 / ERBB4 protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.1 / Receptor, ErbB-4
  •  go-up   go-down


33. Mineva I, Gartner W, Hauser P, Kainz A, Löffler M, Wolf G, Oberbauer R, Weissel M, Wagner L: Differential expression of alphaB-crystallin and Hsp27-1 in anaplastic thyroid carcinomas because of tumor-specific alphaB-crystallin gene (CRYAB) silencing. Cell Stress Chaperones; 2005;10(3):171-84
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential expression of alphaB-crystallin and Hsp27-1 in anaplastic thyroid carcinomas because of tumor-specific alphaB-crystallin gene (CRYAB) silencing.
  • Expression of the small heat shock protein alphaB-crystallin in differentiated thyroid tumors has been described recently.
  • In this study, we investigated the molecular mechanisms that affect the expression of alphaB-crystallin in benign goiters (n = 7) and highly malignant anaplastic thyroid carcinomas (ATCs) (n = 3).
  • Immunoblot and quantitative real-time (RT) polymerase chain reaction revealed marked downregulation of alphaB-crystallin in all the tested ATCs and the ATC-derived cell line C-643 .
  • In contrast, considerable expression of Hsp27-1 in benign and malignant thyroid tissue was demonstrated.
  • In conclusion, we demonstrate downregulation of alphaB-crystallin expression in highly dedifferentiated ATCs because of a tumor-specific transcription factor pattern.
  • [MeSH-major] Carcinoma / genetics. Gene Expression Regulation, Neoplastic. Intermediate Filament Proteins / genetics. Nerve Tissue Proteins / genetics. Protein Kinases / genetics. Repressor Proteins / genetics. Thyroid Neoplasms / genetics. Transcription Factors / genetics

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Antioxid Redox Signal. 2005 Mar-Apr;7(3-4):404-13 [15706087.001]
  • [Cites] J Physiol. 2005 May 1;564(Pt 3):715-22 [15718262.001]
  • [Cites] EMBO J. 1996 Jun 3;15(11):2695-706 [8654367.001]
  • [Cites] Eur J Biochem. 1996 Nov 15;242(1):56-66 [8954153.001]
  • [Cites] J Biol Chem. 2000 Jan 28;275(4):2852-8 [10644752.001]
  • [Cites] Nature. 2000 Aug 17;406(6797):747-52 [10963602.001]
  • [Cites] Nucleic Acids Res. 2001 Jan 1;29(1):152-5 [11125075.001]
  • [Cites] J Biol Chem. 2001 May 11;276(19):16059-63 [11274139.001]
  • [Cites] J Biol Chem. 2001 Feb 2;276(5):3324-32 [11073954.001]
  • [Cites] Biochim Biophys Acta. 2001 Jul 30;1520(1):1-6 [11470154.001]
  • [Cites] Biochem Biophys Res Commun. 2001 Aug 24;286(3):433-42 [11511077.001]
  • [Cites] J Biol Chem. 2002 Oct 11;277(41):38731-6 [12140279.001]
  • [Cites] Exp Eye Res. 2003 Feb;76(2):145-53 [12565801.001]
  • [Cites] Circ Res. 2003 Feb 7;92(2):130-2 [12574138.001]
  • [Cites] Thyroid. 2003 Mar;13(3):283-90 [12729478.001]
  • [Cites] Cell Stress Chaperones. 2003 Spring;8(1):53-61 [12820654.001]
  • [Cites] Head Neck. 2003 Aug;25(8):662-70 [12884350.001]
  • [Cites] Surg Oncol. 2003 Aug;12(2):69-90 [12946479.001]
  • [Cites] Cell Cycle. 2003 Nov-Dec;2(6):579-84 [14512773.001]
  • [Cites] N Engl J Med. 2003 Nov 20;349(21):2042-54 [14627790.001]
  • [Cites] Endocr Relat Cancer. 2004 Jun;11(2):377-89 [15163312.001]
  • [Cites] Cancer. 2004 Jun 15;100(12):2543-8 [15197794.001]
  • [Cites] Nucleic Acids Res. 1986 May 27;14(10):4127-45 [3714473.001]
  • [Cites] Proc Natl Acad Sci U S A. 1988 Dec;85(23):9302-6 [2848260.001]
  • [Cites] Mol Cell Biol. 1989 Mar;9(3):1083-91 [2725488.001]
  • [Cites] J Histochem Cytochem. 1990 Jan;38(1):31-9 [2294148.001]
  • [Cites] Genomics. 1990 Aug;7(4):594-601 [2387586.001]
  • [Cites] Exp Eye Res. 1992 Mar;54(3):461-70 [1381680.001]
  • [Cites] J Cell Biol. 1993 Feb;120(3):639-45 [8425893.001]
  • [Cites] Eur J Biochem. 1994 Oct 1;225(1):1-19 [7925426.001]
  • [Cites] J Pathol. 1994 Nov;174(3):209-15 [7823254.001]
  • [Cites] Hum Genet. 1996 Mar;97(3):299-303 [8786068.001]
  • [Cites] Cancer. 1995 Nov 1;76(9):1643-54 [8635070.001]
  • [Cites] Biochem Biophys Res Commun. 1997 Jun 9;235(1):69-73 [9196037.001]
  • [Cites] J Cell Sci. 1997 Jul;110 ( Pt 13):1431-40 [9224761.001]
  • [Cites] Am J Physiol. 1998 May;274(5 Pt 2):H1457-64 [9612350.001]
  • [Cites] Genes Cells. 1998 Jul;3(7):443-57 [9753426.001]
  • [Cites] Am J Physiol. 1998 Dec;275(6 Pt 2):H2243-9 [9843825.001]
  • [Cites] Invest Ophthalmol Vis Sci. 1999 Apr;40(5):951-8 [10102292.001]
  • [Cites] Prog Retin Eye Res. 1999 Jul;18(4):463-509 [10217480.001]
  • [Cites] Reproduction. 2005 Jan;129(1):115-26 [15615903.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2005 Mar;46(3):1092-8 [15728570.001]
  • [Cites] Proteomics. 2005 Feb;5(3):788-95 [15682460.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2005 Mar;46(3):1085-91 [15728569.001]
  • (PMID = 16184762.001).
  • [ISSN] 1355-8145
  • [Journal-full-title] Cell stress & chaperones
  • [ISO-abbreviation] Cell Stress Chaperones
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CRYAB protein, human; 0 / DNA, Complementary; 0 / HSP27 Heat-Shock Proteins; 0 / HSPB1 protein, human; 0 / Heat-Shock Proteins; 0 / Intermediate Filament Proteins; 0 / Neoplasm Proteins; 0 / Nerve Tissue Proteins; 0 / RNA, Messenger; 0 / Repressor Proteins; 0 / TFCP2L1 protein, human; 0 / Tissue Extracts; 0 / Transcription Factors; 0 / alpha-Crystallin B Chain; EC 1.13.12.- / Luciferases; EC 2.7.- / Protein Kinases
  • [Other-IDs] NLM/ PMC1226015
  •  go-up   go-down


34. Marlow LA, Reynolds LA, Cleland AS, Cooper SJ, Gumz ML, Kurakata S, Fujiwara K, Zhang Y, Sebo T, Grant C, McIver B, Wadsworth JT, Radisky DC, Smallridge RC, Copland JA: Reactivation of suppressed RhoB is a critical step for the inhibition of anaplastic thyroid cancer growth. Cancer Res; 2009 Feb 15;69(4):1536-44
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reactivation of suppressed RhoB is a critical step for the inhibition of anaplastic thyroid cancer growth.
  • Anaplastic thyroid carcinoma (ATC) is a highly aggressive form of the disease for which new therapeutic options are desperately needed.
  • Previously, we showed that the high-affinity peroxisome proliferator-activated receptor gamma (PPARgamma) agonist, RS5444, inhibits cell proliferation of ATC cells via induction of the cyclin-dependent kinase inhibitor p21(WAF1/CIP1) (p21).
  • Using multiple independently derived ATC cell lines, we found that treatment with RS5444 leads to the up-regulation of RhoB and subsequent activation of p21, and that silencing of RhoB by RNAi blocks the ability of RS5444 to induce p21 and to inhibit cell proliferation.
  • We further implicate RhoB as a key signaling effector for the growth inhibition of ATC, as treatment with a histone deacetylase inhibitor shown to increase RhoB expression in lung cancer cells caused the up-regulation of RhoB in ATC cells accompanied by increased expression of p21 and inhibition of cell proliferation; this effect occurred even in ATC cells that were unresponsive to RS5444 due to a lack of expression of PPARgamma.
  • Our results implicate RhoB as a novel intermediate in critical signaling pathways and as an additional target for therapeutic intervention in ATC.

  • Genetic Alliance. consumer health - Thyroid cancer, anaplastic.
  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 1999 Nov 1;59(21):5492-6 [10554025.001]
  • [Cites] Endocr Relat Cancer. 2009 Mar;16(1):17-44 [18987168.001]
  • [Cites] J Biol Chem. 2000 Jun 16;275(24):17974-8 [10770919.001]
  • [Cites] Int J Oncol. 2000 Dec;17(6):1157-64 [11078801.001]
  • [Cites] Semin Cancer Biol. 2000 Dec;10(6):443-52 [11170866.001]
  • [Cites] J Mol Med (Berl). 2001;79(1):30-47 [11327101.001]
  • [Cites] Hepatology. 2001 May;33(5):1087-97 [11343236.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 May 22;98(11):6192-7 [11353846.001]
  • [Cites] Methods. 2001 Dec;25(4):402-8 [11846609.001]
  • [Cites] Nat Rev Cancer. 2001 Nov;1(2):162-8 [11905808.001]
  • [Cites] Clin Exp Metastasis. 2002;19(1):9-15 [11918088.001]
  • [Cites] Clin Cancer Res. 2002 Jul;8(7):2225-32 [12114424.001]
  • [Cites] Mol Cancer Ther. 2001 Dec;1(2):141-9 [12467231.001]
  • [Cites] Clin Cancer Res. 2003 Jan;9(1):1-9 [12538445.001]
  • [Cites] Cell Cycle. 2002 Nov-Dec;1(6):430-7 [12548020.001]
  • [Cites] Endocrinology. 2003 Sep;144(9):3852-9 [12933658.001]
  • [Cites] Oncogene. 2003 Sep 18;22(40):6204-13 [13679859.001]
  • [Cites] Oncogene. 2004 Feb 5;23(5):1136-45 [14647415.001]
  • [Cites] J Cell Sci. 2004 Mar 15;117(Pt 8):1301-12 [15020670.001]
  • [Cites] Clin Cancer Res. 2004 Apr 15;10(8):2742-50 [15102679.001]
  • [Cites] Endocrinology. 2004 Jun;145(6):2865-75 [14976143.001]
  • [Cites] Mol Cell Biol. 2004 Jun;24(12):5565-76 [15169915.001]
  • [Cites] J Clin Invest. 1993 Jan;91(1):179-84 [8423216.001]
  • [Cites] Mol Cell Biol. 1995 Nov;15(11):6443-53 [7565796.001]
  • [Cites] Mol Cell Biol. 1998 Aug;18(8):4689-97 [9671479.001]
  • [Cites] Mol Cell. 1999 Jun;3(6):799-804 [10394368.001]
  • [Cites] Endocrinology. 2004 Dec;145(12):5774-85 [15345676.001]
  • [Cites] Cancer Res. 2004 Nov 15;64(22):8389-96 [15548709.001]
  • [Cites] Oncogene. 2005 Jan 13;24(3):502-11 [15543229.001]
  • [Cites] J Biol Chem. 2005 May 13;280(19):19243-9 [15713677.001]
  • [Cites] Clin Cancer Res. 2005 May 15;11(10):3958-65 [15897598.001]
  • [Cites] Histol Histopathol. 2006 Feb;21(2):213-8 [16329046.001]
  • [Cites] Oncogene. 2006 Apr 13;25(16):2304-17 [16331265.001]
  • [Cites] Oncogene. 2006 May 4;25(19):2736-47 [16314832.001]
  • [Cites] Mol Cell Endocrinol. 2006 Jun 7;251(1-2):17-32 [16574311.001]
  • [Cites] J Cell Biochem. 2006 Jul 1;98(4):1021-35 [16795079.001]
  • [Cites] Cancer Chemother Pharmacol. 2006 Oct;58(4):460-70 [16435154.001]
  • [Cites] Endocrinology. 2006 Sep;147(9):4463-75 [16777971.001]
  • [Cites] Thyroid. 2006 Dec;16(12):1293-302 [17199440.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • [Cites] J Cell Physiol. 2007 Jul;212(1):1-12 [17443682.001]
  • [Cites] J Biol Chem. 2007 Aug 10;282(32):23387-401 [17565986.001]
  • [Cites] BMC Cancer. 2007;7:220 [18047684.001]
  • [Cites] Annu Rev Biochem. 2008;77:289-312 [18518822.001]
  • [Cites] Cancer Gene Ther. 2008 Jul;15(7):456-64 [18340357.001]
  • [Cites] J Clin Endocrinol Metab. 2008 Nov;93(11):4331-41 [18713817.001]
  • [Cites] Cancer Res. 2000 Feb 15;60(4):1129-38 [10706135.001]
  • (PMID = 19208833.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA015083-34; United States / NCI NIH HHS / CA / P30 CA015083; United States / NCI NIH HHS / CA / P30 CA015083-34; United States / NCI NIH HHS / CA / P30CA15083
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / PPAR gamma; 0 / Thiazolidinediones; EC 3.6.5.2 / rhoB GTP-Binding Protein; M17ILL71MC / efatutazone
  • [Other-IDs] NLM/ NIHMS83531; NLM/ PMC2644344
  •  go-up   go-down


35. Al-Zaher N, Al-Salam S, El Teraifi H: Thyroid carcinoma in the United Arab Emirates: perspectives and experience of a tertiary care hospital. Hematol Oncol Stem Cell Ther; 2008 Jan-Mar;1(1):14-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thyroid carcinoma in the United Arab Emirates: perspectives and experience of a tertiary care hospital.
  • BACKGROUND: Although the distribution of thyroid carcinoma in the Arab Gulf States has been described, no previous study has examined the characteristic clinicopathologic features of thyroid carcinoma cases in the United Arab Emirates.
  • METHODS: The medical records of 135 patients with thyroid carcinoma diagnosed over a 15-year period (1991-2005) at Tawam Hospital, the national referral oncology center in the UAE, were retrospectively studied and the cases classified according to the histologic classification of the World Health Organization (WHO).
  • Eighty-four percent had papillary thyroid carcinoma (PTC), while follicular thyroid carcinoma (FTC), anaplastic thyroid carcinoma and medullary carcinoma comprised 14%, 1.4% and 0.6%, respectively.
  • The conventional classical variant of papillary carcinoma was the most common type.
  • Three-quarters of the papillary carcinomas presented as multinodular goiter, while one-fifth presented as a solitary thyroid nodule.
  • Minimal invasive follicular carcinoma was the most common variant of follicular carcinoma.
  • CONCLUSION: Thyroid carcinoma in the United Arab Emirates seems to be more common among females and female gender may be a risk factor.
  • PTC predominates the histologic pattern of thyroid carcinoma, which is usually associated with an iodide-sufficient area.
  • [MeSH-major] Thyroid Neoplasms / classification. Thyroid Neoplasms / epidemiology. Thyroid Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20063523.001).
  • [ISSN] 1658-3876
  • [Journal-full-title] Hematology/oncology and stem cell therapy
  • [ISO-abbreviation] Hematol Oncol Stem Cell Ther
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


36. Carter JR, Fraser TS, Fraser MJ Jr: Examining the relative activity of several dicistrovirus intergenic internal ribosome entry site elements in uninfected insect and mammalian cell lines. J Gen Virol; 2008 Dec;89(Pt 12):3150-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Dual luciferase assays were performed to determine the most effective dicistrovirus IGR IRES in the lepidopteran cell lines Sf9 (Spodoptera frugiperda) and BmN (Bombyx mori), and the dipteran cell lines S2 (Drosophila melanogaster) and ATC-10 (Aedes aegypti).

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19008405.001).
  • [ISSN] 0022-1317
  • [Journal-full-title] The Journal of general virology
  • [ISO-abbreviation] J. Gen. Virol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Intergenic; 0 / RNA, Messenger; 0 / RNA, Viral; EC 1.13.12.- / Luciferases
  •  go-up   go-down


37. Usher C, Teeling M, Bennett K, Feely J: Effect of clinical trial publicity on HRT prescribing in Ireland. Eur J Clin Pharmacol; 2006 Apr;62(4):307-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Prescriptions were identified for HRT and bisphosphonate preparations [using WHO Anatomical Therapeutic Chemical (ATC) classification codes] in female patients aged 45-69 years in Ireland during a 4-year study period (January 2001-December 2004).
  • [MeSH-minor] Aged. Diphosphonates / therapeutic use. Female. Humans. Ireland. Middle Aged. Osteoporosis / drug therapy

  • MedlinePlus Health Information. consumer health - Clinical Trials.
  • MedlinePlus Health Information. consumer health - Hormone Replacement Therapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Gen Pract. 2005 Jul;55(516):555 [16004748.001]
  • [Cites] JAMA. 2003 Feb 19;289(7):895-902 [12588275.001]
  • [Cites] J Clin Pharm Ther. 2002 Aug;27(4):299-309 [12174032.001]
  • [Cites] Pharmacoeconomics. 1999 Aug;16(2):175-81 [10539398.001]
  • [Cites] Lancet. 2002 Dec 7;360(9348):1851-61 [12480376.001]
  • [Cites] JAMA. 2002 Jul 17;288(3):321-33 [12117397.001]
  • [Cites] BMJ. 2003 Feb 8;326(7384):322-6 [12574048.001]
  • [Cites] Lancet. 2003 Aug 9;362(9382):419-27 [12927427.001]
  • [Cites] Ann Intern Med. 2004 Feb 3;140(3):184-8 [14757616.001]
  • [Cites] Pharmacoepidemiol Drug Saf. 2001 Dec;10(7):641-5 [11980254.001]
  • [Cites] Pharmacotherapy. 2004 Apr;24(4):495-9 [15098804.001]
  • [Cites] JAMA. 2004 Jan 7;291(1):47-53 [14709575.001]
  • [Cites] Ir Med J. 2000 Jan-Feb;93(1):10-1, 14 [10740365.001]
  • (PMID = 16432715.001).
  • [ISSN] 0031-6970
  • [Journal-full-title] European journal of clinical pharmacology
  • [ISO-abbreviation] Eur. J. Clin. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Diphosphonates
  •  go-up   go-down


38. Soto-Pérez-de-Celis E, González-Pezzat I: Anaplastic thyroid carcinoma. Intern Med J; 2010 May;40(5):383
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic thyroid carcinoma.
  • [MeSH-major] Carcinoma / radiography. Thyroid Neoplasms / radiography

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20575995.001).
  • [ISSN] 1445-5994
  • [Journal-full-title] Internal medicine journal
  • [ISO-abbreviation] Intern Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


39. Cabello B, Mancebo J: [Result of extubation after spontaneous breathing test with automatic tube compensation versus continuous positive airway pressure]. Med Intensiva; 2007 Oct;31(7):399-401
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Result of extubation after spontaneous breathing test with automatic tube compensation versus continuous positive airway pressure].
  • [Transliterated title] Resultado de la extubación tras una prueba de respiración espontánea con compensación automática del tubo frente a presión positiva continua de la vía aérea.
  • This trial is performed either using the T-piece disconnected from the ventilator, either using a low level of pressure support, with or without positive end-expiratory pressure.
  • A higher rate of failure occurs during the T-piece than during the pressure support trial, but once the patient success once of these trials the rate of reintubation is similar.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17942063.001).
  • [ISSN] 0210-5691
  • [Journal-full-title] Medicina intensiva
  • [ISO-abbreviation] Med Intensiva
  • [Language] SPA
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Number-of-references] 16
  •  go-up   go-down


40. Tsopelas C, Cooper R: Radiolabelling and biodistribution of 111In-antimony trisulphide colloid. Hell J Nucl Med; 2005 May-Aug;8(2):109-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aim of this study was to prepare 111In-antimony trisulphide colloid (111In-ATC) and evaluate its chemical properties in comparison with 99mTc-ATC.
  • After reconstitution of an antimony trisulphide cold Kit with 111In-chloride, 111In-ATC was formed with >95% radiochemical purity in the presence of neutralising phosphate buffer.
  • The product was found to be stable for 4.7 days when stored at room temperature, 80% of radioactive particles were < 20 nm in diameter and the mouse biodistribution assay was identical to that of 99mTc-ATC.
  • In conclusion, pharmaceutical-grade 111In-ATC was successfully prepared and assessed to have properties that are suitable for dual-isotope lymphoscintigraphy studies at the clinical level.
  • [MeSH-minor] Animals. Drug Stability. Metabolic Clearance Rate. Mice. Organ Specificity. Particle Size. Radiopharmaceuticals / chemical synthesis. Radiopharmaceuticals / pharmacokinetics. Technetium Compounds / pharmacokinetics. Tissue Distribution

  • Hazardous Substances Data Bank. ANTIMONY, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16142252.001).
  • [ISSN] 1790-5427
  • [Journal-full-title] Hellenic journal of nuclear medicine
  • [ISO-abbreviation] Hell J Nucl Med
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Colloids; 0 / Radiopharmaceuticals; 0 / Technetium Compounds; 0 / technetium Tc 99m antimony sulfide; 9IT35J3UV3 / Antimony
  •  go-up   go-down


41. Smallridge RC, Copland JA: Anaplastic thyroid carcinoma: pathogenesis and emerging therapies. Clin Oncol (R Coll Radiol); 2010 Aug;22(6):486-97
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic thyroid carcinoma: pathogenesis and emerging therapies.
  • Anaplastic thyroid carcinoma ranges from 1.3 to 9.8% of all thyroid cancers globally.
  • The variables associated with survival in some series included age, tumour size, extent of surgery, higher dose radiotherapy, absence of distant metastases at presentation, co-existence of differentiated thyroid cancer and multimodality therapy.
  • [MeSH-major] Carcinoma / genetics. Carcinoma / therapy. Thyroid Neoplasms / genetics. Thyroid Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.
  • [Cites] J Oncol Pharm Pract. 2009 Jun;15(2):111-7 [19276143.001]
  • [Cites] Cancer Res. 2009 Jun 1;69(11):4885-93 [19487299.001]
  • [Cites] Thyroid. 2009 Jun;19(6):629-37 [19499990.001]
  • [Cites] Horm Metab Res. 2009 Jun;41(6):475-81 [19370508.001]
  • [Cites] Radiother Oncol. 2009 Jul;92(1):100-4 [19328572.001]
  • [Cites] CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49 [19474385.001]
  • [Cites] Anticancer Res. 2009 Jul;29(7):2437-44 [19596911.001]
  • [Cites] Cancer Res. 2009 Aug 1;69(15):6141-8 [19638576.001]
  • [Cites] Cancer. 2009 Aug 15;115(16):3801-7 [19598221.001]
  • [Cites] Horm Metab Res. 2009 Oct;41(10):752-6 [19513966.001]
  • [Cites] Auris Nasus Larynx. 2009 Dec;36(6):729-32 [19269756.001]
  • [Cites] Mol Cancer Res. 2009 Oct;7(10):1645-54 [19825993.001]
  • [Cites] J Clin Pathol. 2009 Nov;62(11):978-85 [19625289.001]
  • [Cites] BMC Cancer. 2009;9:369 [19835629.001]
  • [Cites] J Clin Endocrinol Metab. 2009 Nov;94(11):4423-32 [19820016.001]
  • [Cites] J Clin Endocrinol Metab. 2009 Nov;94(11):4613-8 [19820019.001]
  • [Cites] Clin Cancer Res. 2009 Dec 1;15(23):7153-60 [19934289.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Nov 15;60(4):1137-43 [15519785.001]
  • [Cites] Endocr Relat Cancer. 2004 Dec;11(4):843-54 [15613457.001]
  • [Cites] Cancer. 2005 Apr 1;103(7):1330-5 [15739211.001]
  • [Cites] Clin Oncol (R Coll Radiol). 2005 Apr;17(2):75-8 [15830567.001]
  • [Cites] BMC Cancer. 2006;6:102 [16635261.001]
  • [Cites] Cancer. 2006 Oct 15;107(8):1786-92 [16967442.001]
  • [Cites] Nat Rev Cancer. 2006 Nov;6(11):857-66 [17060945.001]
  • [Cites] J Clin Oncol. 2006 Nov 1;24(31):5043-51 [17075124.001]
  • [Cites] Radiother Oncol. 1991 Jan;20(1):3-9 [1902319.001]
  • [Cites] Surgery. 1991 Dec;110(6):956-61; discussion 961-3 [1745983.001]
  • [Cites] Eur J Surg Oncol. 1992 Apr;18(2):83-8 [1582515.001]
  • [Cites] Langenbecks Arch Surg. 2005 Jun;390(3):203-8 [15599758.001]
  • [Cites] Saudi Med J. 2006 Feb;27(2):185-90 [16501673.001]
  • [Cites] JAMA. 2006 May 10;295(18):2164-7 [16684987.001]
  • [Cites] Eur J Surg. 2000 Jan;166(1):34-8 [10688214.001]
  • [Cites] Ann Surg. 2000 Mar;231(3):329-38 [10714625.001]
  • [Cites] Thyroid. 2000 Jul;10(7):587-94 [10958311.001]
  • [Cites] J Endocrinol Invest. 2000 Dec;23(11):755-61 [11194710.001]
  • [Cites] Cancer. 2001 Jun 15;91(12):2335-42 [11413523.001]
  • [Cites] Radiother Oncol. 2001 Aug;60(2):173-80 [11439212.001]
  • [Cites] Surgery. 2001 Dec;130(6):1028-34 [11742333.001]
  • [Cites] Ann Surg Oncol. 2002 Jan-Feb;9(1):57-64 [11833496.001]
  • [Cites] Surgery. 2002 Mar;131(3):245-8 [11894027.001]
  • [Cites] Thyroid. 2002 Feb;12(2):141-9 [11916283.001]
  • [Cites] Br J Cancer. 2002 Jun 17;86(12):1848-53 [12085174.001]
  • [Cites] Surg Today. 2004;34(5):394-8 [15108075.001]
  • [Cites] Thyroid. 2004 Apr;14(4):277-86 [15142361.001]
  • [Cites] ANZ J Surg. 2004 Jul;74(7):559-62 [15230790.001]
  • [Cites] Cancer. 1985 Nov 1;56(9):2155-60 [3902203.001]
  • [Cites] Cancer. 1987 Nov 15;60(10):2372-5 [3664425.001]
  • [Cites] Cancer. 1990 Jul 15;66(2):321-30 [1695118.001]
  • [Cites] Cancer. 1991 Feb 1;67(3):564-6 [1985750.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1993 Apr 30;26(1):125-8 [8482618.001]
  • [Cites] Eur J Surg Oncol. 1993 Dec;19(6):511-6 [8270035.001]
  • [Cites] Pathologica. 1993 Nov-Dec;85(1100):591-605 [8170710.001]
  • [Cites] Head Neck. 1995 Jan-Feb;17(1):41-7; discussion 47-8 [7883548.001]
  • [Cites] Jpn J Clin Oncol. 1995 Oct;25(5):203-7 [7474408.001]
  • [Cites] Head Neck. 1996 Jan-Feb;18(1):36-41 [8774920.001]
  • [Cites] J Surg Oncol. 1996 Dec;63(4):251-5 [8982370.001]
  • [Cites] Cancer. 1998 Dec 15;83(12):2638-48 [9874472.001]
  • [Cites] Langenbecks Arch Surg. 1999 Jun;384(3):284-93 [10437618.001]
  • [Cites] World J Surg. 1999 Sep;23(9):975-8; discussion 978-9 [10449831.001]
  • [Cites] Cancer Chemother Pharmacol. 2007 Mar;59(4):467-75 [16896930.001]
  • [Cites] Eur J Endocrinol. 2007 Apr;156(4):425-30 [17389456.001]
  • [Cites] Br J Cancer. 2007 Apr 23;96(8):1237-45 [17406368.001]
  • [Cites] Ir J Med Sci. 2007 Jul-Sep;176(2):87-90 [17486294.001]
  • [Cites] Endocr Relat Cancer. 2007 Sep;14(3):791-8 [17914108.001]
  • [Cites] Endocr Relat Cancer. 2007 Sep;14(3):847-52 [17914113.001]
  • [Cites] Oncogene. 2007 Nov 29;26(54):7590-5 [17563749.001]
  • [Cites] Hum Pathol. 2008 Jan;39(1):15-20 [17949783.001]
  • [Cites] Cancer Sci. 2008 Feb;99(2):280-6 [18201269.001]
  • [Cites] Eur J Cancer Prev. 2008 Apr;17(2):111-5 [18287867.001]
  • [Cites] Oncogene. 2008 Mar 6;27(11):1554-61 [17873908.001]
  • [Cites] Cancer Sci. 2008 Jun;99(6):1147-54 [18429962.001]
  • [Cites] Int J Cancer. 2008 Oct 1;123(7):1681-4 [18623130.001]
  • [Cites] Thyroid. 2008 Aug;18(8):853-64 [18651802.001]
  • [Cites] N Z Med J. 2008 Aug 8;121(1279):36-45 [18709046.001]
  • [Cites] Ann Surg Oncol. 2008 Sep;15(9):2500-5 [18581185.001]
  • [Cites] Endocr Relat Cancer. 2008 Sep;15(3):801-15 [18753363.001]
  • [Cites] Am J Clin Oncol. 2008 Oct;31(5):460-4 [18838882.001]
  • [Cites] J Clin Oncol. 2008 Oct 10;26(29):4708-13 [18541897.001]
  • [Cites] J Clin Endocrinol Metab. 2008 Nov;93(11):4331-41 [18713817.001]
  • [Cites] Endocr J. 2008 Dec;55(6):985-9 [18612180.001]
  • [Cites] Cancer Res. 2009 Feb 15;69(4):1536-44 [19208833.001]
  • [Cites] Endocr Relat Cancer. 2009 Mar;16(1):17-44 [18987168.001]
  • [Cites] Thyroid. 2009 Mar;19(3):233-40 [19265494.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2009 Mar;18(3):784-91 [19240234.001]
  • [Cites] Mol Pharmacol. 2009 Apr;75(4):812-9 [19158360.001]
  • [Cites] J Clin Oncol. 2009 Apr 1;27(10):1675-84 [19255327.001]
  • [Cites] J BUON. 2009 Jan-Mar;14(1):41-4 [19373945.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2009 Jun 1;74(2):518-21 [19395202.001]
  • [Cites] Endocr J. 2009;56(2):245-9 [19088401.001]
  • (PMID = 20418080.001).
  • [ISSN] 1433-2981
  • [Journal-full-title] Clinical oncology (Royal College of Radiologists (Great Britain))
  • [ISO-abbreviation] Clin Oncol (R Coll Radiol)
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA136665
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Other-IDs] NLM/ NIHMS461011; NLM/ PMC3905320
  •  go-up   go-down


42. Klotzsche M, Ehrt S, Schnappinger D: Improved tetracycline repressors for gene silencing in mycobacteria. Nucleic Acids Res; 2009 Apr;37(6):1778-88
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In addition to these repressors, for which anhydrotetracycline (atc) functions as an inducer of gene expression, we used codon-usage adaption and structure-based design to develop improved reverse TetRs, for which atc functions as a corepressor.

  • COS Scholar Universe. author profiles.
  • Addgene Non-profit plasmid repository. clones/clone libraries - Get Article's Plasmids - Addgene (subscription/membership/fee required).
  • eagle-i research resources. PMID 19174563 (Special Collections) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell. 2001 Feb 23;104(4):477-85 [11239406.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Jul 18;97(15):8554-9 [10880571.001]
  • [Cites] Gene. 2001 Oct 31;278(1-2):115-24 [11707328.001]
  • [Cites] Mol Microbiol. 2003 Apr;48(1):77-84 [12657046.001]
  • [Cites] Eur J Biochem. 2003 Aug;270(15):3109-21 [12869186.001]
  • [Cites] Mol Microbiol. 2004 Aug;53(3):777-89 [15255892.001]
  • [Cites] J Bacteriol. 1988 Jan;170(1):468-70 [3275630.001]
  • [Cites] Mol Biol Evol. 1989 May;6(3):213-25 [2560115.001]
  • [Cites] Appl Microbiol Biotechnol. 1990 Sep;33(6):657-63 [1369298.001]
  • [Cites] Mol Microbiol. 1990 Nov;4(11):1911-9 [2082148.001]
  • [Cites] Nature. 1991 Jun 6;351(6326):456-60 [1904554.001]
  • [Cites] Annu Rev Microbiol. 1994;48:345-69 [7826010.001]
  • [Cites] Gene. 1994 Dec 30;151(1-2):131-5 [7828861.001]
  • [Cites] Nucleic Acids Res. 1997 Mar 15;25(6):1203-10 [9092630.001]
  • [Cites] Nature. 1998 Jun 11;393(6685):537-44 [9634230.001]
  • [Cites] FEMS Microbiol Lett. 1999 Oct 15;179(2):317-25 [10518732.001]
  • [Cites] Nucleic Acids Res. 2005;33(2):e21 [15687379.001]
  • [Cites] Nucleic Acids Res. 2005;33(2):e22 [15687380.001]
  • [Cites] Appl Environ Microbiol. 2005 Feb;71(2):728-33 [15691923.001]
  • [Cites] Appl Environ Microbiol. 2005 Jun;71(6):3077-84 [15933004.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 May 30;103(22):8511-6 [16709676.001]
  • [Cites] Arch Microbiol. 2006 Dec;186(6):459-64 [16944099.001]
  • [Cites] J Bacteriol. 2007 Jul;189(13):4614-23 [17483222.001]
  • [Cites] Microbiology. 2007 Aug;153(Pt 8):2711-23 [17660435.001]
  • [Cites] Nat Med. 2007 Dec;13(12):1515-20 [18059281.001]
  • [Cites] Nat Struct Biol. 2000 Mar;7(3):215-9 [10700280.001]
  • [Cites] Infect Immun. 2001 Dec;69(12):7851-7 [11705967.001]
  • (PMID = 19174563.001).
  • [ISSN] 1362-4962
  • [Journal-full-title] Nucleic acids research
  • [ISO-abbreviation] Nucleic Acids Res.
  • [Language] ENG
  • [Grant] United States / NIAID NIH HHS / AI / AI063446; United Kingdom / Wellcome Trust / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Codon; 0 / Repressor Proteins; 0 / tetracycline resistance-encoding transposon repressor protein
  • [Other-IDs] NLM/ PMC2665214
  •  go-up   go-down


43. Belge G, Meyer A, Klemke M, Burchardt K, Stern C, Wosniok W, Loeschke S, Bullerdiek J: Upregulation of HMGA2 in thyroid carcinomas: a novel molecular marker to distinguish between benign and malignant follicular neoplasias. Genes Chromosomes Cancer; 2008 Jan;47(1):56-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Upregulation of HMGA2 in thyroid carcinomas: a novel molecular marker to distinguish between benign and malignant follicular neoplasias.
  • The identification of molecular markers allowing to differentiate between benign and malignant thyroid tumors remains a diagnostic challenge.
  • Herein, we have used the expression of the high mobility group protein gene HMGA2 and its protein, respectively, as a possible marker detecting malignant growth of thyroid tumors.
  • The aim of this study was to investigate whether the HMGA2 expression can be used to detect malignant thyroid tumors.
  • RNA from 64 formalin-fixed paraffin-embedded thyroid tissues including normal tissue (n = 3), thyroiditis (n = 2), and follicular adenomas (n = 19) as well as follicular (n = 9), papillary (n = 28), and anaplastic (n = 3) carcinomas was reverse transcribed.
  • Expression differences of up to 400-fold were detected between benign and malignant thyroid tumors.
  • Based on HMGA2 expression alone, it was possible to distinguish between benign and malignant thyroid tissues with a sensitivity of 95.9% and a specificity of 93.9%.
  • Our results show that even as a stand-alone marker HMGA2 expression has a high potential to improve diagnoses of follicular neoplasms of the thyroid.
  • [MeSH-major] Adenocarcinoma, Follicular / genetics. Biomarkers, Tumor / genetics. HMGA2 Protein / genetics. Thyroid Neoplasms / genetics. Up-Regulation / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Diagnosis, Differential. Female. Genetic Markers. Humans. Male. Middle Aged. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17943974.001).
  • [ISSN] 1045-2257
  • [Journal-full-title] Genes, chromosomes & cancer
  • [ISO-abbreviation] Genes Chromosomes Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Genetic Markers; 0 / HMGA2 Protein
  •  go-up   go-down


44. Ishiwata I, Ono I, Kiguchi K, Ishiwata C, Soma M, Ishikawa H: Establishment and characterization of a human thyroid carcinoma cell line (HOTHC) producing colony stimulating factor. Hum Cell; 2005 Sep;18(3):163-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Establishment and characterization of a human thyroid carcinoma cell line (HOTHC) producing colony stimulating factor.
  • A cell line designated HOTHC was established from an anaplastic carcinoma (giant cell type) of the thyroid gland of 80-year-old woman.
  • The cells were spindle or polygonal in shape and revealed neoplastic and pleomorphic features.
  • The HOTHC cells were transplanted into the subcutis of BALB/c nude mice and produced anaplatic carcinomas (giant cell type) resembling the original tumor.
  • [MeSH-major] Colony-Stimulating Factors / biosynthesis. Thyroid Neoplasms / metabolism. Thyroid Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • Cellosaurus - a cell line knowledge resource. culture/stock collections - Cellosaurus - a cell line knowledge resource .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Immunol Methods. 1989 Mar 31;118(2):187-92 [2466903.001]
  • [Cites] Blood. 1978 Mar;51(3):507-19 [304748.001]
  • [Cites] Blood. 1978 Nov;52(5):1068-72 [308824.001]
  • [Cites] Stain Technol. 1964 Mar;39:111-4 [14127791.001]
  • [Cites] J Biol Chem. 1979 Jul 25;254(14):6226-8 [312800.001]
  • [Cites] Aust J Exp Biol Med Sci. 1966 Jun;44(3):287-99 [4164182.001]
  • [Cites] Hum Cell. 1989 Mar;2(1):74-9 [2519207.001]
  • [Cites] Br J Cancer. 1980 May;41(5):689-94 [6968568.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Jun;82(6):1857-62 [9177396.001]
  • [Cites] Clin Exp Immunol. 1996 Jul;105(1):148-154 [8697623.001]
  • [Cites] Cancer Res. 1979 Oct;39(10):4189-94 [476654.001]
  • [Cites] J Natl Cancer Inst. 1982 Dec;69(6):1235-43 [6982994.001]
  • [Cites] J Natl Cancer Inst. 1984 Apr;72(4):789-800 [6323807.001]
  • [Cites] Biochem Biophys Res Commun. 1997 Nov 26;240(3):832-8 [9398654.001]
  • [Cites] Cancer Res. 1978 Nov;38(11 Pt 1):3910-7 [308840.001]
  • [Cites] Bull Cancer. 1991 Nov;78(11):1053-62 [1369551.001]
  • [Cites] J Clin Invest. 1993 Jan;91(1):179-84 [8423216.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Dec;82(12):4094-100 [9398720.001]
  • [Cites] Blood. 1979 Sep;54(3):614-27 [313822.001]
  • [Cites] Blood. 1982 Jan;59(1):86-90 [6274452.001]
  • [Cites] Blood. 1973 Nov;42(5):701-10 [4518063.001]
  • (PMID = 17022149.001).
  • [ISSN] 0914-7470
  • [Journal-full-title] Human cell
  • [ISO-abbreviation] Hum. Cell
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Colony-Stimulating Factors
  •  go-up   go-down


45. Smidt D, Torpet LA, Nauntofte B, Heegaard KM, Pedersen AM: Associations between labial and whole salivary flow rates, systemic diseases and medications in a sample of older people. Community Dent Oral Epidemiol; 2010 Oct;38(5):422-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Systemic diseases, medications (coded according to the Anatomical Therapeutic Chemical (ATC) Classification System), tobacco and alcohol consumption were registered.
  • New insights into medications and their association with salivary gland function were achieved using the ATC classification system.
  • [MeSH-minor] Age Factors. Aged. Aged, 80 and over. Chi-Square Distribution. Cross-Sectional Studies. Disease. Drug-Related Side Effects and Adverse Reactions. Female. Humans. Linear Models. Lip / physiology. Male. Mastication / physiology. Salivary Glands / drug effects. Salivary Glands / physiology. Sex Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 John Wiley & Sons A/S.
  • (PMID = 20545715.001).
  • [ISSN] 1600-0528
  • [Journal-full-title] Community dentistry and oral epidemiology
  • [ISO-abbreviation] Community Dent Oral Epidemiol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  •  go-up   go-down


46. Swaak-Kragten AT, de Wilt JH, Schmitz PI, Bontenbal M, Levendag PC: Multimodality treatment for anaplastic thyroid carcinoma--treatment outcome in 75 patients. Radiother Oncol; 2009 Jul;92(1):100-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multimodality treatment for anaplastic thyroid carcinoma--treatment outcome in 75 patients.
  • PURPOSE: To retrospectively analyze the outcome of patients with anaplastic thyroid carcinoma (ATC) treated in the Erasmus MC.
  • MATERIAL AND METHODS: Seventy-five ATC-patients were treated between 1972 and 2003.
  • CONCLUSION: Despite the ultimately dismal prognosis of ATC-patients, multimodality treatment significantly improved local control and improved the median survival.
  • [MeSH-major] Carcinoma / therapy. Neoplasm Recurrence, Local. Thyroid Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19328572.001).
  • [ISSN] 1879-0887
  • [Journal-full-title] Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  • [ISO-abbreviation] Radiother Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


47. Ha HT, Lee JS, Urba S, Koenig RJ, Sisson J, Giordano T, Worden FP: A phase II study of imatinib in patients with advanced anaplastic thyroid cancer. Thyroid; 2010 Sep;20(9):975-80
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study of imatinib in patients with advanced anaplastic thyroid cancer.
  • BACKGROUND: Currently, there is no standard treatment for metastatic anaplastic thyroid cancer (ATC).
  • DNA microarray analysis has shown platelet-dervived growth factor receptor (PDGFR) overexpression in ATC relative to well-differentiated thyroid cancer.
  • In p53-mutated/deficient ATC cell lines, cABL is overexpressed, and selective inhibition of cABL results in a cytostatic effect.
  • We hypothesize that patients with ATC that over-expresses PDGF receptors or cABL will respond to imatinib.
  • METHODS: Patients with histologically confirmed ATC who had measurable disease and whose disease expressed PDGF receptors by immunohistochemistry were eligible for study.
  • Patients with complete response, partial responses, or stable disease were treated until disease progression.
  • At baseline, 4/11 had locoregional disease, 5/11 had distant metastases, and 2/11 had both.
  • The overall response rates at 8 weeks were complete response 0/8, partial response 2/8, and stable disease 4/8.
  • CONCLUSIONS: Imatinib appears to have activity in advanced ATC and is well tolerated.
  • Due to difficulty of accruing patients with a rare malignancy at a single institution, further investigation of imatinib in ATC may be warranted in a multi-institutional setting.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma / drug therapy. Piperazines / therapeutic use. Protein Kinase Inhibitors / therapeutic use. Pyrimidines / therapeutic use. Thyroid Neoplasms / drug therapy
  • [MeSH-minor] Aged. Benzamides. Disease-Free Survival. Female. Humans. Imatinib Mesylate. Male. Middle Aged. Receptors, Platelet-Derived Growth Factor / analysis. Receptors, Platelet-Derived Growth Factor / antagonists & inhibitors


48. Aguilar G, Jover JL, Soro M, Belda FJ, García-Raimundo M, Maruenda A: Additional work of breathing and breathing patterns in spontaneously breathing patients during pressure support ventilation, automatic tube compensation and amplified spontaneous pattern breathing. Eur J Anaesthesiol; 2005 Apr;22(4):312-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Additional work of breathing and breathing patterns in spontaneously breathing patients during pressure support ventilation, automatic tube compensation and amplified spontaneous pattern breathing.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15892412.001).
  • [ISSN] 0265-0215
  • [Journal-full-title] European journal of anaesthesiology
  • [ISO-abbreviation] Eur J Anaesthesiol
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Letter
  • [Publication-country] England
  •  go-up   go-down


49. Shi RR, Du CM: [Analysis of ethambutol drug-resistance gene mutation in Mycobacterium tuberculosis by specific endonuclease]. Zhonghua Jie He He Hu Xi Za Zhi; 2006 Oct;29(10):702-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • All the 45 EMB-resistant isolates were revealed to harbor embB gene hotspot codon 306 mutation, among which 33 with ATG-->GTG, 3 with ATG-->ATT, 5 with ATG-->ATA, 2 with ATG-->ATC, 2 with ATG-->CTG.

  • Genetic Alliance. consumer health - Tuberculosis.
  • Hazardous Substances Data Bank. ETHAMBUTOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17129501.001).
  • [ISSN] 1001-0939
  • [Journal-full-title] Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases
  • [ISO-abbreviation] Zhonghua Jie He He Hu Xi Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antitubercular Agents; 8G167061QZ / Ethambutol
  •  go-up   go-down


50. Markovic-Pekovic V, Stoisavljevic-Satara S, Skrbic R: Utilisation of cardiovascular medicines in Republic of Srpska, Bosnia and Herzegovina, 5 years study. Pharmacoepidemiol Drug Saf; 2009 Apr;18(4):320-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • ATC/DDD methodology was used to monitor utilisation of medicines.
  • [MeSH-major] Cardiovascular Agents / therapeutic use. Practice Patterns, Physicians' / trends

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19156752.001).
  • [ISSN] 1099-1557
  • [Journal-full-title] Pharmacoepidemiology and drug safety
  • [ISO-abbreviation] Pharmacoepidemiol Drug Saf
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cardiovascular Agents
  •  go-up   go-down


51. Kim DH, Lee NY, Lee MH, Sohn SK, Do YR, Park JY: Vascular endothelial growth factor (VEGF) gene (VEGFA) polymorphism can predict the prognosis in acute myeloid leukaemia patients. Br J Haematol; 2008 Jan;140(1):71-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Accordingly, four haplotypes were generated based on the genotypes of -2578, -460 and +405 as follows: CTC (40.2%), CTG (35.0%), ACG (22.0%) and ATC (1.2%).
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antineoplastic Agents / therapeutic use. Disease-Free Survival. Gene Frequency. Genotype. Humans. Middle Aged. Prognosis

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17983459.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A
  •  go-up   go-down


52. Thirlway J, Soultanas P: In the Bacillus stearothermophilus DnaB-DnaG complex, the activities of the two proteins are modulated by distinct but overlapping networks of residues. J Bacteriol; 2006 Feb;188(4):1534-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We demonstrate the primase activity of Bacillus stearothermophilus DnaG and show that it initiates at 3'-ATC-5' and 3'-ATT-5' sites synthesizing primers that are 22 or 23 nucleotides long.
  • Nine residues from the N- and C-terminal domains of DnaB, as well as its linker region, have been reported previously to affect this interaction.
  • In Bacillus stearothermophilus only three residues from the linker region (I119 and I125) and the N-terminal domain (Y88) of DnaB have been shown previously to have direct structural importance, and I119 and I125 mediate DnaG-induced effects on DnaB activity.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Structure. 2005 Apr;13(4):609-16 [15837199.001]
  • [Cites] J Biol Chem. 2005 Mar 25;280(12):11495-504 [15649896.001]
  • [Cites] Mol Cell. 2005 Nov 11;20(3):391-401 [16285921.001]
  • [Cites] Mol Cell. 1999 Oct;4(4):541-53 [10549286.001]
  • [Cites] Biochemistry. 2000 Jan 11;39(1):171-82 [10625492.001]
  • [Cites] Biochemistry. 2000 Feb 1;39(4):736-44 [10651639.001]
  • [Cites] Biochemistry. 2000 Feb 1;39(4):745-52 [10651640.001]
  • [Cites] Science. 2000 Mar 31;287(5462):2482-6 [10741967.001]
  • [Cites] Structure. 2000 Mar 15;8(3):231-9 [10745010.001]
  • [Cites] J Biol Chem. 2000 Aug 25;275(34):26187-95 [10833513.001]
  • [Cites] Annu Rev Biochem. 2000;69:651-97 [10966472.001]
  • [Cites] Annu Rev Biochem. 2001;70:39-80 [11395402.001]
  • [Cites] J Mol Biol. 2002 Aug 30;321(5):839-49 [12206765.001]
  • [Cites] Nucleic Acids Res. 2002 Sep 15;30(18):4051-60 [12235389.001]
  • [Cites] Biochemistry. 2002 Dec 17;41(50):14820-30 [12475230.001]
  • [Cites] J Biol Chem. 2003 Dec 26;278(52):52253-61 [14557266.001]
  • [Cites] Nucleic Acids Res. 2004;32(10):2977-86 [15173380.001]
  • [Cites] J Bacteriol. 1988 Aug;170(8):3682-8 [2841295.001]
  • [Cites] Mol Gen Genet. 1991 May;227(1):1-8 [1828532.001]
  • [Cites] J Bacteriol. 1996 Aug;178(15):4620-7 [8755893.001]
  • [Cites] J Biol Chem. 1996 Aug 30;271(35):21391-7 [8702920.001]
  • [Cites] Structure. 1999 Jun 15;7(6):681-90 [10404597.001]
  • [Cites] Structure. 1999 Jun 15;7(6):691-8 [10404598.001]
  • [Cites] Structure. 2005 Jun;13(6):839-44 [15939015.001]
  • (PMID = 16452437.001).
  • [ISSN] 0021-9193
  • [Journal-full-title] Journal of bacteriology
  • [ISO-abbreviation] J. Bacteriol.
  • [Language] eng
  • [Grant] United Kingdom / Biotechnology and Biological Sciences Research Council / / BB/C500579/1; United Kingdom / Biotechnology and Biological Sciences Research Council / / BB/E004717/1
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Bacterial Proteins; 0 / DNA Primers; EC 2.7.7.- / DNA Primase; EC 3.6.4.- / DNA Helicases; EC 3.6.4.12 / DnaB Helicases
  • [Other-IDs] NLM/ PMC1367256
  •  go-up   go-down


53. Lee MY, Doh EJ, Park CH, Kim YH, Kim ES, Ko BS, Oh SE: Development of SCAR marker for discrimination of Artemisia princeps and A. argyi from other Artemisia herbs. Biol Pharm Bull; 2006 Apr;29(4):629-33
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Based on nucleotide sequence of the primer 329 product, we designed a Fb (5'-CAT CAA CCA TGG CTT ATC CT-3') and R7 (5'-GCG AAC CTC CCC ATT CCA-3') primer-set to amplify a 254 bp sized SCAR (sequence characterized amplified regions) marker, through which A. princeps and A. argyi can be efficiently discriminated from other Artemisia herbs, particularly, A. capillaris and A. iwayomogi.
  • [MeSH-major] Artemisia / classification

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16595892.001).
  • [ISSN] 0918-6158
  • [Journal-full-title] Biological & pharmaceutical bulletin
  • [ISO-abbreviation] Biol. Pharm. Bull.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / DNA Primers; 0 / DNA, Plant; 0 / Genetic Markers
  •  go-up   go-down


54. Scott A, Khan KM, Duronio V: IGF-I activates PKB and prevents anoxic apoptosis in Achilles tendon cells. J Orthop Res; 2005 Sep;23(5):1219-25
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The objectives of the current study were to (i) investigate the effect of oxygen withdrawal on the viability of porcine Achilles tendon cells (ATCs), and (ii) examine the ability of IGF-I, a factor with known regenerative properties in tendon, to prevent ATC death.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. OXYGEN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Soc Gynecol Investig. 2002 May-Jun;9(3):168-73 [12009392.001]
  • [Cites] Mol Cell Biol. 1998 May;18(5):2845-54 [9566903.001]
  • [Cites] Growth Horm IGF Res. 2002 Aug;12(4):193-7 [12175651.001]
  • [Cites] Arthritis Rheum. 2002 Aug;46(8):1986-96 [12209500.001]
  • [Cites] J Orthop Res. 2002 Sep;20(5):910-9 [12382953.001]
  • [Cites] J Orthop Res. 2002 Sep;20(5):934-8 [12382956.001]
  • [Cites] Equine Vet J Suppl. 2002 Sep;(34):288-92 [12405703.001]
  • [Cites] J Orthop Res. 2002 Nov;20(6):1372-9 [12472255.001]
  • [Cites] Sports Med. 2003;33(5):381-94 [12696985.001]
  • [Cites] Biochim Biophys Acta. 2003 Jun 17;1641(1):35-41 [12788227.001]
  • [Cites] Carcinogenesis. 2003 Jul;24(7):1177-82 [12807744.001]
  • [Cites] Am J Pathol. 2003 Aug;163(2):663-71 [12875985.001]
  • [Cites] Knee Surg Sports Traumatol Arthrosc. 2003 Sep;11(5):334-8 [14520512.001]
  • [Cites] Clin Sports Med. 2003 Oct;22(4):675-92 [14560540.001]
  • [Cites] Clin Sports Med. 2003 Oct;22(4):791-812 [14560548.001]
  • [Cites] J Immunol. 2003 Nov 1;171(9):4672-9 [14568942.001]
  • [Cites] Gen Physiol Biophys. 2003 Jun;22(2):265-73 [14661737.001]
  • [Cites] World J Surg. 2004 Mar;28(3):294-300 [14961188.001]
  • [Cites] Cancer Res. 2004 May 15;64(10):3679-86 [15150128.001]
  • [Cites] Mol Biol Cell. 2004 Jun;15(6):2863-72 [15064349.001]
  • [Cites] Br J Exp Pathol. 1982 Feb;63(1):50-5 [7066184.001]
  • [Cites] Jpn J Physiol. 1988;38(3):361-74 [3184562.001]
  • [Cites] Acta Paediatr Scand Suppl. 1988;347:110-2 [3075835.001]
  • [Cites] Acta Paediatr Scand Suppl. 1990;367:63-6 [2220390.001]
  • [Cites] J Orthop Res. 1991 Jul;9(4):495-502 [2045976.001]
  • [Cites] J Orthop Res. 1991 Jul;9(4):503-15 [2045977.001]
  • [Cites] J Bone Joint Surg Am. 1991 Dec;73(10):1507-25 [1748700.001]
  • [Cites] Bull Mem Acad R Med Belg. 1992;147(6-7):298-306; discussion 306-7 [1286409.001]
  • [Cites] Ann Rheum Dis. 1994 Jun;53(6):359-66 [8037494.001]
  • [Cites] Cytometry. 1994 Sep 1;17(1):59-65 [7528124.001]
  • [Cites] Int J Artif Organs. 1998 Mar;21(3):174-8 [9622117.001]
  • [Cites] J Bone Joint Surg Br. 1998 Jul;80(4):720-5 [9699843.001]
  • [Cites] J Hand Surg Br. 1998 Oct;23(5):627-32 [9821609.001]
  • [Cites] FEBS Lett. 1998 Nov 13;439(1-2):168-72 [9849900.001]
  • [Cites] J Biol Chem. 1999 Mar 19;274(12):8039-45 [10075703.001]
  • [Cites] Am J Sports Med. 1999 May-Jun;27(3):363-9 [10352775.001]
  • [Cites] Prog Neurobiol. 2000 Oct;62(3):215-49 [10840148.001]
  • [Cites] J Orthop Res. 2001 Jan;19(1):143-8 [11332611.001]
  • [Cites] Immunopharmacol Immunotoxicol. 2001 May;23(2):133-52 [11417843.001]
  • [Cites] BMJ. 2002 Mar 16;324(7338):626-7 [11895810.001]
  • [Cites] J Bone Joint Surg Br. 2002 Mar;84(2):276-88 [11922373.001]
  • [Cites] J Biomech. 1995 Dec;28(12):1505-13 [8666590.001]
  • [Cites] J Orthop Res. 1996 May;14(3):370-6 [8676248.001]
  • [Cites] Scand J Med Sci Sports. 1997 Apr;7(2):86-95 [9211609.001]
  • [Cites] Res Vet Sci. 1997 Mar-Apr;62(2):93-7 [9243704.001]
  • [Cites] Eur J Histochem. 2002;46(1):3-12 [12044045.001]
  • (PMID = 16140203.001).
  • [ISSN] 0736-0266
  • [Journal-full-title] Journal of orthopaedic research : official publication of the Orthopaedic Research Society
  • [ISO-abbreviation] J. Orthop. Res.
  • [Language] ENG
  • [Grant] None / None / / 78141-1; Canada / Canadian Institutes of Health Research / / 78141-1
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Proto-Oncogene Proteins; 67763-96-6 / Insulin-Like Growth Factor I; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 3.4.22.- / Caspases; S88TT14065 / Oxygen
  • [Other-IDs] NLM/ CAMS4204; NLM/ PMC3951482
  •  go-up   go-down


55. Yu XH, Zhao TQ, Wang L, Liu ZP, Zhang CM, Chen R, Li L, Liu G, Hu WC: A novel substitution at the translation initiator codon (ATG--&gt;ATC) of the lipoprotein lipase gene is mainly responsible for lipoprotein lipase deficiency in a patient with severe hypertriglyceridemia and recurrent pancreatitis. Biochem Biophys Res Commun; 2006 Mar 3;341(1):82-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A novel substitution at the translation initiator codon (ATG-->ATC) of the lipoprotein lipase gene is mainly responsible for lipoprotein lipase deficiency in a patient with severe hypertriglyceridemia and recurrent pancreatitis.

  • Genetic Alliance. consumer health - Pancreatitis.
  • MedlinePlus Health Information. consumer health - Pancreatitis.
  • MedlinePlus Health Information. consumer health - Triglycerides.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16431216.001).
  • [ISSN] 0006-291X
  • [Journal-full-title] Biochemical and biophysical research communications
  • [ISO-abbreviation] Biochem. Biophys. Res. Commun.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Codon, Initiator; EC 3.1.1.34 / Lipoprotein Lipase
  •  go-up   go-down


56. Wang CY, Shui HA, Chang TC: In vivo evidence of duality effects for lovastatin in a nude mouse cancer model. Int J Cancer; 2010 Jan 15;126(2):578-82
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In vivo evidence of duality effects for lovastatin in a nude mouse cancer model.
  • On the basis of our previous in vitro experimental results on an anaplastic thyroid cancer cell line, we designed a nude mouse model in which cancer cells were seeded subcutaneously to examine the potential anticancer effects of lovastatin in vivo.
  • In this model, we found that lovastatin inhibits tumor growth at a high dosage (5 or 10 mg/kg/day), suggesting it could be used as an effectively adjuvant chemotherapy for cancer.
  • [MeSH-major] Lovastatin / pharmacology. Thyroid Neoplasms / drug therapy. Xenograft Model Antitumor Assays

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • Hazardous Substances Data Bank. LOVASTATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19621388.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hydroxymethylglutaryl-CoA Reductase Inhibitors; 0 / Vascular Endothelial Growth Factor A; 9LHU78OQFD / Lovastatin; EC 2.7.10.1 / Receptors, Vascular Endothelial Growth Factor
  •  go-up   go-down


57. Fujita T, Ogasawara Y, Naito M, Doihara H, Shimizu N: Anaplastic thyroid carcinoma associated with granulocyte colony-stimulating factor: report of a case. Surg Today; 2006;36(1):63-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic thyroid carcinoma associated with granulocyte colony-stimulating factor: report of a case.
  • She had undergone a resection of thyroid carcinoma 13 years earlier, followed by two subsequent operations for recurrent thyroid disease.
  • Surgery was thus performed to control persistent bleeding from the axillary ulcer, and a histopathological examination resulted in a diagnosis of poorly differentiated thyroid carcinoma.
  • [MeSH-major] Carcinoma, Papillary / complications. Granulocyte Colony-Stimulating Factor. Leukocytosis / etiology. Thyroid Neoplasms / complications

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nihon Kokyuki Gakkai Zasshi. 2000 May;38(5):391-7 [10921287.001]
  • [Cites] Intern Med. 1995 Jun;34(6):584-8 [7549149.001]
  • [Cites] J Otolaryngol. 2000 Jun;29(3):174-8 [10883833.001]
  • [Cites] Cancer Res. 1989 Sep 1;49(17):4740-6 [2474371.001]
  • [Cites] Am J Gastroenterol. 1999 Jan;94(1):273-5 [9934773.001]
  • [Cites] Am J Gastroenterol. 2001 Jan;96(1):258-9 [11197273.001]
  • [Cites] Cancer. 1990 May 1;65(9):1971-9 [2196988.001]
  • [Cites] Intern Med. 1992 Feb;31(2):277-80 [1376180.001]
  • [Cites] Surg Today. 1995;25(2):158-60 [7539648.001]
  • [Cites] Jpn J Clin Oncol. 1991 Dec;21(6):395-9 [1666658.001]
  • [Cites] Intern Med. 1996 Oct;35(10):815-20 [8933194.001]
  • [Cites] Cancer. 1989 Dec 1;64(11):2250-3 [2804915.001]
  • [Cites] Nihon Naika Gakkai Zasshi. 1979 Nov;68(11):1466-72 [533818.001]
  • [Cites] Thyroid. 2000 Dec;10(12):1113-8 [11201858.001]
  • [Cites] J Clin Ultrasound. 1990 Jun;18(5):438-41 [2161019.001]
  • [Cites] Blood. 1977 May;49(5):845-52 [300638.001]
  • [Cites] J Gastroenterol. 2003;38(10):1013-5 [14614613.001]
  • (PMID = 16378196.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 143011-72-7 / Granulocyte Colony-Stimulating Factor
  •  go-up   go-down


58. Dralle H, Lorenz K, Machens A: [Surgery of thyroid carcinoma]. Chirurg; 2009 Nov;80(11):1069-82; quiz 1083
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Surgery of thyroid carcinoma].
  • The 5 main types of thyroid cancer (papillary, PTC, follicular, FTC, poorly differentiated, PDTC undifferentiated, UTC, medullary, MTC) not only differ regarding morphology, pathogenesis, genetics,and pathophysiology (iodine metabolism, thyroglobulin and calcitonin production), but also concerning tumor biology, metastatic behavior (lymphogenous, locally invasive and hematogenous routes) and prognosis.
  • Lymph node surgery plays an important role in those cancers exhibiting mainly lymph node metastases (PTC, MTC) not only due to frequent recurrences but also due to its potential curative intent.
  • Differentiated carcinomas may have an acceptable prognosis despite local invasion of the cervical aerodigestive system, thus resections are justified when technical prerequisites are given.
  • [MeSH-major] Adenocarcinoma, Follicular / surgery. Carcinoma / surgery. Carcinoma, Medullary / surgery. Carcinoma, Papillary / surgery. Lymph Node Excision / methods. Thyroid Neoplasms / surgery. Thyroidectomy / methods
  • [MeSH-minor] Algorithms. Biomarkers, Tumor / blood. Calcitonin / blood. Humans. Lymphatic Metastasis / pathology. Microsurgery / methods. Neoplasm Invasiveness. Neoplasm Staging. Neoplasm, Residual / diagnosis. Neoplasm, Residual / mortality. Neoplasm, Residual / pathology. Neoplasm, Residual / surgery. Prognosis. Reoperation. Survival Rate. Trachea / pathology. Trachea / surgery

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • Hazardous Substances Data Bank. Calcitonin .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surgery. 2006 Dec;140(6):1000-5; discussion 1005-7 [17188149.001]
  • [Cites] Chirurg. 1992 Apr;63(4):282-90 [1597092.001]
  • [Cites] World J Surg. 2007 May;31(5):957-68 [17453286.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Jun;91(6):2171-8 [16478817.001]
  • [Cites] J Clin Endocrinol Metab. 2009 Apr;94(4):1086-8 [19349473.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2002 Jul;128(7):751-8 [12117328.001]
  • [Cites] Langenbecks Arch Surg. 1998 Apr;383(2):167-9 [9641892.001]
  • [Cites] Best Pract Res Clin Endocrinol Metab. 2008 Dec;22(6):971-87 [19041826.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Dec;86(12):5658-71 [11739416.001]
  • [Cites] JAMA. 2006 May 10;295(18):2164-7 [16684987.001]
  • [Cites] N Engl J Med. 2005 Sep 15;353(11):1105-13 [16162881.001]
  • [Cites] World J Surg. 2007 Oct;31(10):1960-5 [17665245.001]
  • [Cites] Surgery. 2006 Dec;140(6):953-9 [17188144.001]
  • [Cites] Surg Today. 1994;24(2):112-21 [8054788.001]
  • [Cites] Thyroid. 2009 May;19(5):473-7 [19348582.001]
  • [Cites] Ann Thorac Surg. 2007 Jun;83(6):1952-9 [17532377.001]
  • [Cites] Ann Surg. 2007 Sep;246(3):375-81; discussion 381-4 [17717441.001]
  • [Cites] Ann Surg Oncol. 2009 Jan;16(1):171-6 [18982392.001]
  • [Cites] Surgery. 2001 Jan;129(1):23-8 [11150030.001]
  • [Cites] Br J Surg. 2008 May;95(5):586-91 [18300267.001]
  • [Cites] J Clin Endocrinol Metab. 2008 Jun;93(6):2173-80 [18364376.001]
  • [Cites] Eur J Endocrinol. 2006 Jun;154(6):787-803 [16728537.001]
  • [Cites] Ann Surg. 2007 Apr;245(4):604-10 [17414610.001]
  • [Cites] Ann Thorac Surg. 1992 Jul;54(1):3-9; discussion 9-10 [1610250.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Apr;90(4):2029-34 [15634717.001]
  • [Cites] Chirurg. 2008 Nov;79(11):1017-28 [18818894.001]
  • [Cites] J Clin Endocrinol Metab. 2003 May;88(5):2070-5 [12727956.001]
  • [Cites] World J Surg. 2004 Apr;28(4):397-401 [14994142.001]
  • [Cites] World J Surg. 2000 Nov;24(11):1367-72 [11038208.001]
  • [Cites] World J Surg. 2008 Jul;32(7):1313-24 [18449595.001]
  • [Cites] Surgery. 2002 Mar;131(3):249-56 [11894028.001]
  • [Cites] Chirurg. 1996 Aug;67(8):788-806 [8964151.001]
  • [Cites] World J Surg. 2007 Aug;31(8):1672-6 [17571205.001]
  • [Cites] Surgery. 2004 Dec;136(6):1183-91 [15657574.001]
  • [Cites] Thyroid. 2008 Mar;18(3):309-15 [18341377.001]
  • [Cites] Ann Surg. 2009 Aug;250(2):305-10 [19638924.001]
  • [Cites] World J Surg. 2007 May;31(5):946-56 [17426901.001]
  • [Cites] Thyroid. 2009 May;19(5):487-94 [19348580.001]
  • [Cites] World J Surg. 2002 Jan;26(1):22-8 [11898029.001]
  • [Cites] Exp Clin Endocrinol Diabetes. 2004 Jan;112(1):52-8 [14758572.001]
  • [Cites] World J Surg. 2006 May;30(5):780-6 [16411013.001]
  • [Cites] World J Surg. 2007 May;31(5):895-904 [17347896.001]
  • [Cites] Adv Anat Pathol. 2006 Mar;13(2):69-75 [16670460.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Jan;89(1):163-8 [14715844.001]
  • [Cites] Surgery. 2006 Jan;139(1):28-32 [16364714.001]
  • [Cites] Surgery. 2009 Feb;145(2):176-81 [19167972.001]
  • [Cites] N Engl J Med. 2003 Oct 16;349(16):1517-25 [14561794.001]
  • [Cites] World J Surg. 2001 Jun;25(6):723-7 [11376406.001]
  • [Cites] Chirurg. 2009 Feb;80(2):88-98 [19151959.001]
  • (PMID = 19902289.001).
  • [ISSN] 1433-0385
  • [Journal-full-title] Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen
  • [ISO-abbreviation] Chirurg
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 9007-12-9 / Calcitonin
  •  go-up   go-down


59. Massant J, Glansdorff N: New experimental approaches for investigating interactions between Pyrococcus furiosus carbamate kinase and carbamoyltransferases, enzymes involved in the channeling of thermolabile carbamoyl phosphate. Archaea; 2005 Dec;1(6):365-73
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Using the yeast two-hybrid system, Hummel-Dreyer chromatography and isothermal titration calorimetry, we obtained additional concrete evidence for an interaction between CK and OTC, the first evidence for an interaction between CK and aspartate carbamoyltransferase (ATC) and an estimate of the binding constant between CK and ATC.
  • The physical interaction between CK and OTC or ATC may prevent thermodenaturation of CP in the aqueous cytoplasmic environment.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell Mol Life Sci. 2000 Feb;57(2):250-64 [10766021.001]
  • [Cites] Genetics. 1965 Feb;51:167-79 [14292146.001]
  • [Cites] Methods Enzymol. 2001;331:227-35 [11265465.001]
  • [Cites] Methods Enzymol. 2001;331:236-47 [11265466.001]
  • [Cites] Methods Enzymol. 2001;331:248-70 [11265467.001]
  • [Cites] Curr Opin Struct Biol. 2001 Oct;11(5):560-6 [11785756.001]
  • [Cites] J Biol Chem. 2002 May 24;277(21):18517-22 [11893735.001]
  • [Cites] J Mol Biol. 2003 Feb 7;326(1):203-16 [12547202.001]
  • [Cites] Proteins. 2003 Jul 1;52(1):41-6 [12784366.001]
  • [Cites] Acta Crystallogr D Biol Crystallogr. 2003 Dec;59(Pt 12):2140-9 [14646072.001]
  • [Cites] Biochem Soc Trans. 2004 Apr;32(Pt 2):306-9 [15046596.001]
  • [Cites] Proc Natl Acad Sci U S A. 1982 May;79(10):3236-40 [6954476.001]
  • [Cites] Nature. 1989 Jul 20;340(6230):245-6 [2547163.001]
  • [Cites] Anal Biochem. 1989 May 15;179(1):131-7 [2757186.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Feb 1;88(3):750-4 [1992467.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Nov 1;88(21):9578-82 [1946372.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Mar 15;89(6):2195-9 [1549581.001]
  • [Cites] FASEB J. 1993 Jul;7(10):957-63 [8344494.001]
  • [Cites] Biochemistry. 1993 Oct 19;32(41):11124-31 [8218175.001]
  • [Cites] Adv Enzymol Relat Areas Mol Biol. 1994;68:67-151 [8154326.001]
  • [Cites] Trends Genet. 1994 Aug;10(8):286-92 [7940758.001]
  • [Cites] Microbiol Rev. 1995 Mar;59(1):94-123 [7708014.001]
  • [Cites] Genetics. 1996 Dec;144(4):1425-36 [8978031.001]
  • [Cites] Biochemistry. 1997 Nov 25;36(47):14271-6 [9400365.001]
  • [Cites] Comp Biochem Physiol A Physiol. 1997 Nov;118(3):463-73 [9406429.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Mar 17;95(6):2801-6 [9501170.001]
  • [Cites] J Biol Chem. 1999 Mar 5;274(10):6122-9 [10037695.001]
  • [Cites] Methods. 1999 Oct;19(2):213-21 [10527727.001]
  • [Cites] Methods. 1999 Oct;19(2):278-305 [10527732.001]
  • [Cites] Methods. 1999 Oct;19(2):330-7 [10527735.001]
  • [Cites] Biochim Biophys Acta. 1962 Oct 8;63:530-2 [13955687.001]
  • [Cites] J Mol Biol. 2000 Jun 2;299(2):463-76 [10860751.001]
  • (PMID = 16243776.001).
  • [ISSN] 1472-3646
  • [Journal-full-title] Archaea (Vancouver, B.C.)
  • [ISO-abbreviation] Archaea
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Chemical-registry-number] 590-55-6 / Carbamyl Phosphate; EC 2.1.3.3 / Ornithine Carbamoyltransferase; EC 2.7.2.- / Phosphotransferases (Carboxyl Group Acceptor); EC 2.7.2.2 / carbamate kinase
  • [Other-IDs] NLM/ PMC2685582
  •  go-up   go-down


60. Xing M: Genetic alterations in the phosphatidylinositol-3 kinase/Akt pathway in thyroid cancer. Thyroid; 2010 Jul;20(7):697-706
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic alterations in the phosphatidylinositol-3 kinase/Akt pathway in thyroid cancer.
  • BACKGROUND: Aberrant activation of the phosphatidylinositol-3 kinase (PI3K)/Akt pathway plays a fundamental role in thyroid tumorigenesis, particularly in follicular thyroid cancer (FTC) and aggressive thyroid cancer, such as anaplastic thyroid cancer (ATC).
  • As the drivers of this process, many genetic alterations activating the PI3K/Akt pathway have been identified in thyroid cancer in recent years.
  • Most of these genetic alterations are particularly common in FTC and many of them are even more common in ATC; they are generally less common in papillary thyroid cancer (PTC), in which the MAP kinase (MAPK) pathway activated by the BRAF mutation instead plays a major role.
  • Many of these genetic alterations are mutually exclusive in differentiated thyroid tumors, but with increasing concurrence from benign tumors to FTC to ATC.
  • Most cases of ATC harbor genetic alterations in these genes or other genetic combinations that can activate both pathways.
  • It is proposed that genetic alterations in the PI3K/Akt pathway promote thyroid cell transformation to FTC and that genetic alterations in the MAPK pathway promote cell transformation to PTC; accumulation of multiple genetic alterations that can activate both pathways promotes thyroid cancer aggressiveness and progression to ATC.
  • CONCLUSIONS: Genetic alterations are common in the PI3K/Akt pathway in thyroid cancer and play a fundamental role in the tumorigenesis and progression of this cancer.
  • This provides a strong basis for the emerging development of novel genetic-based diagnostic, prognostic, and therapeutic strategies for thyroid cancer.


61. Volante M, Rapa I, Papotti M: Poorly differentiated thyroid carcinoma: diagnostic features and controversial issues. Endocr Pathol; 2008;19(3):150-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Poorly differentiated thyroid carcinoma: diagnostic features and controversial issues.
  • Poorly differentiated thyroid carcinomas are a heterogeneous group of tumors occupying an area intermediate between well-differentiated follicular or papillary carcinoma and anaplastic carcinomas, from both a histopathogenetic and a clinical point of view.
  • Large tumor series selected on the basis of structural and/or other morphological criteria showed that poorly differentiated carcinomas have a distinct biological behavior, and the classification of these tumors into a separate group appears justified, although strict homogeneous diagnostic criteria should be achieved and widely accepted to better characterize such tumor entity.
  • Molecular data in the literature, although limited by the heterogeneous case series analyzed, identify ras alterations as the most common molecular alteration in poorly differentiated carcinomas, thus, depicting a peculiar molecular pathway in this tumor type as compared to well-differentiated follicular and papillary carcinomas.
  • [MeSH-major] Thyroid Neoplasms / classification. Thyroid Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Histopathology. 2003 Jun;42(6):580-7 [12786894.001]
  • [Cites] Am J Surg Pathol. 1997 Dec;21(12):1466-73 [9414190.001]
  • [Cites] Am J Surg Pathol. 1996 Jun;20(6):686-94 [8651347.001]
  • [Cites] J Clin Invest. 1993 Apr;91(4):1753-60 [8473515.001]
  • [Cites] Virchows Arch. 2004 Jun;444(6):572-6 [15095090.001]
  • [Cites] Cancer. 2004 Mar 1;100(5):950-7 [14983490.001]
  • [Cites] Semin Diagn Pathol. 1995 Aug;12(3):249-55 [8545591.001]
  • [Cites] Endocr Pathol. 2002 Winter;13(4):353-60 [12665653.001]
  • [Cites] Adv Anat Pathol. 1999 Sep;6(5):281-6 [10472380.001]
  • [Cites] Thyroid. 2000 Jan;10(1):19-23 [10691309.001]
  • [Cites] Am J Pathol. 2001 Mar;158(3):987-96 [11238046.001]
  • [Cites] Eur J Cancer. 1979 Aug;15(8):1033-41 [510341.001]
  • [Cites] Am J Surg Pathol. 2000 Feb;24(2):310-3 [10680904.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Jan;87(1):370-9 [11788678.001]
  • [Cites] Cancer. 1994 Jan 15;73(2):416-23 [8293409.001]
  • [Cites] Endocr J. 2007 Apr;54(2):265-74 [17379963.001]
  • [Cites] Am J Surg Pathol. 1993 Mar;17(3):291-301 [8434709.001]
  • [Cites] World J Surg. 2007 May;31(5):934-45 [17431717.001]
  • [Cites] Am J Surg Pathol. 1999 Feb;23(2):205-11 [9989848.001]
  • [Cites] Cancer. 2008 Jul 1;113(1):48-56 [18484584.001]
  • [Cites] Clin Endocrinol (Oxf). 2007 Feb;66(2):224-8 [17223992.001]
  • [Cites] Am J Surg Pathol. 2002 Aug;26(8):1007-15 [12170087.001]
  • [Cites] Hum Pathol. 1984 Mar;15(3):218-28 [6141993.001]
  • [Cites] Cancer. 2007 Sep 15;110(6):1209-17 [17665497.001]
  • [Cites] Am J Surg Pathol. 2007 Aug;31(8):1256-64 [17667551.001]
  • [Cites] Diagn Mol Pathol. 1994 Mar;3(1):9-14 [8162258.001]
  • [Cites] Int J Surg Pathol. 2002 Apr;10(2):123-31 [12075405.001]
  • [Cites] Cancer. 2000 Apr 15;88(8):1902-8 [10760768.001]
  • [Cites] J Clin Oncol. 2003 Sep 1;21(17):3226-35 [12947056.001]
  • [Cites] Thyroid. 2007 Jul;17(7):639-46 [17696834.001]
  • [Cites] Cancer. 1983 Nov 15;52(10):1849-55 [6313176.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Nov;88(11):5399-404 [14602780.001]
  • [Cites] Am J Surg Pathol. 1999 Jun;23(6):678-85 [10366150.001]
  • [Cites] Cancer. 2006 Mar 15;106(6):1286-95 [16470605.001]
  • [Cites] Am J Surg Pathol. 2001 Dec;25(12):1478-84 [11717536.001]
  • [Cites] Pathol Int. 1996 Dec;46(12):939-46 [9110345.001]
  • [Cites] Am J Surg Pathol. 1984 Sep;8(9):655-68 [6476195.001]
  • [Cites] Ann Anat Pathol (Paris). 1974 Apr-Jun;19(2):129-48 [4480015.001]
  • (PMID = 18766471.001).
  • [ISSN] 1046-3976
  • [Journal-full-title] Endocrine pathology
  • [ISO-abbreviation] Endocr. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 40
  •  go-up   go-down


62. Shaha AR: Airway management in anaplastic thyroid carcinoma. Laryngoscope; 2008 Jul;118(7):1195-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Airway management in anaplastic thyroid carcinoma.
  • OBJECTIVES/HYPOTHESIS: In patients who present with advanced anaplastic thyroid cancer, airway management is difficult because of bilateral vocal cord paralysis or tracheal invasion by the tumor.
  • STUDY DESIGN: This is the author's 25 year experience with 30 patients who presented with anaplastic thyroid cancer and acute airway problems.
  • Airway management for these patients depended on the extent of distant disease and the family's understanding of the advanced nature of the disease and the palliative efforts.
  • CONCLUSIONS: Airway management was the most critical issue in patients who presented with anaplastic thyroid cancer and initial airway distress.
  • It is important to distinguish between poorly differentiated and anaplastic thyroid cancer and lymphoma for appropriate airway management.
  • [MeSH-major] Airway Obstruction / surgery. Carcinoma / surgery. Palliative Care. Thyroid Neoplasms / surgery
  • [MeSH-minor] Cricoid Cartilage / surgery. Humans. Neoplasm Invasiveness / pathology. Prognosis. Retrospective Studies. Survival Analysis. Thyroid Gland / surgery. Tomography, X-Ray Computed. Trachea / pathology. Vocal Cord Paralysis / etiology. Vocal Cord Paralysis / mortality

  • MedlinePlus Health Information. consumer health - Choking.
  • MedlinePlus Health Information. consumer health - Palliative Care.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18438260.001).
  • [ISSN] 1531-4995
  • [Journal-full-title] The Laryngoscope
  • [ISO-abbreviation] Laryngoscope
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


63. Dequanter D, Lothaire P, de Saint-Aubain Somerhausen N, Andry G: [Primary lymphoma of the thyroid gland]. Rev Med Brux; 2008 May-Jun;29(3):177-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary lymphoma of the thyroid gland].
  • [Transliterated title] Lymphome primitif de la thyroïde: à propos de 5 cas.
  • Malignant primary lymphoma of the thyroid gland is a rare disease.
  • The principal clinical sign is a rapidly growing goiter, leading to signs of compression, raising the question of differential diagnosis with anaplastic cancer.
  • We retrospectively reviewed the management and outcomes of five consecutives patients with thyroid lymphoma.
  • [MeSH-major] Lymphoma / drug therapy. Lymphoma / surgery. Thyroid Neoplasms / drug therapy. Thyroid Neoplasms / surgery

  • Genetic Alliance. consumer health - Thyroid Lymphoma.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18705599.001).
  • [ISSN] 0035-3639
  • [Journal-full-title] Revue médicale de Bruxelles
  • [ISO-abbreviation] Rev Med Brux
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Belgium
  •  go-up   go-down


64. Pacifico F, Paolillo M, Chiappetta G, Crescenzi E, Arena S, Scaloni A, Monaco M, Vascotto C, Tell G, Formisano S, Leonardi A: RbAp48 is a target of nuclear factor-kappaB activity in thyroid cancer. J Clin Endocrinol Metab; 2007 Apr;92(4):1458-66
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] RbAp48 is a target of nuclear factor-kappaB activity in thyroid cancer.
  • CONTEXT: We have recently shown that nuclear factor (NF)-kappaB activity is constitutively elevated in anaplastic human thyroid carcinomas.
  • The inhibition of NF-kappaB in the anaplastic thyroid carcinoma cell line (FRO) leads to increased susceptibility to apoptosis induced by chemotherapeutic drugs and to the block of oncogenic activity.
  • OBJECTIVES: To understand better the molecular mechanisms played by NF-kappaB in thyroid oncogenesis, we performed a differential proteomic analysis between FRO transfected with a superrepressor form of inhibitor of kappaBalpha (IkappaBalphaM) and the parental counterpart (FRO Neo cells).
  • Immunohistochemical analysis of normal and pathological human thyroid specimens confirmed that RbAp48 is strongly overexpressed in primary human carcinomas.
  • CONCLUSION: Our results show that RbAp48 is a NF-kappaB-regulated gene playing an important role in thyroid cancer cell autonomous proliferation.
  • [MeSH-major] Carrier Proteins / genetics. NF-kappa B / metabolism. Nuclear Proteins / genetics. Thyroid Neoplasms / metabolism


65. Trimboli P, Ulisse S, Graziano FM, Marzullo A, Ruggieri M, Calvanese A, Piccirilli F, Cavaliere R, Fumarola A, D'Armiento M: Trend in thyroid carcinoma size, age at diagnosis, and histology in a retrospective study of 500 cases diagnosed over 20 years. Thyroid; 2006 Nov;16(11):1151-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Trend in thyroid carcinoma size, age at diagnosis, and histology in a retrospective study of 500 cases diagnosed over 20 years.
  • Recently, the Italian Network of Cancer Registries analyzed 5101 cases of thyroid carcinoma showing a reduction of mortality rate of 4%/year.
  • This prompts us to evaluate the temporal trend in tumor size, age at diagnosis, and histology in a retrospective analysis of 500 thyroid cancers diagnosed over 20 years.
  • Thyroid cancers were divided in two groups.
  • In particular, papillary thyroid carcinoma (PTC) size decreased from 28 +/- 1.2mm to 14 +/- 0.8mm and follicular carcinoma from 40 +/- 6.3mm to 17 +/- 4.5 mm.
  • Age at diagnosis of all carcinomas increased significantly from 40 +/- 1.3 years in the first group to 48 +/- 0.9 years in the second group.
  • Analysis of the histological types revealed a significant increase of PTC rate in the second decade from 82% to 92% and a concomitant reduction of anaplastic thyroid carcinoma (ATC) from 3.7% to 1.0%.
  • In conclusion, it may be speculated that the above mentioned decreased mortality rate for thyroid carcinoma could be related to the significant reduction with time of cancer size, to the progressive increase of PTC rate and to the reduction of ATC rate.
  • These data, if confirmed in other series, underscore the importance of evaluating thyroid nodules smaller than 10mm and corroborate recent findings suggesting that age be reconsidered as an independent prognostic factor for differentiated thyroid cancers.
  • [MeSH-major] Carcinoma, Papillary / mortality. Carcinoma, Papillary / pathology. Thyroid Neoplasms / mortality. Thyroid Neoplasms / pathology
  • [MeSH-minor] Age Distribution. Carcinoma / mortality. Carcinoma / pathology. Cell Differentiation. Humans. Italy / epidemiology. Mortality / trends. Registries / statistics & numerical data. Retrospective Studies. Sex Distribution

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17123342.001).
  • [ISSN] 1050-7256
  • [Journal-full-title] Thyroid : official journal of the American Thyroid Association
  • [ISO-abbreviation] Thyroid
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


66. Schuler G, Greven H, Kowalewski MP, Döring B, Ozalp GR, Hoffmann B: Placental steroids in cattle: hormones, placental growth factors or by-products of trophoblast giant cell differentiation? Exp Clin Endocrinol Diabetes; 2008 Jul;116(7):429-36
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Specific features of bovine placental steroidogenesis are 1) the expression of all enzymes needed for the production of estrogens from cholesterol in the trophoblast 2) an only marginal and temporal contribution to peripheral maternal P4 levels restricted to a period between approx. days 150 - 240 of gestation 3) the predominance of sulfoconjugated over free E1 and 4) a complementary setting of steroidogenic enzymes in the two morphologically discriminable trophoblast cell types, the uninucleated trophoblast cells (UTC) and the trophoblast giant cells (TGC).
  • The down-regulation of P450scc and P450c17 and the up-regulation of 3beta-HSD and aromatase during the differentiation of TGC from UTC in parallel with the up-regulation of ER beta and estrogen sulfotransferase in maturing TGC suggests a function of placental estrogens primarily as autoor intracrine regulators during this process and assigns to conjugated placental estrogens a role as inactivated by-products of TGC differentiation intended for excretion.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18704836.001).
  • [ISSN] 0947-7349
  • [Journal-full-title] Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association
  • [ISO-abbreviation] Exp. Clin. Endocrinol. Diabetes
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Gonadal Steroid Hormones
  • [Number-of-references] 74
  •  go-up   go-down


67. Endo T, Nishio M, Enzler T, Cottam HB, Fukuda T, James DF, Karin M, Kipps TJ: BAFF and APRIL support chronic lymphocytic leukemia B-cell survival through activation of the canonical NF-kappaB pathway. Blood; 2007 Jan 15;109(2):703-10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • On the other hand, specifically blocking the canonical NF-kappaB pathway with UTC, an inhibitor of IkappaB kinase beta (IKKbeta), or transfection of CLL cells with the IkappaBalpha super-repressor, blocked the capacity of BAFF and APRIL to promote CLL cell survival in vitro.
  • These findings suggest that inhibitors of protein kinase IKKbeta, which is required for activation of the canonical NF-kappaB pathway, might have a therapeutic role in this disease.
  • [MeSH-minor] B-Cell Maturation Antigen / biosynthesis. B-Cell Maturation Antigen / immunology. Carboxylic Acids / chemical synthesis. Carboxylic Acids / chemistry. Carboxylic Acids / pharmacology. Cell Fractionation. Cell Survival / immunology. Flow Cytometry / methods. Humans. Protein Kinase Inhibitors / chemical synthesis. Protein Kinase Inhibitors / chemistry. Protein Kinase Inhibitors / pharmacology. Sensitivity and Specificity. Thiophenes / chemical synthesis. Thiophenes / chemistry. Thiophenes / pharmacology. Transmembrane Activator and CAML Interactor Protein / biosynthesis. Transmembrane Activator and CAML Interactor Protein / immunology

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • Genetic Alliance. consumer health - Leukemia, B-cell, chronic.
  • COS Scholar Universe. author profiles.
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 2004 Sep 16;431(7006):350-5 [15372042.001]
  • [Cites] Curr Top Microbiol Immunol. 1995;194:117-26 [7895486.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Sep 27;102(39):13944-9 [16166262.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Aug 10;101(32):11755-60 [15284443.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Nov 26;99(24):15524-9 [12434020.001]
  • [Cites] Cell. 2004 Jan 23;116(2):281-97 [14744438.001]
  • [Cites] N Engl J Med. 2005 Oct 27;353(17):1793-801 [16251535.001]
  • (PMID = 16973958.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 5-(4-fluorophenyl)-2-ureido-thiophene-3 carboxylic acid amide; 0 / B-Cell Activating Factor; 0 / B-Cell Maturation Antigen; 0 / Carboxylic Acids; 0 / NF-kappa B; 0 / Protein Kinase Inhibitors; 0 / TNFSF13 protein, human; 0 / TNFSF13B protein, human; 0 / Thiophenes; 0 / Transmembrane Activator and CAML Interactor Protein; 0 / Tumor Necrosis Factor Ligand Superfamily Member 13
  • [Other-IDs] NLM/ PMC1890820
  •  go-up   go-down


68. Zou CC, Zhao ZY, Liang L: Childhood minimally invasive follicular carcinoma: clinical features and immunohistochemistry analysis. J Paediatr Child Health; 2010 Apr;46(4):166-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Childhood minimally invasive follicular carcinoma: clinical features and immunohistochemistry analysis.
  • AIM: To report on two cases of childhood thyroid minimally invasive follicular carcinoma (MIFC) to highlight the clinical features, laboratory findings and diagnosis of this rare disease.
  • RESULTS: From 2000 to 2008, a total of 15 cases of thyroid cancer were confirmed by pathological analysis, which account for about 2.16% of all malignant solid tumours.
  • They included nine of thyroid papillary carcinoma, two of MIFC and one of undifferentiated thyroid carcinoma.
  • Thyroid mass was found as the primary sign.
  • Imaging findings showed well-defined heterogeneous mass and radionuclide scintigraphy with 99mTc demonstrated small cold nodules in the right lobe of thyroid in two cases.
  • Histopathology confirmed the diagnosis of MIFC.
  • Immunohistochemical staining was positive for thyroglobulin, thyroid transcription factor-1, galectin-3, Hector Battifora mesothelial antigen-1, cytokeratin-AE1/AE3, cytokeratin-19, proliferating cell nuclear antigen and E-cadherin in two cases, and S-100 in one case, while CD56, vimentin and desmin were negative.
  • CONCLUSION: MIFC is exceedingly rare in children and should be included in the differential diagnosis of thyroid mass.
  • The diagnosis of MIFC depends mainly on the pathological findings.
  • [MeSH-major] Adenocarcinoma, Follicular / pathology. Thyroid Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20105250.001).
  • [ISSN] 1440-1754
  • [Journal-full-title] Journal of paediatrics and child health
  • [ISO-abbreviation] J Paediatr Child Health
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  •  go-up   go-down


69. Stulp RP, Herkert JC, Karrenbeld A, Mol B, Vos YJ, Sijmons RH: Thyroid cancer in a patient with a germline MSH2 mutation. Case report and review of the Lynch syndrome expanding tumour spectrum. Hered Cancer Clin Pract; 2008;6(1):15-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thyroid cancer in a patient with a germline MSH2 mutation. Case report and review of the Lynch syndrome expanding tumour spectrum.
  • Lynch syndrome (HNPCC) is a dominantly inherited disorder characterized by germline defects in DNA mismatch repair (MMR) genes and the development of a variety of cancers, predominantly colorectal and endometrial.
  • Recently, she had been diagnosed with an undifferentiated carcinoma of the thyroid and an adenoma of her coecum.
  • Although the thyroid carcinoma was not MSI-high (1 out of 5 microsatellites instable), it did show complete loss of immunohistochemical expression for the MSH2 protein, suggesting that this tumour was not coincidental.
  • Although the risks for some tumour types, including breast cancer, soft tissue sarcoma and prostate cancer, are not significantly increased in Lynch syndrome, MMR deficiency in the presence of a corresponding germline defect has been demonstrated in incidental cases of a growing range of tumour types, which is reviewed in this paper.
  • Interestingly, the MSH2-associated tumour spectrum appears to be wider than that of MLH1 and generally the risk for most extra-colonic cancers appears to be higher for MSH2 than for MLH1 mutation carriers.
  • Together with a previously reported case, our findings show that anaplastic thyroid carcinoma can develop in the setting of Lynch syndrome.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2004 Nov 15;22(22):4486-94 [15483016.001]
  • [Cites] Cancer Genet Cytogenet. 2004 Dec;155(2):149-51 [15571801.001]
  • [Cites] Int J Cancer. 1999 Apr 12;81(2):214-8 [10188721.001]
  • [Cites] Cancer Res. 1999 Jan 15;59(2):294-7 [9927034.001]
  • [Cites] Cancer Res. 1999 Jan 15;59(2):290-3 [9927033.001]
  • [Cites] Fam Cancer. 2008;7(3):191-8 [18049911.001]
  • [Cites] Genes Chromosomes Cancer. 2008 Apr;47(4):326-32 [18181177.001]
  • [Cites] Eur J Hum Genet. 2008 Jan;16(1):62-72 [17851451.001]
  • [Cites] Hum Mutat. 2007 Nov;28(11):1084-90 [17557300.001]
  • [Cites] Obstet Gynecol. 2007 Aug;110(2 Pt 2):543-5 [17666659.001]
  • [Cites] Fam Cancer. 2007;6(1):141-5 [17051350.001]
  • [Cites] J Med Genet. 2007 Jul;44(7):e83 [17601929.001]
  • [Cites] Cancer. 2007 Jun 1;109(11):2349-56 [17440981.001]
  • [Cites] Nat Clin Pract Oncol. 2007 Feb;4(2):130-4 [17259933.001]
  • [Cites] Gut. 2006 Dec;55(12):1781-8 [16636019.001]
  • [Cites] Hum Pathol. 2006 Nov;37(11):1498-502 [16996571.001]
  • [Cites] Nat Genet. 1997 Oct;17(2):135-6 [9326924.001]
  • [Cites] Genes Chromosomes Cancer. 1997 Apr;18(4):269-78 [9087566.001]
  • [Cites] Hum Mol Genet. 1997 Jan;6(1):105-10 [9002677.001]
  • [Cites] Cancer. 1996 May 1;77(9):1836-43 [8646682.001]
  • [Cites] Gastroenterology. 1996 Apr;110(4):1020-7 [8612988.001]
  • [Cites] N Engl J Med. 1995 Mar 30;332(13):839-47 [7661930.001]
  • [Cites] Fam Cancer. 2004;3(2):123-7 [15340263.001]
  • [Cites] Mod Pathol. 2004 Aug;17(8):981-9 [15143336.001]
  • [Cites] Gastroenterology. 2004 Jul;127(1):17-25 [15236168.001]
  • [Cites] Am J Hum Genet. 2004 Jun;74(6):1262-9 [15098177.001]
  • [Cites] Am J Hum Genet. 2004 May;74(5):954-64 [15077197.001]
  • [Cites] Gastroenterology. 2004 Feb;126(2):576-85 [14762794.001]
  • [Cites] J Natl Cancer Inst. 2004 Feb 18;96(4):261-8 [14970275.001]
  • [Cites] Fam Cancer. 2001;1(2):101-5 [14574005.001]
  • [Cites] Histopathology. 2003 Sep;43(3):297-9 [12940783.001]
  • [Cites] Am J Med Genet A. 2003 Aug 30;121A(2):159-62 [12910497.001]
  • [Cites] Am J Hum Genet. 2003 Jan;72(1):213-6 [12549480.001]
  • [Cites] J Med Genet. 2002 May;39(5):335-9 [12011152.001]
  • [Cites] Cancer Res. 2002 Jan 15;62(2):359-62 [11809679.001]
  • [Cites] Am J Hum Genet. 2002 Jan;70(1):26-37 [11709755.001]
  • [Cites] J Clin Oncol. 2001 Oct 15;19(20):4074-80 [11600610.001]
  • [Cites] Cancer Res. 2001 Jun 1;61(11):4541-4 [11389087.001]
  • [Cites] Breast Cancer Res Treat. 1999 Jan;53(1):87-91 [10206076.001]
  • [Cites] J Med Genet. 2005 Jun;42(6):491-6 [15937084.001]
  • [Cites] Clin Cancer Res. 2005 Jul 1;11(13):4689-93 [16000562.001]
  • [Cites] Gastroenterology. 2005 Aug;129(2):415-21 [16083698.001]
  • [Cites] Eur J Hum Genet. 2006 May;14(5):561-6 [16418736.001]
  • [Cites] J Natl Cancer Inst. 2006 Mar 1;98(5):358-61 [16507833.001]
  • [Cites] Hum Genet. 1999 Nov;105(5):437-41 [10598809.001]
  • [Cites] Oncogene. 2000 Mar 23;19(13):1719-23 [10763829.001]
  • [Cites] Genes Chromosomes Cancer. 2000 Dec;29(4):353-5 [11066081.001]
  • [Cites] Am J Med Genet A. 2006 Feb 1;140(3):195-9 [16372347.001]
  • [Cites] Am J Gastroenterol. 2006 Jan;101(1):193-6 [16405554.001]
  • [Cites] Am J Med Genet A. 2005 Dec 1;139A(2):96-105; discussion 96 [16283678.001]
  • [Cites] Hum Pathol. 2005 Dec;36(12):1322-6 [16311127.001]
  • [Cites] Am J Gastroenterol. 2005 Aug;100(8):1886-91 [16144131.001]
  • (PMID = 19706203.001).
  • [ISSN] 1897-4287
  • [Journal-full-title] Hereditary cancer in clinical practice
  • [ISO-abbreviation] Hered Cancer Clin Pract
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Poland
  • [Other-IDs] NLM/ PMC2735069
  •  go-up   go-down


70. Milder IE, Klungel OH, Mantel-Teeuwisse AK, Verschuren WM, Bemelmans WJ: Relation between body mass index, physical inactivity and use of prescription drugs: the Doetinchem Cohort Study. Int J Obes (Lond); 2010 Jun;34(6):1060-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Obesity and physical inactivity are associated with several diseases such as diabetes, cardiovascular diseases, musculoskeletal complaints, osteoporosis, certain types of cancer and depression.
  • Drugs were coded according to the WHO Anatomical Therapeutic Chemical (ATC) classification system.
  • Persons were defined as a user of a certain drug class if they filed at least one prescription in the year around (+/-6 months) the examination.
  • [MeSH-major] Body Mass Index. Obesity / complications. Prescription Drugs / therapeutic use. Sedentary Lifestyle. Smoking

  • MedlinePlus Health Information. consumer health - Health Risks of an Inactive Lifestyle.
  • MedlinePlus Health Information. consumer health - Obesity.
  • MedlinePlus Health Information. consumer health - Smoking.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20125097.001).
  • [ISSN] 1476-5497
  • [Journal-full-title] International journal of obesity (2005)
  • [ISO-abbreviation] Int J Obes (Lond)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Prescription Drugs
  •  go-up   go-down


71. Kolar M, Urbanek K, Vagnerova I, Koukalova D: The influence of antibiotic use on the occurrence of vancomycin-resistant enterococci. J Clin Pharm Ther; 2006 Feb;31(1):67-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • DHO antibiotic consumption data were processed according to the anatomical therapeutic chemical (ATC)/defined daily dose (DDD) system valid in 2003 and expressed in defined daily dose per 100 bed-days (DDD/100 bed-days) for each year of the period.
  • [MeSH-major] Anti-Bacterial Agents / therapeutic use. Enterococcus / isolation & purification. Vancomycin Resistance

  • MedlinePlus Health Information. consumer health - Antibiotics.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16476122.001).
  • [ISSN] 0269-4727
  • [Journal-full-title] Journal of clinical pharmacy and therapeutics
  • [ISO-abbreviation] J Clin Pharm Ther
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents
  •  go-up   go-down


72. Htwe TT, Hamdi MM, Swethadri GK, Wong JO, Soe MM, Abdullah MS: Incidence of thyroid malignancy among goitrous thyroid lesions from the Sarawak General Hospital 2000-2004. Singapore Med J; 2009 Jul;50(7):724-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidence of thyroid malignancy among goitrous thyroid lesions from the Sarawak General Hospital 2000-2004.
  • INTRODUCTION: Thyroid cancer is the most common among all endocrine malignancies.
  • The worldwide prevalence of goitre in the general population is estimated at 4-7 percent and the incidence of malignancy in goitrous thyroid is about ten percent.
  • It is postulated that goitrous thyroid is a precursor lesion to the development of malignant thyroid diseases.
  • As Sarawak is a state well known for endemic goitre, this study focused on establishing the incidence of thyroid malignancy among goitrous thyroid swellings.
  • METHODS: This study was a hospital-based retrospective study on the archived collection of the surgically-removed thyroid specimens from the Sarawak General Hospital, Malaysia.
  • Cases were grouped into cancer and non-cancer groups.
  • The cancer group included papillary thyroid carcinoma (PTC), PTC follicular variant, follicular carcinoma and anaplastic carcinoma (ANA).
  • RESULTS: A total of 820 thyroid cases which underwent surgical removal in years 2000 to 2004 were collected.
  • It was observed that the highest prevalence of thyroid swelling cases occurred in the age group 41-60 years while the lowest prevalence occurred in the age group under 21 years, 371 (45.2 percent) vs. 31 (3.8 percent).
  • 55 cases (6.7 percent) were found to be cancerous and the rest (93.3 percent) were non-cancerous thyroid swellings.
  • Histologically, the highest incidence of carcinoma was PTC (4.0 percent) and the lowest was ANA (0.2 percent).
  • CONCLUSION: Based on our observations, although goitrous thyroid swelling is quite a common problem in Sarawak, thyroid malignancy is not a major issue.
  • Among thyroid malignancies, PTC is the most common histological type of malignancy.
  • [MeSH-major] Goiter / complications. Goiter / epidemiology. Thyroid Neoplasms / complications. Thyroid Neoplasms / epidemiology
  • [MeSH-minor] Adenocarcinoma, Follicular / diagnosis. Adenocarcinoma, Follicular / epidemiology. Adenocarcinoma, Follicular / ethnology. Adult. Aged. Carcinoma / diagnosis. Carcinoma / epidemiology. Carcinoma / ethnology. Carcinoma, Papillary, Follicular / diagnosis. Carcinoma, Papillary, Follicular / epidemiology. Carcinoma, Papillary, Follicular / ethnology. Female. Humans. Incidence. Malaysia. Male. Middle Aged. Prevalence. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19644631.001).
  • [ISSN] 0037-5675
  • [Journal-full-title] Singapore medical journal
  • [ISO-abbreviation] Singapore Med J
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Singapore
  •  go-up   go-down


73. Trajkov D, Trajchevska M, Arsov T, Petlichkovski A, Strezova A, Efinska-Mladenovska O, Sandevski A, Spiroski M: Association of 22 cytokine gene polymorphisms with tuberculosis in Macedonians. Indian J Tuberc; 2009 Jul;56(3):117-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: TNF-alpha-238/G, IL-1R psti1970/C, IL-1beta + 3962/T:T, IL-4-1098/T:T, IFNgamma utr5644/A:A, IL-10-1082/G:G, IL-4-590/C:C, IL-10/ATC, IL-4/TCT, IL-4/TCC, IL-10/ATC:GCC, IL-4/TCT:TTT, IL-4/TCC:TTC, IL-10/GCC:GCC and IL-4/TCC:TCC were positively associated with TB, while protective association was identified for IL-4-098/G, IL-1beta + 3962/C, IFNgamma utr5644/T, IL-1beta + 3962/C:T, IL-4-1098/G:T, IL-4-590/C:T, IFNgamma utr5644/A:T, IL-4/GCC, IL-4/TTC and IL-4/GCC:TTC.
  • [MeSH-major] Cytokines / genetics. Genetic Predisposition to Disease. Polymorphism, Genetic. Tuberculosis / epidemiology

  • Genetic Alliance. consumer health - Tuberculosis.
  • MedlinePlus Health Information. consumer health - Tuberculosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20349753.001).
  • [ISSN] 0019-5707
  • [Journal-full-title] The Indian journal of tuberculosis
  • [ISO-abbreviation] Indian J Tuberc
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Cytokines; 0 / Interleukin-2; 0 / Interleukins
  •  go-up   go-down


74. Zerilli M, Zito G, Martorana A, Pitrone M, Cabibi D, Cappello F, Giordano C, Rodolico V: BRAF(V600E) mutation influences hypoxia-inducible factor-1alpha expression levels in papillary thyroid cancer. Mod Pathol; 2010 Aug;23(8):1052-60
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] BRAF(V600E) mutation influences hypoxia-inducible factor-1alpha expression levels in papillary thyroid cancer.
  • In thyroid carcinomas, hypoxia-inducible factor-1alpha expression was found increased in differentiated, poorly differentiated, medullary and anaplastic variants.
  • We have previously shown the role of BRAF(V600E) mutation in papillary thyroid cancer cells as a factor that facilitates tumor cell growth and progression.
  • In this study, we tested the hypothesis that BRAF(V600E) mutation influences hypoxia-inducible factor-1alpha expression in papillary thyroid carcinoma cells.
  • We analyzed 27 papillary thyroid carcinomas, 13 of which presented BRAF(V600E) mutation.
  • A BRAF wild-type papillary thyroid carcinoma cell line and a BRAF(V600E) mutated papillary thyroid carcinoma cell line were selected to study the effects of BRAF mutation on hypoxia-inducible factor-1alpha expression in vitro.
  • Pharmacological inhibition of BRAF significantly reduces hypoxia-inducible factor-1alpha expression levels in papillary thyroid carcinoma cell line harboring BRAF(V600E) mutation.
  • Our results suggest that hypoxia-inducible factor-1alpha is expressed in papillary thyroid carcinomas and is regulated not only by hypoxia but also by BRAF(V600E)-mediated signaling pathway.
  • [MeSH-major] Adenocarcinoma, Papillary / genetics. Mutation. Proto-Oncogene Proteins B-raf / genetics. Repressor Proteins / genetics. Thyroid Neoplasms / genetics

  • Genetic Alliance. consumer health - Thyroid cancer, papillary.
  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20473281.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Small Interfering; 0 / Repressor Proteins; EC 1.- / Mixed Function Oxygenases; EC 1.14.11.- / HIF1AN protein, human; EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf
  •  go-up   go-down


75. Chung KW, Yang SK, Lee GK, Kim EY, Kwon S, Lee SH, Park DJ, Lee HS, Cho BY, Lee ES, Kim SW: Detection of BRAFV600E mutation on fine needle aspiration specimens of thyroid nodule refines cyto-pathology diagnosis, especially in BRAF600E mutation-prevalent area. Clin Endocrinol (Oxf); 2006 Nov;65(5):660-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of BRAFV600E mutation on fine needle aspiration specimens of thyroid nodule refines cyto-pathology diagnosis, especially in BRAF600E mutation-prevalent area.
  • BACKGROUND: Between 10 and 30% of the fine needle aspiration biopsies (FNABs) of thyroid nodules are diagnosed as 'indeterminate'.
  • In Korea, most thyroid cancer is the classic papillary type and the BRAF(V600E) mutation is highly prevalent.
  • AIM: To evaluate the role of pre-operative detection of BRAF(V600E) mutation in the FNAB specimens of thyroid nodules in a BRAF(V600E) mutation-prevalent geographical area.
  • PATIENTS AND METHODS: In 137 specimens of FNAB (107 papillary thyroid carcinomas (PTC); 3 follicular thyroid carcinomas (FTC); 2 undifferentiated thyroid carcinomas; 25 benign lesions), both direct DNA sequencing and PCR-RFLP were used for detecting the BRAF(V600E) mutation.
  • RESULTS: The BRAF(V600E) mutation was present in 93 (83%) of 112 thyroid cancers.
  • CONCLUSION: Detection of the BRAF(V600E) mutation in FNAB specimens refines the FNAB-cytology diagnosis, especially in a BRAF(V600E) mutation-prevalent area.
  • [MeSH-major] Carcinoma, Papillary / genetics. Point Mutation. Proto-Oncogene Proteins B-raf / genetics. Thyroid Neoplasms / genetics. Thyroid Nodule / genetics
  • [MeSH-minor] Adenocarcinoma, Follicular / genetics. Adult. Aged. Biopsy, Fine-Needle. Carcinoma, Papillary, Follicular / genetics. DNA Mutational Analysis. DNA, Neoplasm / analysis. Diagnosis, Differential. Female. Humans. Korea. Male. Middle Aged. Polymorphism, Restriction Fragment Length. Prospective Studies. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17054470.001).
  • [ISSN] 0300-0664
  • [Journal-full-title] Clinical endocrinology
  • [ISO-abbreviation] Clin. Endocrinol. (Oxf)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Neoplasm; EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf
  •  go-up   go-down


76. Kárpati K, Brandtmüller A, Májer I, Gulácsi L: [Priorisation in health-care; drug-reimbursement priorities in Hungary in 2004]. Acta Pharm Hung; 2006;76(4):191-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In our research we assessed the drug reimbursement of the National Health Insurance Fund Administration (NHIFA) in different ATC groups.
  • As for the number of patients in the cancer group it is much smaller, but as a result of the huge costs of their therapies these belong to the highest reimbursed categories as well.
  • HUF spent on the treatment of cancer, diabetic and some psychiatric disorders.

  • MedlinePlus Health Information. consumer health - Medicines.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17575799.001).
  • [ISSN] 0001-6659
  • [Journal-full-title] Acta pharmaceutica Hungarica
  • [ISO-abbreviation] Acta Pharm Hung
  • [Language] hun
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Hungary
  • [Chemical-registry-number] 0 / Pharmaceutical Preparations
  •  go-up   go-down


77. Guida T, Salvatore G, Faviana P, Giannini R, Garcia-Rostan G, Provitera L, Basolo F, Fusco A, Carlomagno F, Santoro M: Mitogenic effects of the up-regulation of minichromosome maintenance proteins in anaplastic thyroid carcinoma. J Clin Endocrinol Metab; 2005 Aug;90(8):4703-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mitogenic effects of the up-regulation of minichromosome maintenance proteins in anaplastic thyroid carcinoma.
  • CONTEXT: Anaplastic thyroid carcinomas (ATC) are among the most aggressive human malignancies and are characterized by high mitotic activity.
  • OBJECTIVE: In an attempt to cast light on the mechanisms governing ATC, we evaluated MCM5 and MCM7 expression in human normal, papillary (PTC), and anaplastic thyroid samples, as well as in primary culture cells and transgenic mouse models.
  • RESULTS: MCM5 and MCM7 expression was high in 65% of ATC and negligible in normal thyroid tissue and papillary thyroid carcinomas.
  • In ATC, high MCM5 and MCM7 expression was paralleled by high levels of MCM2 and MCM6.
  • An analysis of human ATC primary cell cultures and of a transgenic mouse model of ATC confirmed these findings.
  • An increased transcription rate accounted for MCM7 up-regulation, because the activity of the MCM7 promoter was more than 10-fold higher in ATC cells compared with normal thyroid cells.
  • Adoptive overexpression of wild-type p53, but not of its inactive (R248W and R273H) mutants, strongly down-regulated transcription from the MCM7 promoter, suggesting that p53 knock-out contributes to MCM7 up-regulation in ATC.
  • Treatment with small inhibitory duplex RNAs, which decrease MCM7 protein levels, reduced the rate of DNA synthesis in ATC cells.
  • CONCLUSION: MCM proteins are overexpressed in ATC and sustain the high proliferative capacity of ATC cells.
  • [MeSH-major] Carcinoma, Papillary / physiopathology. Cell Cycle Proteins / genetics. Cell Cycle Proteins / metabolism. Nuclear Proteins / genetics. Nuclear Proteins / metabolism. Thyroid Neoplasms / physiopathology

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15899946.001).
  • [ISSN] 0021-972X
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / DNA-Binding Proteins; 0 / MCM5 protein, human; 0 / Mitogens; 0 / Nuclear Proteins; 0 / RNA, Messenger; 9007-49-2 / DNA; EC 3.6.4.12 / MCM2 protein, human; EC 3.6.4.12 / MCM6 protein, human; EC 3.6.4.12 / MCM7 protein, human; EC 3.6.4.12 / Minichromosome Maintenance Complex Component 2; EC 3.6.4.12 / Minichromosome Maintenance Complex Component 6; EC 3.6.4.12 / Minichromosome Maintenance Complex Component 7
  •  go-up   go-down


78. King AD, Yeung DK, Ahuja AT, Tse GM, Chan AB, Lam SS, van Hasselt AC: In vivo 1H MR spectroscopy of thyroid carcinoma. Eur J Radiol; 2005 Apr;54(1):112-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In vivo 1H MR spectroscopy of thyroid carcinoma.
  • To determine if proton magnetic resonance spectroscopy (1H MRS) of thyroid carcinoma is feasible and to determine if 1H MRS spectra of malignant tumors differ from that of normal thyroid tissue.
  • We performed 1H MRS at 1.5 T at echo-times (TE) 136 and 272 ms to examine eight patients with thyroid cancer (primary tumour or nodal metastasis) larger than 1 cm3 in size and five volunteers with normal thyroids.
  • Spectra acquired from six primary tumors (three anaplastic carcinomas, two papillary carcinomas and one follicular carcinoma) and two nodes (two papillary carcinoma metastases) were analyzed in the time-domain using a non-linear least squares fitting algorithm with incorporation of prior knowledge.
  • Choline (3.2 ppm) was identified in all solid carcinomas with a mean choline/creatine of 4.3 at TE 136 ms and 5.4 at TE 272 ms.
  • Ratios for malignant tumors at TE 136 ms ranged from 1.6 in well differentiated follicular carcinoma to 9.4 in anaplastic carcinoma.
  • No choline was detected in normal thyroid tissues.
  • Our results showed that 1H MRS is a feasible technique for the evaluation of malignant thyroid tumors larger than 1 cm3 and that proton spectra of malignant tumors differ from that of normal thyroid tissue.
  • [MeSH-major] Carcinoma / diagnosis. Magnetic Resonance Spectroscopy / methods. Thyroid Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Algorithms. Choline / metabolism. Creatine / metabolism. Diagnosis, Differential. Female. Humans. Least-Squares Analysis. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CREATINE .
  • Hazardous Substances Data Bank. CHOLINE CHLORIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15797300.001).
  • [ISSN] 0720-048X
  • [Journal-full-title] European journal of radiology
  • [ISO-abbreviation] Eur J Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] MU72812GK0 / Creatine; N91BDP6H0X / Choline
  •  go-up   go-down


79. Prommegger R, Häussler B, Gabriel M, Ensinger C, Sauper T, Hager J: Insular-type component follicular thyroid carcinoma in a 10-year-old girl--case report. J Pediatr Surg; 2006 Jun;41(6):e5-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Insular-type component follicular thyroid carcinoma in a 10-year-old girl--case report.
  • Insular-type carcinoma of the thyroid is a rare form of undifferentiated thyroid cancer.
  • The manifestation of disease occurs mainly in adults and is extremely rare in children.
  • Prognosis of this type of thyroid carcinoma is unfavorable in childhood.
  • The history of a 10-year-old girl with insular-type thyroid carcinoma is presented.
  • [MeSH-major] Adenocarcinoma, Follicular / classification. Adenocarcinoma, Follicular / surgery. Rare Diseases / pathology. Rare Diseases / surgery. Thyroid Neoplasms / classification. Thyroid Neoplasms / surgery. Thyroidectomy

  • MedlinePlus Health Information. consumer health - Rare Diseases.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16769328.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


80. Mensch J, Mitchell M: Choosing a career in athletic training: exploring the perceptions of potential recruits. J Athl Train; 2008 Jan-Mar;43(1):70-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Choosing a career in athletic training: exploring the perceptions of potential recruits.
  • CONTEXT: The success of any academic program, including athletic training, depends upon attracting and keeping quality students.
  • Therefore, understanding potential recruits' perceptions of athletic training is important.
  • OBJECTIVE: To (1) gain insight regarding undergraduate students' decisions to enter or not enter an athletic training education program (ATEP), and (2) examine potential athletic training recruits' perceptions of the roles and responsibilities of certified athletic trainers.
  • DESIGN: We used a descriptive study employing a grounded theory approach to explore perceptions of the athletic training profession by college students with various levels of interest in athletic training.
  • SETTING: Athletic training education program from a National Collegiate Athletic Association Division I research-intensive university.
  • RESULTS: Three contributing factors appeared to influence the recruitment of students to a career in athletic training:.
  • (1) a strong affiliation to a sports/team model, (2) initial exposure at the high school level, and (3) an incomplete understanding of athletic training.
  • Educators and administrators must create a comprehensive recruitment strategy using factors that influence potential recruits' decisions to enter the athletic training profession, specifically their association with sports and their experiences during high school.
  • [MeSH-major] Athletic Injuries / prevention & control. Career Choice. Decision Making. Perception. Professional Role. Sports. Sports Medicine. Students

  • MedlinePlus Health Information. consumer health - Sports Fitness.
  • MedlinePlus Health Information. consumer health - Sports Injuries.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Med Educ. 2002 May;36(5):466-71 [12028397.001]
  • [Cites] Nurs Stand. 2001 Jun 27-Jul 3;15(41):33-8 [12205845.001]
  • [Cites] Soc Sci Med. 2003 Feb;56(3):603-16 [12570977.001]
  • [Cites] J Prof Nurs. 2003 Jan-Feb;19(1):38-48 [12649818.001]
  • [Cites] Med Teach. 2003 Mar;25(2):155-60 [12745523.001]
  • [Cites] J Nurs Educ. 2003 May;42(5):227-30 [12769428.001]
  • [Cites] Qual Health Res. 2004 Mar;14(3):411-29 [15011907.001]
  • [Cites] J Nurs Educ. 2004 Aug;43(8):346-51 [15344370.001]
  • [Cites] Res Q. 1979 Oct;50(3):482-93 [545535.001]
  • [Cites] Res Q Exerc Sport. 1989 Mar;60(1):81-92 [2489828.001]
  • [Cites] Fam Med. 2005 May;37(5):348-53 [15883901.001]
  • [Cites] Int J Nurs Pract. 2007 Apr;13(2):75-80 [17394514.001]
  • (PMID = 18335016.001).
  • [ISSN] 1938-162X
  • [Journal-full-title] Journal of athletic training
  • [ISO-abbreviation] J Athl Train
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2231402
  • [Keywords] NOTNLM ; career choice / recruitment / socialization / subjective warrant
  •  go-up   go-down


81. Rusinek D, Gubała E: [BRAF initiating mutations in the papillary thyroid carcinoma]. Endokrynol Pol; 2006 Jul-Aug;57(4):438-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [BRAF initiating mutations in the papillary thyroid carcinoma].
  • Among genetic alterations most important for the initiation of papillary thyroid carcinoma (PTC) is mutation T1799A in the BRAF gene which is the most frequent event (54.5%) in this type of thyroid cancer.
  • It is seen in all stages, from microcarcinoma through clinically overt disease to anaplastic cancer.
  • In PTC cases with BRAF mutation V600E the prognosis is poorer, with more cancer invasiveness, metastasis and recurrence.
  • The presence of BRAF mutation is related to the specific gene expression signature, different than in cancer cases showing RET/PTC rearrangement or no known initiating mutation.
  • [MeSH-major] Biomarkers, Tumor / genetics. Carcinoma, Papillary / genetics. Point Mutation / genetics. Proto-Oncogene Proteins B-raf / genetics. Thyroid Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17006850.001).
  • [ISSN] 0423-104X
  • [Journal-full-title] Endokrynologia Polska
  • [ISO-abbreviation] Endokrynol Pol
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Oncogene Proteins, Fusion; EC 2.7.10.1 / Proto-Oncogene Proteins c-ret; EC 2.7.10.1 / RET protein, human; EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf; EC 3.6.5.2 / ras Proteins
  • [Number-of-references] 60
  •  go-up   go-down


82. Duborija-Kovacević N, Tomić Z: [Did a reform strategy in drug management improve doctors' prescribing habits in Montenegro: the example for the cardiovascular drugs]. Vojnosanit Pregl; 2006 May;63(5):451-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The reform strategy covered: an information system named "The Control of Distribution and Use of Drugs", a new List of Essential Drugs (that are reimbursed by the Republic Fund for Health), legislative and regulatory measures in order to establish a better control of drug prescribing and more efficient processing of the prescriptions.
  • All the drugs were classified according to the uniform anatomical-therapeutic-chemical (ATC) classification of the drugs.
  • RESULTS: Although prescribing and the resulting outpatient use of cardiovascular drugs (ATC group C) that were reimbursed by the Republic Fund for Health was increased approximately by 13% in 2004 in comparison with 2000 (67.98 vs. 60.17 DDD/1000 inh.
  • [MeSH-major] Cardiovascular Agents / therapeutic use. Practice Patterns, Physicians'

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16758794.001).
  • [ISSN] 0042-8450
  • [Journal-full-title] Vojnosanitetski pregled
  • [ISO-abbreviation] Vojnosanit Pregl
  • [Language] srp
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Serbia and Montenegro
  • [Chemical-registry-number] 0 / Cardiovascular Agents
  •  go-up   go-down


83. Kozlowski P, de Mezer M, Krzyzosiak WJ: Trinucleotide repeats in human genome and exome. Nucleic Acids Res; 2010 Jul;38(12):4027-39
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We found that some triplet repeats, specifically CNG, are overrepresented, while CTT, ATC, AAC and AAT are underrepresented in exons.

  • Hazardous Substances Data Bank. Glutamine .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nucleic Acids Res. 2008 Nov;36(19):6260-8 [18832370.001]
  • [Cites] Nat Protoc. 2009;4(1):44-57 [19131956.001]
  • [Cites] PLoS Genet. 2009 Mar;5(3):e1000397 [19266028.001]
  • [Cites] Am J Hum Genet. 2000 Jan;66(1):6-15 [10631132.001]
  • [Cites] Am J Hum Genet. 2000 Jan;66(1):187-95 [10631150.001]
  • [Cites] Genome Res. 2000 Jan;10(1):62-71 [10645951.001]
  • [Cites] Biochem Biophys Res Commun. 2000 Jan 19;267(2):509-15 [10631092.001]
  • [Cites] Nat Genet. 2000 May;25(1):25-9 [10802651.001]
  • [Cites] Am J Hum Genet. 2000 Aug;67(2):345-56 [10889045.001]
  • [Cites] Genome Res. 2000 Jul;10(7):967-81 [10899146.001]
  • [Cites] EMBO J. 2000 Sep 1;19(17):4439-48 [10970838.001]
  • [Cites] Nucleic Acids Res. 2000 Oct 15;28(20):3943-9 [11024174.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Jan 8;99(1):333-8 [11782551.001]
  • [Cites] Science. 2002 Apr 5;296(5565):79-92 [11935017.001]
  • [Cites] Oligonucleotides. 2009 Jun;19(2):179-90 [19355811.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Oct 6;106(40):17095-100 [19805156.001]
  • [Cites] J Biol Chem. 2010 Apr 23;285(17):12755-64 [20159983.001]
  • [Cites] Proteins. 2002 Jul 1;48(1):134-40 [12012345.001]
  • [Cites] Genome Res. 2002 Jun;12(6):909-15 [12045144.001]
  • [Cites] Genome Res. 2002 Jun;12(6):996-1006 [12045153.001]
  • [Cites] Hum Mol Genet. 2002 Jun 15;11(13):1487-96 [12045202.001]
  • [Cites] Nucleic Acids Res. 2002 Aug 15;30(16):3540-7 [12177295.001]
  • [Cites] Nucleic Acids Res. 2003 Jan 1;31(1):51-4 [12519945.001]
  • [Cites] Genome Biol. 2003;4(2):R13 [12620123.001]
  • [Cites] Genome Biol. 2003;4(5):P3 [12734009.001]
  • [Cites] Mol Cell Biol. 2003 Jul;23(13):4485-93 [12808091.001]
  • [Cites] Nucleic Acids Res. 2003 Jul 1;31(13):3406-15 [12824337.001]
  • [Cites] Neuron. 2003 Aug 28;39(5):739-47 [12948442.001]
  • [Cites] Nucleic Acids Res. 2003 Oct 1;31(19):5463-8 [14500808.001]
  • [Cites] Nucleic Acids Res. 2003 Oct 1;31(19):5469-82 [14500809.001]
  • [Cites] Gene. 2003 Oct 23;317(1-2):117-25 [14604799.001]
  • [Cites] Genomics. 2004 Mar;83(3):373-83 [14962663.001]
  • [Cites] Am J Hum Genet. 2004 May;74(5):1051-6 [15065016.001]
  • [Cites] J Biol Chem. 2004 May 14;279(20):21217-22 [14993218.001]
  • [Cites] Mol Biol Evol. 2004 Jun;21(6):991-1007 [14963101.001]
  • [Cites] Nat Rev Genet. 2004 Jun;5(6):435-45 [15153996.001]
  • [Cites] Nature. 1991 Jul 4;352(6330):77-9 [2062380.001]
  • [Cites] Nature. 1992 Oct 29;359(6398):794-801 [1436057.001]
  • [Cites] Cell. 1993 Mar 26;72(6):971-83 [8458085.001]
  • [Cites] Hum Mol Genet. 1993 Sep;2(9):1429-35 [8242066.001]
  • [Cites] Genomics. 1994 May 1;21(1):116-21 [8088779.001]
  • [Cites] Nat Genet. 1994 Jun;7(2 Spec No):246-339 [7545953.001]
  • [Cites] Protein Eng. 1995 Nov;8(11):1069-73 [8819972.001]
  • [Cites] Trends Genet. 1997 Feb;13(2):74-8 [9055609.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Apr 1;94(7):3320-3 [9096391.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Nov;82(11):3777-82 [9360540.001]
  • [Cites] J Biol Chem. 1997 Dec 5;272(49):31079-85 [9388259.001]
  • [Cites] Science. 1997 Dec 19;278(5346):2117-20 [9405346.001]
  • [Cites] Biochim Biophys Acta. 1998 Jul 9;1398(3):315-20 [9655925.001]
  • [Cites] FEBS Lett. 1999 Jul 16;455(1-2):70-4 [10428474.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Dec 28;101(52):18058-63 [15596718.001]
  • [Cites] Nucleic Acids Res. 2005;33(2):451-63 [15659577.001]
  • [Cites] Biochim Biophys Acta. 2005 May 15;1748(2):174-9 [15769594.001]
  • [Cites] Genome Res. 2005 Apr;15(4):537-51 [15805494.001]
  • [Cites] Mol Ecol. 2005 Sep;14(10):3235-45 [16101788.001]
  • [Cites] Nat Rev Genet. 2005 Oct;6(10):729-42 [16205713.001]
  • [Cites] Nat Rev Genet. 2005 Oct;6(10):743-55 [16205714.001]
  • [Cites] Genomics. 2006 Jan;87(1):57-67 [16316739.001]
  • [Cites] Trends Genet. 2006 May;22(5):253-9 [16567018.001]
  • [Cites] In Silico Biol. 2006;6(3):237-42 [16922687.001]
  • [Cites] Nucleic Acids Res. 2007 Jan;35(Database issue):D61-5 [17130148.001]
  • [Cites] Dev Genes Evol. 2007 Jan;217(1):79-85 [17066275.001]
  • [Cites] J Biomol Struct Dyn. 2007 Feb;24(4):325-42 [17206849.001]
  • [Cites] Hum Mutat. 2007 May;28(5):451-8 [17226796.001]
  • [Cites] BMC Genomics. 2007;8:126 [17519034.001]
  • [Cites] Annu Rev Neurosci. 2007;30:575-621 [17417937.001]
  • [Cites] Protein Sci. 2007 Oct;16(10):2195-204 [17766374.001]
  • [Cites] Clin Chem Lab Med. 2007;45(8):987-92 [17579569.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Oct 16;104(42):16621-6 [17921251.001]
  • [Cites] J Clin Endocrinol Metab. 2007 Nov;92(11):4319-26 [17684052.001]
  • [Cites] Mol Genet Genomics. 2008 Jan;279(1):53-61 [17926066.001]
  • [Cites] Gene. 2008 Jan 15;407(1-2):54-62 [17964742.001]
  • [Cites] Genome Res. 2008 Jan;18(1):30-8 [18032720.001]
  • [Cites] Trends Neurosci. 2008 Jul;31(7):328-34 [18550185.001]
  • [Cites] Genome Res. 2008 Jul;18(7):1011-9 [18593815.001]
  • [Cites] BMC Genomics. 2008;9:410 [18789129.001]
  • [Cites] Genome Res. 2008 Oct;18(10):1545-53 [18687880.001]
  • [Cites] Ann Oncol. 2008 Nov;19(11):1910-4 [18632724.001]
  • (PMID = 20215431.001).
  • [ISSN] 1362-4962
  • [Journal-full-title] Nucleic acids research
  • [ISO-abbreviation] Nucleic Acids Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / RNA, Messenger; 0RH81L854J / Glutamine
  • [Other-IDs] NLM/ PMC2896521
  •  go-up   go-down


84. Marley MS, Givens MD, Galik PK, Riddell KP, Stringfellow DA: Amplification of bovine viral diarrhoea virus introduced into an in vitro embryo production system via oocytes from persistently infected cattle. Reprod Domest Anim; 2009 Jun;44(3):532-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Amplification of bovine viral diarrhoea virus introduced into an in vitro embryo production system via oocytes from persistently infected cattle.
  • 1) oocytes and uterine tubal cells (UTC) free of bovine viral diarrhoea virus (BVDV) (negative control), 2)oocytes free of BVDV fertilized and cultured in media containing UTC obtained from PI heifers, and 3) oocytes from PI heifers fertilized and cultured in media containing UTC free of BVDV.
  • The developmental media, UTC and embryos (individual or groups of five) were assayed for virus.Virus was not isolated from any samples in treatment group 1.As shown in previous studies, a proportion of embryo samples were positive for BVDV in treatment group 2.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19655440.001).
  • [ISSN] 1439-0531
  • [Journal-full-title] Reproduction in domestic animals = Zuchthygiene
  • [ISO-abbreviation] Reprod. Domest. Anim.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Culture Media
  •  go-up   go-down


85. Wreesmann VB, Singh B: Clinical impact of molecular analysis on thyroid cancer management. Surg Oncol Clin N Am; 2008 Jan;17(1):1-35, vii
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical impact of molecular analysis on thyroid cancer management.
  • Thyroid cancer constitutes a progressive continuum of disease ranging from indolent well-differentiated carcinomas to aggressive poorly differentiated carcinomas and universally fatal anaplastic carcinomas.
  • Moreover, therapeutic armentarium against aggressive thyroid cancers remains limited.
  • Recent studies have identified a range of molecular alterations in thyroid cancers.
  • Continued molecular analysis of thyroid cancers promises to increase our understanding of its biologic behavior and is expected to have further impact on its clinical management.
  • [MeSH-major] Molecular Biology. Thyroid Neoplasms / physiopathology

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18177798.001).
  • [ISSN] 1055-3207
  • [Journal-full-title] Surgical oncology clinics of North America
  • [ISO-abbreviation] Surg. Oncol. Clin. N. Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / beta Catenin
  • [Number-of-references] 245
  •  go-up   go-down


86. Cariou JL: [Composite tissues allotransplantation (CTA). Conclusions]. Ann Chir Plast Esthet; 2007 Oct;52(5):551-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Allotransplantation de tissus composites (ATC). Conclusions.

  • MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17766025.001).
  • [ISSN] 0294-1260
  • [Journal-full-title] Annales de chirurgie plastique et esthétique
  • [ISO-abbreviation] Ann Chir Plast Esthet
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


87. Wada N, Yoshida A, Miyagi Y, Yamamoto T, Nakayama H, Suganuma N, Matsuzu K, Masudo K, Hirakawa S, Rino Y, Masuda M, Imada T: Overexpression of the mitotic spindle assembly checkpoint genes hBUB1, hBUBR1 and hMAD2 in thyroid carcinomas with aggressive nature. Anticancer Res; 2008 Jan-Feb;28(1A):139-44
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overexpression of the mitotic spindle assembly checkpoint genes hBUB1, hBUBR1 and hMAD2 in thyroid carcinomas with aggressive nature.
  • MSAC gene expressions have been reported to be associated with tumor cell proliferation or unfavorable cancer behavior.
  • The present study was conducted to preliminary investigate the MSAC gene expressions in thyroid neoplasms.
  • MATERIALS AND METHODS: Expression levels of MSAC genes (hBUB1, hBUBR1, hBUB3 and hMAD2) were evaluated in 9 follicular thyroid adenomas (FAs), 9 follicular thyroid carcinomas (FTCs), 21 papillary thyroid carcinomas (PTCs), 5 anaplastic (undifferentiated) thyroid carcinomas (ATCs) and 3 adjacent normal thyroid tissues (NTs) by real-time quantitative RT-PCR.
  • These gene expressions were compared between undifferentiated thyroid carcinomas (ATCs) and differentiated thyroid carcinomas (DTCs) and between advanced DTCs and non-advanced DTCs.
  • Advanced DTCs were defined as carcinoma with aggressive nature such as extrathyroid extension, distant metastasis, recurrence or death from the disease.
  • RESULTS: MSAC gene expressions varied in different thyroid tumors and fell in the order of ATC, DTC (PTC and FTC), FA and NT Carcinomas had higher expression compared to adenoma or normal tissue. hBUB1, hBUBR1 and hMAD2 expressions in ATCs were significantly higher than those in DTCs (p<0.005).
  • CONCLUSION: The MSAC genes were overexpressed in thyroid carcinomas with aggressive nature.
  • Further studies are required to clarify the relationship between the MSAC gene expressions and thyroid cancer behavior.
  • [MeSH-major] Calcium-Binding Proteins / genetics. Cell Cycle Proteins / genetics. Protein-Serine-Threonine Kinases / genetics. Repressor Proteins / genetics. Spindle Apparatus / genetics. Thyroid Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18383837.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Calcium-Binding Proteins; 0 / Cell Cycle Proteins; 0 / MAD2L1 protein, human; 0 / Mad2 Proteins; 0 / RNA, Messenger; 0 / Repressor Proteins; EC 2.7.11.1 / BUB1 protein, human; EC 2.7.11.1 / Bub1 spindle checkpoint protein; EC 2.7.11.1 / Protein-Serine-Threonine Kinases
  •  go-up   go-down


88. Uchida N, Chong MY, Tan CH, Nagai H, Tanaka M, Lee MS, Fujii S, Yang SY, Si T, Sim K, Wei H, Ling HY, Nishimura R, Kawaguchi Y, Edwards G, Sartorius N, Shinfuku N: International study on antidepressant prescription pattern at 20 teaching hospitals and major psychiatric institutions in East Asia: Analysis of 1898 cases from China, Japan, Korea, Singapore and Taiwan. Psychiatry Clin Neurosci; 2007 Oct;61(5):522-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Out of 56 antidepressants listed in the Anatomical Therapeutic Chemical Classification (ATC) index by the World Health Organization (WHO) Collaborating Center for Drug Statistics Methodology (Oslo), only 26 antidepressants were prescribed in participating countries in East Asia.
  • [MeSH-major] Antidepressive Agents / therapeutic use. Cross-Cultural Comparison. Depressive Disorder / drug therapy. Drug Prescriptions / statistics & numerical data. Hospitals, Psychiatric / statistics & numerical data. Hospitals, Teaching / statistics & numerical data
  • [MeSH-minor] Adult. Antidepressive Agents, Second-Generation / therapeutic use. China. Cross-Sectional Studies. Drug Utilization / statistics & numerical data. Female. Humans. Japan. Korea. Male. Middle Aged. Serotonin Uptake Inhibitors / therapeutic use. Singapore. Taiwan. World Health Organization

  • MedlinePlus Health Information. consumer health - Antidepressants.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17875031.001).
  • [ISSN] 1323-1316
  • [Journal-full-title] Psychiatry and clinical neurosciences
  • [ISO-abbreviation] Psychiatry Clin. Neurosci.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antidepressive Agents; 0 / Antidepressive Agents, Second-Generation; 0 / Serotonin Uptake Inhibitors
  •  go-up   go-down


89. Lee JJ, Foukakis T, Hashemi J, Grimelius L, Heldin NE, Wallin G, Rudduck C, Lui WO, Höög A, Larsson C: Molecular cytogenetic profiles of novel and established human anaplastic thyroid carcinoma models. Thyroid; 2007 Apr;17(4):289-301
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular cytogenetic profiles of novel and established human anaplastic thyroid carcinoma models.
  • In this study we present two novel anaplastic thyroid carcinoma (ATC) lines (HTh 104 and HTh 112) and further characterize six frequently used ATC lines (HTh 7, HTh 74, HTh 83, C 643, KAT-4, and SW 1736).
  • Three of the lines carried a heterozygous BRAF mutation V600E, which is in line with reports of BRAF mutations in primary ATC and papillary thyroid cancer.
  • Several nonrandom breakpoints were identified by spectral karyotyping (SKY) and G-banding in these lines including the novel 1p36 and 17q24-25 as well as 3p21-22 and 15q26 that are also implicated in well-differentiated thyroid cancers.
  • Our results concur with previous studies in both primary tumors and cell lines, indicating that gain of chromosome 20 is important in the pathogenesis of ATC and/or progression of differentiated thyroid cancers to ATC.
  • [MeSH-major] Carcinoma / genetics. Chromosome Aberrations / classification. Chromosomes, Human / genetics. Proto-Oncogene Proteins B-raf / genetics. Thyroid Neoplasms / genetics


90. Collin AC, Chekaroua K, Delaporte T, Droz JP, Peix JL, Delay E: [Anaplastic thyroid carcinoma: aggressive radical resection and cervical reconstruction. A case report]. Ann Chir; 2006 Dec;131(10):631-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Anaplastic thyroid carcinoma: aggressive radical resection and cervical reconstruction. A case report].
  • [Transliterated title] Chirurgie d'exérèse élargie et reconstruction cervicale pour cancer anaplasique de la thyroïde. A propos d'un cas.
  • STUDY AIM: Anaplastic carcinoma of the thyroid is a rare but highly malignant tumor.
  • PATIENT AND METHODS: We present the case of a patient treated in 1996 for an anaplasic thyroid carcinoma with cervical cutaneous invasion.
  • CONCLUSION: Anaplastic carcinoma is one of more aggressive neoplasm affecting humans.
  • [MeSH-major] Carcinoma / surgery. Neck Dissection / methods. Reconstructive Surgical Procedures / methods. Thyroid Neoplasms / surgery. Thyroidectomy / methods
  • [MeSH-minor] Chemotherapy, Adjuvant. Disease-Free Survival. Female. Follow-Up Studies. Humans. Middle Aged. Muscle, Skeletal / transplantation. Radiotherapy, Adjuvant. Skin Transplantation / methods

  • MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16824476.001).
  • [ISSN] 0003-3944
  • [Journal-full-title] Annales de chirurgie
  • [ISO-abbreviation] Ann Chir
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


91. Vukusić I, Culig J: [Data sources on drug utilization in Croatia and Europe]. Acta Med Croatica; 2005;59(3):277-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this brief survey, the methodology of drug utilization monitoring is critically reviewed, emphasizing the need of implementing the World Health Organization (WHO) Anatomical-Therapeutic-Chemical (ATC) system of drug classification and drug utilization monitoring by use of WHO Defined Daily Doses (DDD).
  • The use of ATC/DDD system and other methods of drug utilization monitoring in Scandinavian countries is then presented.
  • In Croatia, the ATC/DDD system has to date been only used by researchers and Zagreb Institute of Public Health in the work on the project entitled Drug Utilization in the City of Zagreb, launched in 2002.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16095204.001).
  • [ISSN] 1330-0164
  • [Journal-full-title] Acta medica Croatica : c̆asopis Hravatske akademije medicinskih znanosti
  • [ISO-abbreviation] Acta Med Croatica
  • [Language] hrv
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Croatia
  •  go-up   go-down


92. Campo E, Chott A, Kinney MC, Leoncini L, Meijer CJ, Papadimitriou CS, Piris MA, Stein H, Swerdlow SH: Update on extranodal lymphomas. Conclusions of the Workshop held by the EAHP and the SH in Thessaloniki, Greece. Histopathology; 2006 Apr;48(5):481-504
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Classification and proper treatment of extranodal lymphoma is hindered by the diversity of lymphoma types and the relative rarity of many of these tumour types.
  • In order to review controversial issues in extranodal lymphoma diagnosis, a joint Workshop of the European Haematopathology Association (EAHP) and the Society for Hematopathology (SH) was held, where 99 selected cases were reviewed and discussed.
  • This Workshop summary is focused on the most controversial aspect of cutaneous B-cell lymphoma, other extranodal B-cell lymphomas, plasmablastic lymphoma and anaplastic large-cell lymphoma in extranodal sites, and makes practical recommendations about diagnosis and therapeutic approaches.
  • [MeSH-minor] Diagnosis, Differential. Gastrointestinal Tract / pathology. Humans. Lung / pathology. Salivary Glands / pathology. Skin / pathology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mod Pathol. 2005 Jun;18(6):806-15 [15578069.001]
  • [Cites] Hum Pathol. 2005 May;36(5):494-504 [15948116.001]
  • [Cites] Immunol Res. 2005;32(1-3):75-83 [16106060.001]
  • [Cites] Blood. 2005 Oct 1;106(7):2491-7 [15947086.001]
  • [Cites] Genes Chromosomes Cancer. 2000 Jan;27(1):52-8 [10564586.001]
  • [Cites] Thyroid. 1999 Dec;9(12):1273-80 [10646671.001]
  • [Cites] Blood. 2000 Feb 1;95(3):802-6 [10648389.001]
  • [Cites] Mod Pathol. 2000 Jan;13(1):19-28 [10658906.001]
  • [Cites] Blood. 2000 Feb 15;95(4):1406-12 [10666218.001]
  • [Cites] J Clin Pathol. 1999 Nov;52(11):849-50 [10690178.001]
  • [Cites] Am J Surg Pathol. 2000 May;24(5):623-39 [10800981.001]
  • [Cites] Am J Surg Pathol. 2000 May;24(5):688-93 [10800987.001]
  • [Cites] Blood. 2000 Jun 15;95(12):3653-61 [10845893.001]
  • [Cites] Hum Pathol. 2004 May;35(5):632-5 [15138941.001]
  • [Cites] Am J Clin Pathol. 2004 May;121(5):709-17 [15151211.001]
  • [Cites] Am J Surg Pathol. 2004 Jun;28(6):736-47 [15166665.001]
  • [Cites] Am J Surg Pathol. 2004 Jun;28(6):748-55 [15166666.001]
  • [Cites] J Neurooncol. 2004 May;68(1):19-23 [15174517.001]
  • [Cites] J Invest Dermatol. 2004 Jun;122(6):1495-502 [15175042.001]
  • [Cites] Hum Pathol. 2004 Jun;35(6):711-21 [15188137.001]
  • [Cites] J Invest Dermatol. 2004 Jul;123(1):213-9 [15191563.001]
  • [Cites] Br J Dermatol. 2004 Jun;150(6):1202-7 [15214912.001]
  • [Cites] Mod Pathol. 2004 Aug;17(8):946-53 [15105813.001]
  • [Cites] Mod Pathol. 2004 Aug;17(8):954-61 [15133473.001]
  • [Cites] Nat Rev Cancer. 2004 Aug;4(8):644-53 [15286744.001]
  • [Cites] Leukemia. 2004 Oct;18(10):1722-6 [15356642.001]
  • [Cites] Am J Clin Pathol. 2004 Oct;122(4):582-7 [15487457.001]
  • [Cites] J Clin Oncol. 1991 Apr;9(4):539-47 [1648596.001]
  • [Cites] Lancet. 1991 Nov 9;338(8776):1175-6 [1682595.001]
  • [Cites] Cancer. 1993 Mar 15;71(6):2097-104 [8382999.001]
  • [Cites] J Clin Oncol. 1993 May;11(5):937-42 [8387578.001]
  • [Cites] Am J Surg Pathol. 1993 Sep;17(9):859-68 [8394652.001]
  • [Cites] Ultrastruct Pathol. 1993 May-Aug;17(3-4):455-8 [7505507.001]
  • [Cites] Am J Pathol. 1988 Dec;133(3):446-50 [2849300.001]
  • [Cites] Blood. 1989 Oct;74(5):1678-89 [2477085.001]
  • [Cites] Blood. 1989 Oct;74(5):1796-800 [2506953.001]
  • [Cites] Hum Pathol. 1990 Jun;21(6):624-9 [1693592.001]
  • [Cites] Am J Surg Pathol. 1990 Nov;14(11):1047-60 [2173429.001]
  • [Cites] Am J Pathol. 1991 Jun;138(6):1413-22 [1711289.001]
  • [Cites] J Invest Dermatol. 1994 Feb;102(2):231-5 [8106752.001]
  • [Cites] Ann Hematol. 1995 Feb;70(2):103-5 [7880923.001]
  • [Cites] J Clin Oncol. 1995 Jun;13(6):1343-54 [7751878.001]
  • [Cites] Blood. 1996 Apr 15;87(8):3437-41 [8605362.001]
  • [Cites] Histopathology. 1996 Jan;28(1):25-32 [8838117.001]
  • [Cites] Am J Clin Pathol. 1996 Oct;106(4):498-503 [8853039.001]
  • [Cites] Arch Dermatol. 1996 Nov;132(11):1304-8 [8915307.001]
  • [Cites] Histopathology. 1996 Nov;29(5):455-9 [8951491.001]
  • [Cites] Oncogene. 1997 Jan 30;14(4):439-49 [9053841.001]
  • [Cites] Blood. 1997 Feb 15;89(4):1394-404 [9028963.001]
  • [Cites] Blood. 1997 Feb 15;89(4):1413-20 [9028965.001]
  • [Cites] J Clin Pathol. 1996 Sep;49(9):762-3 [9038763.001]
  • [Cites] Blood. 1997 Mar 1;89(5):1483-90 [9057627.001]
  • [Cites] N Engl J Med. 1997 May 8;336(19):1391-2 [9139227.001]
  • [Cites] J Pediatr Hematol Oncol. 1997 Mar-Apr;19(2):135-8 [9149743.001]
  • [Cites] Hum Pathol. 1997 Jul;28(7):757-9 [9224740.001]
  • [Cites] Hum Pathol. 1997 Jul;28(7):850-61 [9224756.001]
  • [Cites] Plast Reconstr Surg. 1997 Aug;100(2):554-5 [9252643.001]
  • [Cites] Arch Esp Urol. 1997 Oct;50(8):906-8 [9463289.001]
  • [Cites] J Clin Oncol. 1998 Jun;16(6):2080-5 [9626207.001]
  • [Cites] Am J Clin Pathol. 1998 Sep;110(3):327-33 [9728607.001]
  • [Cites] Ann Oncol. 1998 Jul;9(7):779-81 [9739446.001]
  • [Cites] Am J Surg Pathol. 1998 Oct;22(10):1192-202 [9777981.001]
  • [Cites] Am J Clin Pathol. 1999 Jan;111(1):111-6 [9894461.001]
  • [Cites] Am J Clin Pathol. 1999 Apr;111(4):488-94 [10191768.001]
  • [Cites] Cancer. 1999 Apr 1;85(7):1626-35 [10193956.001]
  • [Cites] Blood. 1999 Apr 15;93(8):2697-706 [10194450.001]
  • [Cites] Blood. 1999 Jun 1;93(11):3913-21 [10339500.001]
  • [Cites] Am J Clin Pathol. 1999 Aug;112(2):263-70 [10439808.001]
  • [Cites] Mod Pathol. 1999 Sep;12(9):903-6 [10496599.001]
  • [Cites] Ann Oncol. 2004 Nov;15(11):1673-9 [15520070.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Feb;90(2):720-3 [15536159.001]
  • [Cites] Mod Pathol. 2005 Feb;18(2):235-43 [15475930.001]
  • [Cites] Histopathology. 2005 Mar;46(3):241-55 [15720410.001]
  • [Cites] Blood. 2005 May 1;105(9):3671-8 [15308563.001]
  • [Cites] Leukemia. 2005 Apr;19(4):652-8 [15703784.001]
  • [Cites] Blood. 2005 May 15;105(10):3768-85 [15692063.001]
  • [Cites] Clin Cancer Res. 2005 May 1;11(9):3349-52 [15867234.001]
  • [Cites] Leukemia. 2004 Jan;18(1):146-55 [14603341.001]
  • [Cites] N Engl J Med. 2004 Jan 15;350(3):239-48 [14724303.001]
  • [Cites] J Pediatr Hematol Oncol. 2004 Feb;26(2):104-7 [14767197.001]
  • [Cites] Histopathology. 2004 Mar;44(3):268-76 [14987231.001]
  • [Cites] Am J Clin Pathol. 2004 Mar;121(3):408-16 [15023046.001]
  • [Cites] J Natl Cancer Inst. 2004 Apr 21;96(8):586-94 [15100336.001]
  • [Cites] Blood. 2004 May 15;103(10):3662-8 [14726400.001]
  • [Cites] Blood. 2004 Nov 15;104(10):3343-8 [15256428.001]
  • [Cites] Blood. 2004 Nov 15;104(10):3358-60 [15297316.001]
  • [Cites] Clin Cancer Res. 2004 Nov 1;10(21):7179-81 [15534090.001]
  • [Cites] J Clin Pathol. 2004 Dec;57(12):1258-63 [15563664.001]
  • [Cites] J Pathol. 2005 Jan;205(1):92-101 [15586381.001]
  • [Cites] Am J Surg Pathol. 2005 Jan;29(1):69-82 [15613857.001]
  • [Cites] J Pathol. 2005 Jan;205(2):255-74 [15643667.001]
  • [Cites] Hum Pathol. 1988 Nov;19(11):1315-26 [3141260.001]
  • [Cites] Blood. 2000 Jul 15;96(2):398-404 [10887098.001]
  • [Cites] J Clin Pathol. 2000 Jun;53(6):445-50 [10911802.001]
  • [Cites] Histopathology. 2000 Jul;37(1):10-8 [10931213.001]
  • [Cites] Am J Surg Pathol. 2000 Sep;24(9):1257-65 [10976700.001]
  • [Cites] Leukemia. 2000 Sep;14(9):1533-59 [10994999.001]
  • [Cites] Mod Pathol. 2000 Oct;13(10):1143-9 [11048810.001]
  • [Cites] Am J Surg Pathol. 2004 Nov;28(11):1401-16 [15489644.001]
  • [Cites] Virchows Arch A Pathol Anat Histol. 1979 Aug 23;383(3):293-317 [158873.001]
  • [Cites] Am J Med. 1983 Feb;74(2):228-31 [6824003.001]
  • [Cites] Cancer. 1984 Jun 1;53(11):2515-24 [6424928.001]
  • [Cites] Histopathology. 1985 Jan;9(1):81-97 [3884481.001]
  • [Cites] Blood. 1985 Oct;66(4):848-58 [3876124.001]
  • [Cites] Blood. 2000 Nov 1;96(9):2993-3000 [11049976.001]
  • [Cites] Arch Pathol Lab Med. 2000 Dec;124(12):1804-8 [11100061.001]
  • [Cites] J Clin Lab Anal. 2000;14(6):299-304 [11138613.001]
  • [Cites] Am J Pathol. 2001 Feb;158(2):699-706 [11159207.001]
  • [Cites] Br J Haematol. 2001 Mar;112(4):909-15 [11298585.001]
  • [Cites] Br J Haematol. 2001 May;113(2):275-95 [11380391.001]
  • [Cites] Am J Surg Pathol. 2001 Jul;25(7):875-83 [11420458.001]
  • [Cites] Blood. 2001 Aug 15;98(4):1209-16 [11493472.001]
  • [Cites] J Clin Oncol. 2001 Aug 15;19(16):3602-10 [11504742.001]
  • [Cites] Mod Pathol. 2001 Nov;14(11):1093-9 [11706069.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Jan;87(1):105-11 [11788631.001]
  • [Cites] Am J Surg Pathol. 2002 Feb;26(2):216-24 [11812943.001]
  • [Cites] Am J Hematol. 2002 Feb;69(2):127-31 [11835349.001]
  • [Cites] Am J Surg Pathol. 2002 Jun;26(6):724-32 [12023576.001]
  • [Cites] Am J Surg Pathol. 2002 Jun;26(6):733-41 [12023577.001]
  • [Cites] J Invest Dermatol. 2002 Jun;118(6):941-8 [12060387.001]
  • [Cites] J Clin Pathol. 2002 Sep;55(9):684-8 [12194999.001]
  • [Cites] Am J Clin Pathol. 2002 Nov;118(5):773-9 [12428799.001]
  • [Cites] Mod Pathol. 2002 Nov;15(11):1221-6 [12429802.001]
  • [Cites] Surv Ophthalmol. 2002 Sep-Oct;47(5):470-90 [12431695.001]
  • [Cites] Virchows Arch. 2002 Dec;441(6):614-7 [12461620.001]
  • [Cites] Am J Surg Pathol. 2003 Jan;27(1):16-26 [